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3Abstract
Hypertrophic cardiomyopathy (HCM) is the commonest inherited cardiac condition. Many patients
have resting or provocable left ventricular outflow tract (LVOT) obstruction. Symptoms treated with
drugs or surgery may improve. There is a need to improve the clinical assessment in individual
patients, because of the often poor correlation between symptoms and LVOT gradient, and the
association with complications such as stroke, heart failure and sudden cardiac death. In addition, in
a proportion of patients with significant LVOT gradients, relief of obstruction does not adequately
improve symptoms.
Reduced angulation between the inter-ventricular septum and the aorta is a determinant of LVOT
obstruction. However, lack of a standardised method of measurement in HCM without recourse to
complex 3-D imaging limits the usefulness of this parameter in routine practice. Transthoracic
echocardiography is widely available, and can be used to measure aorto-septal angulation. However,
data in HCM are lacking. I validated a simple measurement of aorto-septal angulation using 2-D
echocardiography and cardiac magnetic resonance imaging and determined its relation to
provocable LVOT obstruction in HCM. I showed this technique to be easy, reproducible, comparable
to magnetic resonance imaging, and can be quickly calculated using standard echocardiographic
software. Patients have a smaller aorto-septal angle than controls, where it is associated with higher
peak LVOT gradient. A reduced aorto-septal angle is highly specific for provocable LVOT obstruction
and should prompt further evaluation in symptomatic patients without resting gradients.
I used a non-invasive technique for measuring cardiac output to determine the relation between
LVOT obstruction, cardiac output and peripheral oxygen utilisation in patients with HCM during
exercise. I demonstrated that cardiac output response to exercise is impaired, caused largely by
failure to appropriately augment stroke volume. LVOT obstruction is associated with greater
impairment of stroke volume at peak exercise and is an independent and modifiable predictor of
cardiac output reserve. However, heterogenous responses are seen between patients who
otherwise appear similar using standard clinical criteria. There is therefore a strong argument for the
individualisation of therapy in patients with LVOT obstruction. Invasive therapies to reduce gradients
may work better in those with genuine obstruction to the outflow of blood, rather than for example
myocardial ischaemia or mitral regurgitation. The non-invasive measurement of haemodynamic
indices during exercise is practical, aids understanding of the complex physiological basis behind
symptoms and may help to tailor therapy for HCM, and in particular LVOT obstruction.
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1 Preface
1.1 Statement of originality
The work submitted in this thesis to the University of London is original, and has not been submitted
elsewhere for any other professional qualification. Published results are detailed in chapter 9. This
thesis has been checked using University College London turnitin plagiarism detection software.
Other than the citations listed, no significant similarities or matches were seen.
1.2 Aims and clinical relevance of the thesis
The broad theme of this thesis is LVOT obstruction in HCM, and is split into structural and
physiological aspects.1.2.1 Structural determinants of LVOT obstruction: 3D imaging before andafter myectomy surgery in patients with HCM
Surgical myectomy is the gold standard procedure for patients with HCM and drug-refractory
symptoms of LVOT obstruction. In current practice patients have trans-thoracic echocardiography
prior to the procedure and 2D trans-oesophageal echocardiography (TOE) at the time of surgery.
Patients also have conventional coronary angiography to exclude significant coronary disease which
could be treated at the time of surgery if needed. A proportion of patients also undergo cardiac
magnetic resonance (CMR) imaging as part of their workup. Ventricular septal myectomy
substantially reduces the gradient and improves exercise capacity and symptoms. In experienced
centres, mortality rates are less than 1% and complications such as atrio-ventricular block and
ventricular septal defects rare. These good results, however, belie the challenge that patients with
more complex anatomical abnormalities pose for surgical correction. In addition to hypertrophy of
the interventricular septum, leaflet elongation or restriction, accessory mitral valve attachments and
abnormalities of the papillary muscles and chordae are very common and are often only detected at
the time of operation. Various modifications of the standard surgical technique have been proposed
to deal with such anomalies including mitral valve plication or patching, chordal remodelling and
edge to edge repair, but the choice of technique and their contribution to successful relief of
obstruction is difficult to predict peri-operatively. Similarly, variable distribution of hypertrophy
between patients often results in sub-optimal resection. This project proposed that all patients
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undergo pre and post surgical evaluation with 3D TOE, CMR and computed tomography (CT) and the
data integrated to improve surgical planning and ultimately outcome. Although individually these
investigations are commonly performed in patients with HCM, this integreation has not been
attempted before. Specifically, the original aims were:
1. To characterise the morphological and haemodynamic determinants of left ventricular
outflow tract obstruction in individual patients with hypertrophic cardiomyopathy with the
intention of improving their subsequent surgical treatment.
2. To create a single, realistic, 4D animation of each individual patient’s heart and great vessels
which can be used to create a real-time tool combining echocardiography, MR and CT data.
I commenced data collection for this project in Autumn 2010 immediately prior to my out of
cardiology program research period. Unfortunately, shortly afterwards due to circumstances beyond
my control the surgical myectomy program at The Heart Hospital was temporaily halted, and did not
restart until October 2012. During this time, 18 patients had CT scanning pre- LVOT reduction
therapy, and 10 had post- operative scanning, having had operations carried out at another centre,
or alcohol septal ablation (ASA). As a result, it was only possible to collect preliminary pilot data. A
description of methods and results are detailed in the appropriate sections.
The Heart hospital has the largest cohort of patients with HCM in Europe, all of whom undergo
cardiopulmonary exercise testing, and many have been investigated with stress echocardiography. It
is also the UK’s leading centre for interventional LVOT gradient reduction. A unique opportunity
therefore existed to expand my project to other aspects of LVOT obstuction in HCM.
1.2.2 Structural determinants of LVOT obstruction: Analysis of aorto-septal angulation using 2-D transthoracic echocardiography
The aorto-septal angle is formed between the plane of the inter-ventricular septum and the aorta. A
smaller angulation is an anatomical feature commonly seen in advancing age and hypertension. In
addition, in children it has been associated with sub-aortic valve obstruction. Recently, it has been
shown to be predictive of LVOT obstruction in HCM using 3D imaging techniques. Whilst a
standardised measurement technique using echocardiography has been described, this has never
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been applied to patients with HCM, in whom it might be expected to be inaccurate given the highly
variable LVOT geometry. In routine clinical practice, aorto-septal angulation in HCM is commonly
described as being suggestive of provocable LVOT obstruction. However, on review of the literature
few data exist as to its importance in this disease. I therefore sought to determine whether this was
an anatomical predictor of provocable LVOT obstruction in a cohort of patients with HCM and no
resting obstruction, and whether it could be reliably and accurately measured using transthoracic
echocardiography. The result is a description of a novel mechanism by which the risk of provocable
LVOT obstruction may be predicted from a standard resting transthoracic echocardiogram of a
patient with HCM. This may help identify patients who would benefit from further assessment and
treatment.
1.2.3 Functional consequences of left ventricular outflow tract obstruction
The primary aim of this study was to determine the relation between LVOT obstruction, cardiac
output and peripheral oxygen utilisation in patients with HCM during exercise using symptom
limited cardiopulmonary exercise testing. Compared to some areas of research in HCM, for example
genetics, this subject is largely unstudied in the literature, and in particular in recent years. In part,
this likely relates to the difficulties in investigating exercise physiology in these patients. Typically
HCM cohorts in most hospitals are small, and physiological expertise limited; larger numbers may be
needed to determine the relative importance of a variety of complex factors which may have a role
in exercise limitation. The techniques available to study exercise physiology, in particular cardiac
output, also have their own limitations: invasive techniques carry associated risks (which are often
less acceptable to research populations than work done in the 20th century), and non-invasive
techniques are either unable to capture the rapid changes in dynamic variables, or are unsuited to
use during exercise. I therefore wanted first to validate a non-invasive technique for measuring
cardiac output. I chose finger plethysmography, as the design lends itself to use during exercise, and
captures beat by beat physiological data which may be of importance in HCM.
The physiological data shed new light on the mechanism of exercise limitation in patients with HCM.
Cardiac output response to exercise was shown to be impaired in HCM, driven predominantly by a
failure to appropriately augment stroke volume. Peak LVOT gradient was an independent predictor
of cardiac output reserve. In some patients, stroke volume impairment is compensated for by an
ability to mount an exaggerated heart rate response. Most importantly, the stroke volume response
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between patients with LVOT obstruction was heterogeneous, implying that better haemodynamic
characterisation of patients may help determine those who may derive maximal benefit from
invasive treatment.
1.3 Statement of individual contribution
1.3.1 Physiology study
All cardiopulmonary exercise tests were performed as part of routine patient care at The Heart
Hospital by Dr Bryan Mist. I performed finger plethysmography during those tests. All
echocardiograms were also performed as part of routine patient care at The Heart Hospital by the
imaging department. I analysed all the resulting data.1.3.2 Aorto-septal angulation study
The original echocardiograms and magnetic resonance scans were all performed by the imaging
department at The Heart Hospital. I retrospectively analysed the images and data. Another research
fellow Dr Joel Salazar also independently measured the aorto septal angles for the purpose of
assessing inter-observer variability.1.3.3 Myectomy imaging study
I recruited patients from the Heart Hospital, and transported them to Great Ormond Street Hospital
where the CT scans were performed by myself and Professor Andrew Taylor, and Dr Claudio Capelli
reconstructed the CT images. The cardiopulmonary exercise tests and echocardiograms in these
patients were performed by Dr Bryan Mist and the imaging department respectively as part of their
routine clinical care at The Heart Hospital. I analysed the resulting data.
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2 Introduction
2.1 Definition and classification of the cardiomyopathies
Cardiomyopathies are myocardial disorders in which the heart is structurally and functionally
abnormal, in the absence of coronary artery, congenital or valvular heart disease, or hypertension
sufficient to cause the observed myocardial abnormality (1). Cardiomyopathies are classified into
four main subtypes, based on ventricular morphology and physiology; HCM is defined as left
ventricular hypertrophy in the absence of abnormal loading conditions sufficient to explain the
degree of hypertrophy (1). HCM is the commonest inherited cardiac disease, with a population
prevalence of approximately 1 in 500 (2).
2.2 Genetics and associated syndromes
In one half to two thirds of individuals, HCM is inherited as an autosomal dominant trait caused by
mutations in cardiac sarcomeric protein genes (3-5). The commonest are ß-myosin heavy chain, cardiac
troponin T, cardiac troponin I, -tropomyosin, cardiac myosin binding protein C, the essential and
regulatory myosin light chains, and cardiac actin. Other genes, such as those encoding -myosin, titin
and proteins of the Z-disc, account for less than 1% of cases (6).
Given the extent of genetic heterogeneity and the variable effect of different mutations, it is not
surprising that HCM is characterised by marked heterogeneity in disease severity and outcomes. Clinical
manifestations of identical mutations are highly variable, even within the same family, indicating that
other genetic and possibly environmental factors influence disease expression (7).
A number of malformation syndromes and other conditions, many of which present in childhood,
are associated with HCM. These include Noonan (8-10)and LEOPARD (11) syndromes, Anderson-
Fabry disease (X-linked dominant lysosomal storage disorder) (12), Danon disease (13-15) , Pompe
disease (glycogen storage disease type IIa) (16,17), primary respiratory chain diseases (18,19) and
Friedreich’s ataxia (20,21).
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2.3 Mitochondrial mutations and hypertrophic cardiomyopathy
Mitochondrial diseases are a group of maternally inherited conditions with a variety of phenotypes.
Increasingly mitochondrial mutations are recognised as being associated with cardiomyopathy,
which may be hypertrophic in nature (22). Mitochondria are essential components of cellular
respiration, and mitochondrial disorders are often associated with profound effort intolerance as a
result of skeletal and respiratory muscle abnormalities. Patients with HCM who display these
symptoms in excess of the apparent cardiac phenotype can be considered for further assessment to
explore the possibility of mitochondrial disease. A raised serum creatinine kinase is a simple
investigation which can be suggestive. More specialised tests include electromyography and skeletal
muscle biopsy, both of which have been found to be abnormal in some patients with HCM (23). A
morphological study of 9 HCM patients found mitochondria were significantly greater in number and
smaller in size than in controls (24). In a murine HCM model, mitochondrial mutations are associated
with cellular respiratory abnormalities, which therefore may contribute to haemodynamic
dysfunction (25). In addition, HCM phenotypic expression in an individual with a causal sarcomeric
mutation may be influenced by additional ‘modifier’ mutations and/or environmental factors, which
can include mitochondrial mutations (26). This may be important in the interpretation of the
relationship between oxygen consumption (VO2) and work. Abnormal peripheral muscle oxygen use
could affect the ‘gross’ measurement of oxygen consumption, and also relatively little work may be
performed for a given VO2. Further evidence for abnormal myocardial metabolism was observed by
an increased lactate production and higher myocardial oxygen consumption in HCM patients with
LVOT obstruction during atrial pacing (27), and by a greater fall in coronary sinus pH during
dipyridamole stress in HCM compared to normal controls (28). It is not known whether
mitochondrial abnormalities were present in these studies.
When studying exercise physiology in a patient population with HCM, the absence of genotyping
data (as in my cohort) can potentially therefore make interpretation of haemodynamic data more
challenging. An observed abnormality during cardiopulmonary exercise testing may for example be
influenced by cellular respiration and skeletal muscle function in addition to gross cardiac
dysfunction. No patient had an elevated serum creatinine kinase to suggest an underlying muscle
disorder, although this does not exclude a problem as levels typically fluctuate.
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2.4 Pathology of hypertrophic cardiomyopathy
The hypertrophic phenotype may vary with the underlying genetic aetiology. The most common
appearance is asymmetric septal hypertrophy (ASH), but any pattern of ventricular hypertrophy can
be seen, including eccentric, concentric and apical. The classical form originally described in 1958 by
Sir Donald Teare of St George’s medical school has left ventricular basal anterior septal hypertrophy,
which bulges into the LVOT causing obstruction to blood flow. A pathological specimen is shown in
figure 2.1. Hypertrophy may not be confined to the basal segments; mid-cavity obstruction may be
associated with a figure of eight left ventricular configuration, possibly due to high systolic pressures
forcing the thinner apical region outwards. This can be associated with aneurysmal dilatation and
thrombus formation. Apical HCM was originally thought to be a more benign variant, although is
now undifferentiated from other forms in contemptoray risk stratification. The papillary muscles are
often anteriorly displaced, and may be multiple, with abnormal insertion into the mitral valve.
Primary mitral valve abnormalities are very common, particularly elongated (anterior) leaflets. If
LVOT obstruction is present, endocardial thickening may be seen at the point of mitral valve-septal
contact, known as a contact lesion. Right ventricular hypertrophy is also seen in a significant number
of cases, although when seen should prompt exclusion of other infiltrative conditions.
Microscopically, HCM is characterised by myocyte hypertrophy and disarray, interstitial fibrosis and
expansion of the interstitial compartment (29,30), figure 2.1. Small intramural coronary arteries are
often dysplastic and narrowed due to wall thickening by smooth muscle cell hyperplasia (31). These
changes are not confined to areas of hypertrophy, but may be found in apparently macroscopically
normal myocardium. Differing microscopic features have no prognostic significance, although
extensive fibrosis is associated with a poorer outcome. Myocyte disarray is absent in some other
common causes of ventricular hypertrophy such as hypertensive or aortic stenotic heart disease and
so may be a useful diagnostic feature.
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Figure 2.1. Transverse section of both ventricles at the mid-septal level from a patient with
hypertrophic cardiomyopathy (30).
A. The hypertrophy involves both the free and septal walls of the left ventricle with marked
asymmetric thickening of the septum. B. Apical variant of HCM.
Figure 2.2. Photomicrograph of myocytes from a patient with familial hypertrophic
cardiomyopathy (30)
Normal parallel arrangement of myocytes has been replaced with myocyte disarray and increased
connective tissue.
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2.5 Clinical features of hypertrophic cardiomyopathy2.5.1 Physical examination
The cardiovascular examination in most patients is normal. In some, the jugular venous pulsation
may have a prominent ‘a’ wave, caused by reduced right ventricular compliance. The left ventricular
impulse is typically sustained, or double, reflecting an atrial impulse followed by left ventricular
contraction. LVOT obstruction causes a rapid up and downstroke to the arterial pulse, occasionally
followed by a palpable reflected wave, resulting in a bisferiens pulse. On auscultation, LVOT
obstruction causes a harsh ejection systolic murmur at the left sternal edge, which increases in
intensity during strain phase of the Valsalva or when standing from the squatting position. Most
patients with LVOT obstruction also have mitral regurgitation (caused by abnormal coaptation of the
mitral valve leaflets during systole). This causes a pansystolic, high frequency murmur at the apex,
radiating to the axilla. A third or fourth heart sound is common.2.5.2 Natural history
HCM can present at any age, from infancy to old age (32). Many patients follow a stable and benign
course, with a low risk of adverse events. In some series, HCM is the most common cause of sudden
death in young people (33,34) but the majority of patients are asymptomatic and therefore often
remain undiagnosed. Long-term, many patients develop progressive heart failure symptoms caused by
a gradual deterioration in left ventricular function. This so-called “end-stage” is characterised by severe
impairment of contractile performance and is associated with a poor prognosis (35). Diastolic function
is impaired in the majority of patients and may in some individuals resemble restrictive
cardiomyopathy (36).2.5.3 Sudden cardiac death
HCM is one of the commonest causes of sudden cardiac death in the young. Most contemporary
studies report an annual incidence of sudden death in HCM populations of 0.5-1% per year, rising to
2% or higher in certain groups (37-42). The mechanism of sudden cardiac death is rarely
documented. Factors that contribute to a propensity to ventricular arrhythmia include: dispersion of
repolarisation which increases susceptibility to triggered arrhythmias; myocyte disarray and areas of
conduction block which predispose to re-entry arrhythmias; and abnormal ion fluxes causing after-
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depolarisations and triggered activity. Other morphological and physiological factors may influence
the vulnerability of the underlying substrate, such as myocardial ischaemia, LVOT obstruction and
diastolic dysfunction.
2.5.4 Heart Failure
End-stage HCM develops at all ages, but in the majority of patients, the time from onset of heart
failure symptoms to diagnosis of severe systolic impairment is about 10-15 years (35). The
development of severe systolic heart failure is associated with a poor prognosis, with rapid
progression to death or transplantation and an overall mortality rate of up to 11% per year (35). The
prevalence of severe systolic impairment in HCM using conventional echocardiographic criteria
ranges from 2% to nearly 10%, with an annual incidence of less than 1% (35,43). However, the true
incidence of systolic left ventricular impairment may be much higher as clinically significant
reductions in systolic performance may occur while the measured ejection fraction remains within
the normal range on account of the hypertrophied myocardium and small left ventricular cavity.
2.5.5 Stroke
The annual incidence of stroke varies from 0.56%-0.8%/year rising to 1.9% for patients in patients
>60 years old (44). The major cause is atrial fibrillation (AF) which affects about a quarter of HCM
patients, with an incidence of up to 3% per annum (45,46). A meta-analysis by Guttmann et al
showed the prevalence of AF in HCM to be 22.5%, and in those patients the prevalence of
thromboembolism was 27.1% (46). The odds ratio for stroke in AF patients is 17.7 (95% CI, 4.1 to
75.9; P=0.0001; 23% of strokes are fatal (44)). Risk factors for AF include age and left atrial dilation (a
consequence of diastolic dysfunction, LVOT obstruction and mitral regurgitation) (45,46).
2.5.6 Infective endocarditis
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Patients with obstructive HCM have an increased risk of developing infective endocarditis, usually on
the anterior mitral valve leaflet (47). The incidence of infective endocarditis is 1.4 per 1000 person-
years (95% CI, 0.5 to 3.2) (3.8 per 1000 person-years (95% CI, 1.6 to 8.9 in patients with obstruction),
compared with 1.7 – 6.2 cases per 100,000 years in the general population (48).
2.6 Diagnosis of Hypertrophic Cardiomyopathy
2.6.1 Electrocardiography
The resting 12-lead electrocardiogram (ECG) is abnormal in 95% of patients with HCM. The
commonest abnormalities are ventricular hypertrophy, repolarisation abnormalities, pathological Q
waves and left atrial enlargement. Giant negative T waves in the mid-praecordial leads are
characteristic of apical HCM (49), figure 2.3. A short PR interval without ventricular pre-excitation is
common. Atrioventricular conduction delay (including first-degree block) is rare except in particular
subtypes of hypertrophic cardiomyopathy (e.g. PRKAG2 mutations and mitochondrial disease)
(50,51).
Figure 2.3. Twelve lead electrocardiogram from a patient with apical hypertophic cardiomyopathy
Note marked left ventricular hypertrophy and giant negative T waves in the praecordial leads.2.6.2 Echocardiography
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The diagnosis of HCM relies on the demonstration of a maximal left ventricular wall thickness (MWT)
more than two standard deviations from the normal (typically ≥13mm in an adult) (52), figure 2.4. 
The hypertrophy is typically asymmetric, involving the interventricular septum more than other
segments, but any pattern of left ventricular hypertrophy including concentric , eccentric, distal and
apical is consistent with the diagnosis of HCM (53-56).
Figure 2.4. Parasternal long axis echocardiographic view from a patient with hypertrophic
cardiomyopathy
Note marked hypertrophy of the inter-ventricular septum (arrowed)
Left ventricular systolic function assessed from changes in ventricular volume during the cardiac
cycle, is typically increased, but regional and long-axis function is usually reduced (57). A proportion
of adults with HCM develop progressive myocardial thinning, global left ventricular systolic
impairment and cavity dilatation (35). Characteristically, patients with HCM have diastolic left
ventricular impairment demonstrated by reduced early diastolic (Ea) velocities in the mitral annulus
and septum and reversal of the ratio of early to late diastolic velocities (Ea/Aa). Abnormalities of the
mitral valve and its apparatus are extremely common in HCM, and are readily assessed using
echocardiography.
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2.6.3 Cardiac Magnetic Resonance Imaging
CMR provides a detailed assessment of cardiac morphology as well as accurate assessment of
systolic function. It also permits tissue characterisation, particularly detection of myocardial scarring
by the assessment of delayed gadolinium enhancement. Many patients with HCM have areas of
patchy gadolinium hyper-enhancement and studies suggest that the extent of gadolinium
enhancement correlates with risk factors for sudden death and with progressive left ventricular
remodelling (58,59).2.6.4 Cardiac Catheterisation
Left and right heart catheterisation is rarely necessary to make a diagnosis of HCM. The main
indications are exclusion of coronary artery disease and much less commonly assessment of cardiac
output, filling pressures and intraventricular pressure gradients in patients with severe symptoms.
Endomyocardial biopsy is occasionally indicated when an infiltrative or metabolic disease such as
amyloidosis, or Anderson-Fabry disease is suspected.2.6.5 Ambulatory ECG Monitoring
Ambulatory electrocardiographic monitoring is important in the assessment of symptoms and in the
prediction of arrhythmic risk. Non-sustained ventricular tachycardia (VT) occurs in approximately
one fifth of adults with HCM. Most episodes are relatively slow, asymptomatic, and occur during
periods of increased vagal tone. In contrast, sustained VT is uncommon, and may occur in
association with apical aneurysms (60). Paroxysmal supraventricular arrhythmias occur in 30-50% of
patients; sustained AF is present in 5% of patients at diagnosis, and develops in a further 10% in the
subsequent 5 years (45,61).
2.7 Clinical management of hypertrophic cardiomyopathy
23
The treatment of most patients with HCM focuses on the counselling of family members, the
management of symptoms, and the prevention of disease-related complications. Exceptions include
lysosomal storage diseases, such as Pompe and Anderson Fabry disease where specific therapies are
available.2.7.1 Genetic counselling and evaluation of families
All patients with HCM should be counselled on the implications of their diagnosis for other family
members (34). Analysis of carefully constructed family pedigrees can reassure relatives who are not
at risk of inheriting the disease (figure 2.5).
Figure 2.5. Example of a pedigree from a family with a history of hypertrophic cardiomyopathy
HCM – hypertrophic cardiomypathy, LVH – left ventricular hypertrophy.
Circles – female, squares – male, line through shape – dead, white shape - unaffected
For those who are at risk, current guidelines recommend screening with a 12-lead ECG and
echocardiogram at intervals of 12-18 months, usually starting at the age of 12 years, unless there is a
family history of premature sudden death, the child is symptomatic or a competitive athlete, or
there is a clinical suspicion of left ventricular hypertrophy, until full growth and maturation is
achieved (34). Thereafter, if there are no signs of disease expression, clinical screening should be
performed every five years, as left ventricular hypertrophy can develop well into adulthood.
Modified diagnostic criteria that take into account the high probability that otherwise unexplained
ECG and echocardiographic findings in first-degree relatives reflect incomplete disease expression
should be used when evaluating other family members.
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When genetic testing is available, affected individuals should be counselled on the purpose of the
test, the likely mode of inheritance, and the potential hazards and limitations of genetic testing.
These include:
 Psychological consequences of a test result, for example:
o Anger
o Depression
o Guilt
o Change in family relations / dynamics
 Financial consequences of a test result, for example increased insurance premiums
 Possibility of discrimination
 Inability of a test to predict the natural history of the condition
 Genetic abnormalities of uncertain clinical significance
 Potential lack of treatment strategy once a diagnosis has been made2.7.2 Symptom management
In patients with symptoms caused by LVOT obstruction, the aim of treatment is to reduce the
outflow tract gradient. Typically, symptoms include chest pain, syncope or pre-syncope and
breathlessness. These are, of course, also seen in patients with HCM without LVOT obstruction.
Clues to help discrimate include symptoms made worse by exertion (particularly of sudden onset
such as running for a bus), dehydration, any form of Valsalva, alcohol and eating are more commonly
seen with LVOT obstruction. Patients often report symptoms which initially occurred in early
adulthood, and may have adapted their lives to cope wih them. Options for treatment include
negatively inotropic drugs (ß-blockers, disopyramide and verapamil), atrio-ventricular sequential
pacing, percutaneous alcohol septal ablation of the inter-ventricular septum and surgery. This will be
discussed in more detail later.
Approximately 60 to 70% of patients improve with medical therapy but high doses are frequently
required and side effects are common (34). Dual-chamber pacing using a short-programmed atrio-
ventricular delay to produce maximum pre-excitation while maintaining effective atrial function can
reduce the outflow gradient by 30 to 50%, but provides little objective improvement in exercise
capacity in most patients (62). Selective injection of alcohol into a septal branch of the left anterior
descending coronary artery to create a localised septal infarction can be effective, but is associated
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with atrio-ventricular block requiring a pacemaker in 5-20% of patients and is unsuitable for all
patients because of variation in coronary artery anatomy and co-existent mitral valve abnormalities
(63).
Surgery is considered in patients with significant outflow obstruction (gradient >50 mmHg) and
symptoms refractory to medical therapy. The most commonly performed surgical procedure,
ventricular septal myectomy, substantially reduces the gradient and improves exercise capacity and
symptoms. In experienced centres, mortality rates are less than 1% and complications such as atrio-
ventricular block and ventricular septal defects are rare (64).
Therapeutic options in patients without LVOT gradients are limited predominantly to
pharmacological therapy. ß-blockade, calcium antagonists such as verapamil and diltiazem can
relieve chest pain and dyspnoea. In patients with paroxysmal nocturnal dyspnoea and chronically
raised pulmonary pressures diuretics can be effective, but the dose and duration of therapy should
be minimised particularly in patients with severe diastolic impairment or labile obstruction. At
present, pharmacological therapy of systolic heart failure in HCM is initiated only when patients
develop symptoms and a low ejection fraction. The drugs used (ACE inhibitors (or angiotensin
receptor blockers), ß-adrenoreceptor blockers, diuretics and digoxin) are identical to those
employed at an earlier stage in patients with dilated cardiomyopathy. In HCM, the benefit of
treatment at this later stage is unknown, but it may not substantially improve prognosis.2.7.3 Management of atrial arrhythmia
Anticoagulation should be considered in all patients with sustained or paroxysmal AF (46).
Treatment with amiodarone is effective in maintaining sinus rhythm and in controlling the
ventricular response during paroxysmal episodes. The addition of a low-dose ß-blocker, verapamil or
diltiazem may be required for rate control. In general, the principles of managing AF in patients with
HCM are similar to those in other conditions, with the proviso that the threshold to use
anticoagulation should be lower.
2.7.4 Prevention of sudden cardiac death
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The published annual incidence of sudden cardiac death in patients with HCM has declined from
between 2-4% to 1% or less (65,66). The reasons for this change are complex and relate not only to
medical intervention but also to the identification of patients with milder disease. Sudden cardiac
death occurs throughout life with a maximum incidence in adolescence and young adulthood, often
without warning signs or symptoms (67). Although there is an excess of deaths during or after
strenuous exertion, most occur during mild exertion or sedentary activities (34). The mechanism
underlying most sudden cardiac deaths is thought to be ventricular tachyarrhythmia, but conduction
disease and thrombo-embolism may account for some cases (34). Rapid AF and myocardial
ischaemia appear to be important triggers for sudden ventricular arrhythmia (68).
Although sudden death rates are generally low, when it occurs it is often without warning in young
and often mildly symptomatic patients. There is therefore a need to accurately identify high risk
patients. This is challenging because of the different aetiologies of HCM, a heterogeneous clinical
phenotype and evolution of the arrhythmogenic substrate with time. Nevertheless, traditionally a
high risk cohort were identified using a small number of readily determined clinical parameters
(table 2.1) (34,69).
Table 2.1 – ‘Traditional’ risk factors for sudden death in hypertrophic cardiomyopathy
Ventricular tachycardia Sustained or non-sustained on Holter ECG
Familial sudden hypertrophic
cardiomyopathy-related death
(particularly in a first degree relative and/or
multiple in
occurrence)
Syncope one or more episode, and particularly if
recurrent, exertional, or in the young
Abnormal blood pressure response with
exercise
a fall or sustained failure to rise ≥20 mm Hg 
during exercise or recovery
Extreme left ventricular hypertrophy maximum left ventricular thickness ≥30 mm 
from echocardiogram
The risk associated with individual risk factors is cumulative (70). Prior to 2014, the presence of two
or more conventional risk factors prompted consideration of an implantable cardioverter
defibrillator (ICD), as patients with 2 risk factors have a 4% to 5% annual risk of sudden cardiac
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death (34,71). More problematic are patients that have only a single risk factor (up to 25% of
patients). When assessing the need for ICDs in this group, age, symptoms and the presence of so
called ‘minor’ risk factors such as LVOT obstruction were taken into account and balanced against
the risk of complications of ICD therapy, particularly in young people (69). These factors are all taken
into account in contemporary risk stratification, which uses a sophistiscated algorithm (which can be
accessed online) to predict 5 year sudden cardiac death risk (70).
Patients with HCM and risk factors should refrain from intense exercise. This of course has significant
implications for many patients, underlining the importance of accurate diagnosis.
2.7.5 Role of electrophysiological testing in HCM
Current guidelines suggest that electrophysiological testing might have a role in some borderline
cases (72), but 36% percent of patients have inducible sustained VT (73). VT induced by aggressive
protocols may be associated with a higher risk of cardiac events but as the predictive accuracy for
sudden death is very low routine use of electrophysiology testing is not recommended (73). One
study has suggested that paced ventricular electrogram fractionation may have greater value for
predicting sudden cardiac death than conventional invasive criteria or the non-invasive risk factors,
but the exact role of this technique requires corroboration in larger populations (74).
2.7.6 Exercise testing in HCM
Cardiopulmonary exercise testing is an important part of the assessment of patients with HCM,
providing information on clinical status as well as influencing risk assessment (75,76). It should be a
part of the assessment of all new patients attending cardiomyopathy clinic, whether as part of a
screening process or in patients with proven disease. Subsequent testing will depend on clinical
status: any change in symptomatology, response to drug or outflow tract gradient reduction
therapy; transplant assessment; or simply to assess progress over time should all include
quantification of exercise tolerance using cardiopulmonary exercise testing.
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There are various modes of exercise that can be employed when testing. Simple methods may be
designed predominantly to identify provocable LVOT gradients, such as postural manoeuvres, hand-
grip exercise and dobutamine infusion. Other modalities designed to better simulate physiological
stress in normal life include bicycle ergometer (both upright and supine) and treadmill. Bicycle
ergometer studies have the advantage that it is practically easier to make multiple blood pressure
recordings, record accurate ECG tracings, quantify power output (measurement of watts) and is
generally better accepted by patients, many of whom are not used to treadmills.
Any mode of exercise testing where the aim is to assess maximal oxygen uptake should utilise large
muscle groups, and be amenable to performance without prior training which may influence the
results achieved. It should avoid undue pressor effects of isometric exercise. In the majority of cases
the test should begin with submaximal exercise to allow physiological adaptation; the exception to
this is the attempt by a clinician at provocation of a latent LVOT gradient by sudden near maximal
effort. The physician and physiologist must determine an individual patient’s ability to perform any
such test so that diagnostic information is captured. Upright, symptom limited exercise testing is
safe in HCM and acceptable to patients. It provides a quantitative assessment of a patient’s exercise
tolerance, particularly when combined with metabolic functional testing.
2.8 Exercise physiology in hypertrophic cardiomyopathy
Patients who do not report symptoms are often found to have sub-optimal exercise tests when
objectively measured and exercise capacity is not well predicted in HCM from conventional markers
such as magnitude of left ventricular hypertrophy or peak LVOT gradient (75,77,78). Exercise
intolerance is common in HCM, although the exact mechanisms in each individual are likely to vary.
A number of variables have been shown to be of importance, including myocardial ischaemia,
diastolic dysfunction, chronotropic incompetence, ventilation perfusion mismatch, an inability to
augment cardiac output on exercise, and LVOT obstruction, each of which will be discussed.
Determining the interplay of these factors in a patient is challenging. LVOT obstruction is often
targeted to reduce symptoms, although a significant number of patients continue to experience
symptoms even after successful gradient reduction therapy. This is likely due to the complex
interaction of these variables. A number of physiological parameters have been studied in HCM with
varying degrees of success and importance. However, most of this work, particularly during exercise,
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dates from the 1990s or earlier. In particular, the majority of invasive haemodynamic studies are
over two decades old. Perhaps this is in part explained by the difficulties in investigating such
dynamic variables. There has also been an increased focus on underlying genetic mechanisms behind
the disease, risk management, and treatment. In addition, the numbers of patients studied with
significant LVOT obstruction in most studies investigating exercise physiology in HCM is small, and
the modes used to investigate them often invasive with technical limitations (discussed later).
HCM is a common condition, and prevalence of obstruction is high. There is a need to characterise
haemodynamic responses to exercise in a larger number of patients. Current practice in many
medical specialities often aims to use non-invasive alternatives to traditional invasive techniques,
and there have been technological advances in non-invasive haemodynamic monitoring which have
not been applied to this population. The large population of patients seen at the Heart Hospital with
HCM, and the availability of non-invasive haemodynamic monitoring make this an ideal environment
to add to the research literature. It is clear that despite attention to treatment of LVOT obstruction,
a significant number of patients remain functionally limited. There is therefore the need for a
greater understanding of the physiological basis for symptoms, which may then translate to
improvement in treatment.
2.8.1 Oxygen consumption
Peak VO2 is routinely measured in patients as an objective assessment of cardiovascular and
respiratory performance. Individuals with HCM usually have a reduced peak oxygen consumption
and a lower anaerobic threshold compared with healthy age-matched controls (75,79-81).
Additionally, some neuromuscular conditions are associated with a hypertrophic cardiomyopathy
phenotype. Some sarcomere protein gene mutations are expressed in skeletal muscle and could
conceivably affect exercise performance, via reduced peripheral oxygen extraction and anaerobic
threshold.
In Sharma’s study of 135 patients with HCM, 98% were limited to a peak VO2 <80% predicted, and
less than 1.5% of patients achieved more than their predicted value (75). Increasing New York Heart
Association (NYHA) functional class was loosely correlated with peak VO2. The independent
determinants of functional limitation were LVOT obstruction, abnormal blood pressure response
(ABPR) and chronotropic incompetence.
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It is well recognised that patients with HCM who claim they are asymptomatic often have an
objective impairment in VO2 when assessed (81). Recent retrospective data from 182 minimally
symptomatic patients with obstructive HCM have suggested an association between impaired peak
VO2 and prognosis (82). The severity of LVOT obstruction and percent predicted peak VO2 were
identified as independent predictors of death and severe symptoms (NYHA III or IV), suggesting
closer follow up of patients with poor exercise tolerance may be necessary. Furthermore, they
identified cut off values that predicted adverse events (table 2.2). To my knowledge most studies do
not report the amount of exercise performed by patients with HCM, and therefore the effect of
detraining on haemodynamics and oxygen consumption is unknown.
Table 2.2. Risk stratified by oxygen consumption in hypertophic cardiomyopathy (82)
% predicted VO2 Risk 4-year event free survival (%)
>80 Low 85.4
60-80 Moderate 67.2
<60 High 58.5
Frenneaux et al investigated the relationship between haemodynamic indices measured invasively
and respiratory gas analysis in 23 patients with HCM (8 with LVOT obstruction) (81). Maximal oxygen
consumption was reduced in 11 of 13 patients who were in NYHA class I and who denied limitation
of exercise capacity and in all 10 patients who were in functional class II or III. Haemodynamic results
of this study are discussed in the appropriate sections.
Jones et al investigated the exercise VO2 response of 50 patients with HCM (11 with resting LVOT
obstruction) using cycle ergometry and respiratory gas analysis (79). They demonstrated a reduction
in peak VO2 and anaerobic threshold. Specifically, 59% of patients achieved less than 60% peak VO2
and only 2 patients >80%. The anaerobic threshold was <60% predicted in 31 patients and >80% in
only 3 patients. The slope of the oxygen uptake/ work rate relationship (a major determinant of the
subject’s aerobic efficiency) was decreased in 16 patients (32%). The maximum oxygen pulse
(numerically equivalent to VO2 / heart rate, or the product of stroke volume x arterio-venous (A-V)
oxygen difference) was reduced as a percentage of the predicted value, and became flat at high
work rates in 32 patients. There was a significant correlation between anaerobic threshold and peak
VO2, work efficiency (the slope of increase in VO2 as a function of work rate) and maximum oxygen
pulse. The slope of change in ventilation against change in carbon dioxide output (VE / VCO2) for the
sub-anaerobic threshold range was increased in 36 patients (72%) and was inversely correlated with
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anaerobic threshold. The authors concluded that exercise intolerance in HCM could be caused by
failure of stroke volume augmentation, ventilation perfusion mismatch and abnormal peripheral
oxygen utilisation. No further differentiation between these possibilities could be made from their
data.
Sharma et al demonstrated an additional impairment to maximal VO2 in HCM patients with an ABPR
to exercise than those without (75). These findings have also been demonstrated in smaller numbers
by Ciampi (ABPR 63% ±11% vs 78% ±15%) (83).
In patients with non-obstructive HCM, VO2 and minute ventilation / carbon dioxide ratio (VE /
VCO2) at peak exercise correlate modestly (negative and positive respectively) with resting
haemodynamics including pulmonary artery systolic, diastolic and mean pressures and pulmonary
capillary wedge pressure (84).
2.8.2 Blood pressure response to exercise
An ABPR to exercise has been seen in approximately one third of HCM patients, is associated with an
increased risk of sudden cardiac death (37,85-88) and makes up part of contemporary risk
stratification algorithms (34). Several researchers have noted those with ABPR tend to be younger
(83,87,88). A normal blood-pressure response is usually defined as a gradual increase of at least 20
mm Hg in systolic blood pressure during exercise. An ABPR may take one of several forms: an
increase or decrease in systolic blood pressure during exercise < 20 mm Hg compared with baseline;
an initial increase in systolic blood pressure with a subsequent fall >20 mm Hg compared with peak
blood-pressure value; a continuous decrease in systolic blood pressure throughout the exercise test
>20 mm Hg compared with baseline (85-88). These last two conditions are termed “hypotensive
blood pressure response,” while the first condition represents a flat response.
There are a variety of explanations for this, including abnormal vasodilatation of non-exercising
vascular beds triggered by inappropriate firing of left ventricular baroreceptors (85) and abnormal
cardiac output responses (83,89), which itself has several explanations, including ischaemia and
LVOT obstruction (90-93).
A recent study by Heffernan et al investigated the correlation between pulse pressure (arterial
systolic minus diastolic blood pressure) and an ABPR to exercise (94). Interestingly they found in a
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group of 70 patients with HCM that pulse pressure at rest was significantly greater in patients who
went on to demonstrate an ABPR (n = 19) than in the patients without an ABPR to exercise. There
was no difference in systolic, diastolic or mean arterial pressure (MAP) between the groups. Those
within the greatest tertile of pulse pressure at rest were 4.8 times more likely to have an ABPR than
those within the lowest tertile (95% confidence interval 1.24 to 18.2, p <0.05). In their study there
was no difference in pulse pressure or ABPR rates between obstructive and non-obstructive groups.
They proposed that this may be a useful tool to identify those patients who may have an ABPR.
The increased pulse pressure was felt to be a manifestation of increased arterial stiffness and
augmented pressure from wave reflections, both of which have the effect of increasing cardiac
energetic demand, reducing myocardial oxygen supply / consumption, reducing sub-endocardial
perfusion (95) impairing cardiac systolic and diastolic function, and blunting stroke volume (96). In
patients with HCM in whom these abnormalities often exist, it may be difficult to determine cause
and effect.
Patients with HCM have been shown to have greater arterial stiffness than controls, particularly in
the setting of associated myocardial fibrosis (97). The underlying reason is uncertain, although may
relate to abnormal endothelial function. This is discussed in more detail in section 6.2.4. This group
demonstrated age and aortic stiffness (assessed using MRI) to be independently associated with
maximal VO2 (98). It seems reasonable then that a wide pulse pressure in patients with HCM reflects
increased aortic stiffness, and thus a propensity to ABPR and impaired exercise capacity for all the
reasons cited above. What is less easily explained by this theory is the increased incidence of ABPR
in young people, when aortic stiffness should be a phenomenon associated with older age.
Traditional markers of ‘severity’ seen in younger patients with ABPR could be associated with an
increased aortic stiffness.
An increase in arterial stiffness in the vasculature containing baroreceptors (shown in hypertension
and aortic stenosis) could explain the reduction in sensitivity to afferent arterial pressure stimuli in
HCM patients with ABPR. This would result in a reduction of baroreceptor afferent firing per given
unit of arterial pressure change, less inhibition of sympathetic outflow (altering peripheral vascular
tone), and lessened amplification of cardiac vagal tone (altering left ventricular contractility) (99).
Thaman et al demonstrated a lower resting baroreflex sensitivity and exaggerated changes in
baroreflex sensitivity during lower body negative pressure in a group of HCM patients with high
prevalence of ABPR (100). It seems plausible then that in the presence of baroreceptor dysfunction,
autonomic control of vascular function should also be impaired and contribute to ABPR to exercise.
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Yoshida et al found evidence of sub-endocardial ischaemia during exercise in patients with HCM
(90). They used left ventricular cavity dilatation measured using thallium-201 scintigraphy after
exercise as a marker of sub-endocardial hypoperfusion and found a higher prevalence in those with
an abnormal compared to those with normal blood pressure response (47.1 vs. 10%, p < 0.0002). On
multivariate logistic regression left ventricular cavity dilatation was independently associated with
ABPR (odds ratio 3.76, 95% confidence interval 1.61 to 8.76). Sub-endocardial ischaemia could
contribute to a worsening of systolic performance on exercise and the resulting ABPR (91-93).
Ciampi felt the reasons for an ABPR to exercise were a cascade beginning with systolic impairment
due to an inability to tolerate an increased end systolic volume, then a reduction in cardiac output
which then manifests as a hypotensive response (83). These authors felt the observed responses
were consistent with myocardial ischaemia.
Kim demonstrated an improvement in exercise capacity and ABPR when LVOT obstruction was
abolished by ASA (101) suggesting the cavity gradient may have a role in the blood pressure
response. In their group 9 patients with an ABPR had this resolved following treatment. 17 of their
20 patients demonstrated a symptomatic improvement with an increase in exercise duration and
VO2.2.8.3 Myocardial perfusion and ischaemia
Evidence for myocardial ischaemia during dipyridamole stress has been demonstrated in HCM
patients by invasively monitoring changes in coronary sinus pH (28). This study demonstrated a
larger fall in pH in HCM patients symptomatic with chest pain. There was a correlation between
maximal pH change and higher heart rates upon stress. Myocardial ischaemia has also been
demonstrated by lactate production during atrial pacing (27). In this study, those with resting LVOT
obstruction had higher myocardial VO2, lower coronary resistance and higher basal coronary flow
than those without obstruction. Interestingly in both groups there was evidence of symptomatic
myocardial ischaemia beyond heart rates of 130 beats / minute, with exhaustion of transmural
coronary flow reserve in those with LVOT obstruction. In the non-obstructive group, evidence of
ischaemia occurred at lower coronary flow rates with lower myocardial VO2, suggesting a lower
threshold to symptoms upon stress. Marked elevation in filling pressures were noted in both groups.
Perfusion defects on nuclear imaging, both fixed and reversible, are common amongst patients with
HCM in the absence of stenotic coronary disease (90,91). In the study by Yamada et al fixed
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perfusion defects detected during dipyridamole stress in patients with HCM were associated with
syncope, larger LV cavity dimensions and reduced exercise capacity (91).
Abnormalities of coronary vasodilatation have been demonstrated in HCM compared with controls
using positron emission tomography to assess regional myocardial blood flow after pharmacological
dilation using dipyridamole (102). Resting blood flow was similar between groups. Although a
reduction in coronary resistance was seen in all groups, this was significantly less in those with HCM,
which was also associated with a history of chest pain.
2.8.4 Left ventricular systolic function and cardiac output
Accurate measurement of left ventricular systolic function is notoriously difficult in routine clinical
practice, yet is an important determinant of exercise capacity in health. It has been the focus of
extensive research in HCM. Pump function must be sufficient to supply exercising muscles with
sufficient blood and oxygen to perform work, and to the respiratory muscles to allow efficient
respiration. In non-obstructive HCM, a reduction in systolic performance was observed in about half
of patients in a study using continuous ventricular monitoring with a cadmium telluride detector
(CdTe-VEST) (92). Systolic dysfunction was not related to the degree of septal hypertrophy. These
findings were replicated by Okeie et al, who also demonstrated regional wall motion abnormalities
in hypertrophied segments on dobutamine stress in the absence of coronary disease (93).
Ciampi et al demonstrated a difference in end systolic volume (using nuclear scintigraphy) on
exercise between HCM patients with and without ABPR to exericse (83). In those with a normal
response, end systolic volume increased less. Both groups were noted to have a reduction in
ejection fraction on exercise, with a greater fall in the ABPR group. In their small (ABPR = 8, NBPR =
14) group of patients, there was a small increase in stroke volume on exercise in the NBPR group,
and a fall in the ABPR group (3% ±28% and -21% ±21% respectively). Their nuclear data were
however averaged over 60 second intervals, and taken at baseline, 3 minutes of exercise and peak
exercise only. This infrequent sampling rate is inadequate to monitor physiological changes during
an exercise test. Similarly, cardiac output response to exercise was shown to be an increase of 94% ±
44% in the NBPR group and only 49% ±44% in ABPR group. This implies augmentation of heart rate
to be the mechanism for an increase in cardiac output in the ABPR group.
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The same group had previously shown a statistically significant increase in ejection fraction and
stroke volume in control subjects compared with the reverse in HCM (89). Overall HCM patient’s
stroke volume fell by 5% ± 27% relative to baseline. When subdivided into NBPR and ABPR groups,
stroke volume increased in the former and fell in the latter (2 ±27% and -18±21% over baseline).
Cardiac output increased on exercise in both groups, although significantly more in controls (132% ±
70% vs 78% ± 50% compared with baseline). Heart rates have been shown to rise appropriately in
HCM patients on exercise both with and without ABPR (83,89).
Frenneaux et al showed a significant correlation between peak exercise cardiac index (measured
using Fick method) and the change in index from baseline with maximal VO2 (81). There was no
correlation with diastolic parameters (discussed in the relevant section) and the authors concluded
that cardiac output was a major determinant of exercise capacity but that the role of diastolic
function and other parameters required further investigation.
Jones et al investigated the relationship of gas exchange indices during incremental exercise in
patients with HCM. They found a low maximum value of oxygen pulse and felt this was consistent
with the failure to continue to increase stroke volume during exercise (79). They noted that the
possibility that this pattern of oxygen pulse may have been associated with a decreasing stroke
volume and further widening of the A-V oxygen content difference could not be excluded.2.8.5 Systemic vascular resistance
Counihan and co-workers assessed forearm vascular responses to supine and upright exercise in
patients with HCM (85). Their normal control population demonstrated a mean decrease in forearm
blood flow of 12% during exercise. Approximately two thirds of their patients had a ‘normal’
response to exercise, and in one third they noted either a failure to decrease or an increase in blood
flow. There was an association in this latter group with younger age, family history of HCM and
sudden cardiac death. They also noted an association with smaller cavity dimensions, leading them
to conclude that this comparatively large increase in wall stress during exercise may activate left
ventricular mechanoreceptors which play a part in an abnormal vascular response. When the
investigators went on to perform upright exercise, they found 79% of those patients with abnormal
forearm vascular response on exercise also had a systemic hypotensive response to upright exercise.
Of the remaining ‘normal’ response group, 63% actually had what were described as abnormal
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oscillations in recovery (defined as a rapid decrease of 10 mm Hg or more and subsequent increase
in systolic blood pressure of more than 10 mm Hg from the minimum recovery blood pressure).
In the ABPR group there was no association between peripheral haemodynamic indices and LVOT
gradient, although those with abnormal responses had smaller left atrial and left ventricular end
diastolic size. There was also a significant association with a family history of sudden cardiac death,
prompting the authors to conclude that abnormal peripheral responses could be a marker of
haemodynamic instability causing this increased risk. In a subset of HCM patients studied invasively,
there was no significant difference in peak cardiac index between those with and without ABPR to
exercise although this was marginally higher in the former group (86). Cardiac index increased
fivefold in both groups though magnitude of increase was greater in hypotensive patients, implying
blood pressure change on exercise was not related to cardiac output. There was no difference in
LVOT obstruction between groups suggesting that obstruction was not a factor in exercise
hypotension.
In the more recent paper by Ciampi, they showed a fall in systemic vascular resistance (SVR) on
exercise in both NBPR and ABPR groups (-34% ±26% and -28% ± 26%, respectively, over baseline; P
=NS). SVR was not measured directly but a global assessment was made by calculating it according
to the following formula: SVR = 80 x (MAP / cardiac output), and was considered to be 100% at the
beginning of the study, subsequently expressed relative to this value. This group had previously
demonstrated a similar fall in SVR between normal controls and HCM (89). Although there was a
trend to a greater decrease in the control group this did not reach statistical significance. The
difference in methodology (in addition to the omission of right atrial pressure from the calculation)
may explain the findings contradictory to the work on local SVR by Counihan and Frenneaux (85,86).
Global SVR is the sum of different adaptation processes to exercise: the local effect of exercise
metabolites, cortical influences, reflex activation of metabolic receptors in skeletal muscle, and
increased ventricular baroreceptor activity (103). As such the local changes observed by Counihan
and Frenneaux are unlikely to be reflected in the more general assessment performed by Ciampi’s
group.
2.8.6 Diastolic function
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Diastolic dysfunction has been shown to cause impaired exercise tolerance in non-HCM populations.
Cardiac output during exercise depends on the left ventricle increasing its ability to fill without
adversely increasing left atrial pressure (104). Historical studies demonstrated resting diastolic
abnormalities and increased left atrial pressure in HCM patients compared with controls (105,106),
and diastolic dysfunction has long been regarded a contributor to exercise limitation (81,107,108).
The abnormalities of filling have been proposed as a contributory mechanism to exercise limitation
(81), and are compounded by the reduced filling time encountered at higher heart rates on exercise.
The optimal technique to measure diastolic function, particularly on exercise due to technical
considerations, is not clearly established. Conventional Doppler indices of left ventricular diastolic
function do not correlate with symptoms or exercise capacity in patients with HCM (109,110). The
mitral valve Doppler profile is affected by variables independent of diastolic function, such as filling
(111) and have not been shown to correlate with invasively measured diastolic parameters (112).
An early study in 52 patients with HCM using transthoracic echocardiography showed that exercise
capacity was determined by passive LV diastolic function, as assessed by the resting left atrial M-
mode and Doppler-derived pulmonary venous flow velocities (113). Left atrial fractional shortening
and the pulmonary venous systolic filling fraction were however the only determinants of the
maximum VO2 (r = 0.70; p <0.001). However, correlation coefficients were low, and no attempt was
made to study Doppler indices on exercise. This group did not show any significant correlation
between mitral valve Doppler parameters and peak VO2. A more contemporary study using tissue
Doppler showed that early diastolic mitral annular velocities are reduced in patients with HCM and
unlike conventional Doppler indices alone, the transmitral E to lateral Ea ratio correlates with NYHA
functional class and exercise capacity (114). However in that study the correlation between the
transmitral E to lateral Ea ratio and VO2 was relatively modest, suggesting that other factors such as
a reduced stroke volume response, ventilation / perfusion mismatch, and abnormal peripheral
oxygen utilisation also influence exercise capacity.
Abnormal Doppler diastolic indices have been identified with similar frequency in patients with
(78%) or without (83%) LVOT obstruction, as well as in patients with (84%) or without (80%) cardiac
symptoms (109). However, patients with non-obstructive HCM showed more severe alterations in
the Doppler indexes of diastolic function than did patients with obstruction.
Frenneaux et al showed no correlation between indices of diastolic function (pulmonary capillary
wedge pressure (PCWP) – at rest and peak, and the change during exercise, left atrial size) and
maximal VO2 in 23 HCM patients studied invasively (81). Despite the lack of correlation with cardiac
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index, abnormal responses of PCWP to exercise were observed, and the authors felt their population
was representative of a wider HCM population. They excluded anyone with severe mitral
regurgitation as the resulting increase in left atrial pressure may have affected their results. Similarly
no significant relationship has been shown between left atrial pressure and exercise capacity in a
general heart failure population (115,116). PCWP itself is a reflection of left atrial pressure assuming
there is no trans-pulmonary gradient. In the longer term elevations may point towards diastolic
dysfunction. However, it does not really represent a good measure of left ventricular filling, or
indeed the ‘stiffness’ which may accompany an inability to augment stroke volume at higher heart
rates and therefore influence exercise capacity.
Dumont et al attempted to quantify left ventricular stiffness by using the ratio of PCWP (derived
from the E/Ea ratio) to LV end-diastolic volume (assessed by CMR) (117). By using a different
definition of resting diastolic dysfunction to Frenneaux, they found a LV stiffness level of 0.18 mm
Hg/ml had 100% sensitivity and 75% specificity (area under the curve 0.84) for predicting <7
metabolic equivalents (METs) achieved. In their study there were inverse correlations between
METS achieved and age, heart rate deficit, E/Ea ratio, left ventricular stiffness and wall thickness and
a positive correlation with left ventricular volume, although only left ventricular stiffness was
associated with an impaired exercise capacity on multivariate analysis. Whilst often measured, MWT
has not been shown to be a determinant of exercise capacity in HCM (118).
2.9 Left ventricular outflow tract obstruction
LVOT obstruction by definition implies an obstruction to the forward flow of blood being ejected
from the left ventricle. However, it is a complex phenomenon which is incompletely understood.
What is clear is that it is common, often associated with significant symptoms and a worse
prognosis, and is commonly targeted as a treatment strategy. It can be detected during physical
examination, and usually quantified using echocardiography by measuring the pressure gradient
between the left ventricular cavity and the aorta (figure 2.6). Under resting conditions, 25% of
patients have obstruction to the LVOT, whilst up to 70% of symptomatic patients may have latent, or
provocable LVOT obstruction during manoeuvres that increase contractility or reduce afterload and
preload (119,120).
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Figure 2.6. Echocardiographic doppler profile demonstrating a significant left ventricular outflow
tract gradient.
2.9.1 Mechanism
LVOT obstruction has long been recognised as an important phenomenon in HCM. However despite
being the subject of intense scrutiny the complex underlying mechanism of LVOT obstruction
remains incompletely defined. Essentially four anatomical features predispose an individual heart to
LVOT obstruction, but their pathophysiological interaction may be complex: the muscular
hypertrophy extending into the outflow tract (121); abnormal mitral valve leaflets capable of moving
anteriorly (122-128); the mitral valve annular position in the cavity and the size and orientation of
papillary muscles which position the mitral valve leaflets into the path of blood leaving the ventricle
(124,129-132). The relative importance of each factor in any given individual can be difficult to
determine, but is usually seen in combination with hyperdynamic ejection (133).
2.9.1.1 Systolic anterior motion of the mitral valve
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In most cases, obstruction is associated with systolic anterior motion (SAM) of the mitral valve, in
which the anterior mitral valve leaflet and/or its sub-valvular apparatus move towards and makes
contact with the ventricular septum in systole (figure 2.7). The most commonly accepted
explanation for SAM is that septal hypertrophy, and consequent narrowing of the outflow tract,
increase the velocity of blood above the mitral valve. The leaflet tips are projected into this stream,
exposing them to the hydrodynamic force of drag and pushing them further towards the septum
(134-136). The leaflet tips may also be exposed to the “sucking” effect of Venturi forces generated
by the high velocity blood in the LVOT (137-139). The relative contribution of each of these
mechanisms remains unclear, and in practice may vary between individuals with differing ventricular
and valvular geometry. Most patients with SAM have a posteriorly directed jet of mitral
regurgitation, but the presence of complex jets (e.g. anteriorly-directed or central) suggests
additional mitral valve abnormalities.
Experimental and observational data suggest that abnormalities of the sub-valvular apparatus such
as anterior papillary muscle displacement and primary mitral valve abnormalities such as accessory
mitral tissue create leaflet “slack” to allow SAM at low flows (136,140). Systolic obliteration of the
ventricular cavity can also produce a high velocity gradient in the mid-ventricle (141) and right
ventricular outflow tract obstruction is common in Noonan syndrome and some metabolic disorders
(142).
2.9.1.2 Primary mitral valve abnormalities
The heterogeneity of mitral valve abnormalities has long been recognised (127). Enlargement of
mitral valve leaflets is a feature of both obstructive and non-obstructive HCM, suggesting that this is
a primary abnormality rather than a consequence of being stretched over time with LVOT
obstruction (127). 3D imaging modalities have helped shed light on the specific role of the mitral
valve in LVOT obstruction (143,144). Using 3D echocardiography, Kim et al investigated the relative
effects of mitral valve anatomy and geometry on LVOT obstruction (140). They found that mitral
annular areas, annular height and mitral leaflet areas were larger in patients with resting obstruction
than non-obstructive HCM and controls.
Figure 2.7. Systolic anterior motion of the mitral valve (145).
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ASH: Asymmetric septal hypertrophy; LVOT: left ventricular outflow tract; MR: mitral regurgitation;
SAM: systolic anterior motion of the mitral valve
This cartoon demonstrates anterior movement of the mitral valve during systole as a result of ASH,
causing both LVOT obstruction and mitral regurgitation.
2.9.1.3 Papillary muscle abnormalities
Anterior displacement of the papillary muscles has the effect of interposing the mitral valve leaflets
into the LVOT, pushing them into the septum (134,136,146,147). This also reduces the ability of the
posterior leaflet to coapt with the anterior leaflet. Additional congenital abnormalities such as a
solitary or multi-headed papillary muscle or direct insertion into the mitral valve leaflets, are
commonly seen. Papillary muscle abnormalities have been cited as a potential cause for residual
LVOT gradients after ASA therapy (147). In addition they have provided a potential target for surgical
therapies (129,148-150). If a mitral valve ring is required at surgery the shape can potentially exert
an effect over LVOT obstruction. A flat ring exerts more stress on the leaflets which decreases leaflet
slack (151,152).
2.9.2 Provocable left ventricular outflow tract obstruction
In contrast to a fixed obstruction such as aortic stenosis, LVOT obstruction is to a varying degree
dynamic; that is, subject to change and influence by factors such volume loading, heart rate and
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contractility. Traditionally clinical assessment for LVOT obstruction was made at rest. It is now well
recognised that latent, or provocable obstruction must be actively sought during clinical assessment.
Provocable LVOT obstruction should be excluded in patients with suggestive symptoms and no
resting LVOT gradient (120,153,154) as it is associated with reduction in functional class (155).
Furthermore, interventional treatment improves both exercise tolerance and outcome (156,157).
Common stress techniques to provoke obstruction during Doppler echocardiography include
physiological (Valsalva manoeuvre, exercise) or non-physiological (drug administration e.g. sub-
lingual nitrate). However, few data exist on methods for determining which patients may benefit
from further investigation with stress echocardiography, which is a decision primarily based on
clinical opinion. At the heart hospital current practice aims to replicate situations which might
provoke patient symptoms in day to day life. Standard Bruce protocol exercise tests are therefore
not ideal due to the graded nature of exertion. We perform exercise in the upright position, with the
intention of rapidly increasing the incline and speed of the treadmill to simulate, for example,
hurrying for a bus. Doppler echocardiography is then performed immediately, still in the upright
position, on cessation of exercise at the limit of effort tolerance.
2.9.3 Clinically important associations
In addition to symptoms, there is an association between LVOT obstruction and various disease
related complications. Traditionally, it was considered to be a risk factor which may prompt the
clinician towards more aggressive treatment in an otherwise equivocal case (158) 194, 196]. LVOT
obstruction is now part of contemporary risk stratification, appearing in a recently published
sophisticated algorithm (70) . LVOT obstruction is also associated with stroke. In an unselected HCM
population, prevalence was found to be 6% and incidence 0.8% per year (44). Embolic phenomenon
are largely related to AF, and in a recent large metanalysis of 7381 patients (including 33 studies),
overall prevalence in HCM patients with AF was 27.09% (95% CI 20.94% to 33.25%). Death from
heart failure, or NYHA class III or IV symptoms are more common in patients with LVOT obstruction
(relative risk, 2.7; P<0.001), especially in those aged over 40 ( (159). However, no excess incidence in
heart failure has been seen in patients with severe obstruction. Provocable LVOT obstruction is
associated with functional impairment and heart failure symptoms,(154,155,159) and there is good
evidence that invasive treatments should be offered to these patients (156,157).
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2.9.4 Treatment of LVOT obstruction
In patients with symptoms caused by LVOT obstruction, the aim of treatment is to reduce the
outflow tract gradient. Options include negatively inotropic drugs (ß-blockers, disopyramide and
verapamil), atrioventricular sequential pacing, percutaneous ASA of the interventricular septum and
surgery. With both invasive procedures, results are improved with experience and higher volume
centres should be preferred for referral.
2.9.4.1 Medical
Approximately 60 to 70% of patients improve with medical therapy but high doses are frequently
required and side effects are common (34). β-blockers are recommended as first line treatment for 
exercise intolerance in HCM, particularly in patients with LVOT obstruction (34). Diastolic
characteristics and ischaemia are improved by reducing heart rate and improving filling time.
Although β blockade is useful for rate-control in the treatment of atrial arrhythmia (common in 
HCM), and are used to help prevent ventricular arrhythmia (34), a mortality benefit has not been
clearly established and they do not appear to adequately protect against sudden cardiac death
(160). A recent trial of bisoprolol in patients with provocable obstruction demonstrated a significant
reduction in outflow tract gradient (161).
Non-dihydropyridine calcium channel blockers are frequently used in the treatment of both non-
obstructive and obstructive HCM, with verapamil being the most common agent. Negative
chronotropic and inotropic effects help to reduce the gradient in patients with obstruction and
improve symptoms. However, as with β blockers contemporary trial data is scant (162-166). The use
of verapamil is not uncommonly restricted by side effects including constipation and peripheral
oedema, although haemodynamic consequences such as depression of sino-atrial function,
hypotension and rarely pulmonary oedema should also be recognised (167). Diltiazem is routinely
used in non-obstructive patients and improves diastolic relaxation and filling (168), and ischaemia on
exercise (169).
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Disopyramide is a class 1a anti-arrhythmic agent used as an adjunct in medical therapy of patients
with obstruction to improve haemodynamics and exercise tolerance (170-172), often prior to
invasive septal reduction therapy. It has been shown to be safe (173) although should be
concomitantly administered with either β blockers or rate slowing calcium channel blockers as atrio-
ventricular nodal conduction can be accelerated. QT interval must be monitored after prescription to
exclude significant lengthening. Other common side effects limiting its use are related to
anticholinergic action, such as dry eyes and mouth, constipation and urinary retention.
2.9.4.2 Right ventricular apical pacing
Dual-chamber pacing using a short-programmed atrio-ventricular delay has been used as a less
invasive method of treating LVOT obstruction. Initial work investigating the effects of RV apical
pacing appeared promising, showing improvement in symptoms and haemodynamics in the first few
months after pacemaker implantation in patients with resting and provocable LVOT obstruction
(174), with benefit maintained at one year (175). Later prospective randomised studies showed little
objective evidence of benefit, with significant placebo effect, although there is some suggestion
older patients may respond more favourably (62,176). Lastly, pacing has been shown inferior to
surgery (177).
2.9.4.3 Alcohol septal ablation
ASA is a trans-catheter interventional procedure designed to treat LVOT obstruction. Either femoral
or radial routes may be used. A septal perforator vessel is identified, and balloon occlusive
angiography performed following which a contrast agent is injected. This is visualised using
echocardiography, with the intention of localising dye to the point of SAM septal contact. Once a
suitable target vessel has been identified, a small quantity of neat alcohol is injected. This has the
effect of initially stunning the myocardium, followed in subsequent months by necrosis and
regression of hypertrophy with the intention of reducing LVOT gradients. The procedure is generally
well tolerated. Standard risks of coronary angioplasty include bleeding, vascular damage,
arrhythmia, tamponade, myocardial infarction, stroke, emergency bypass surgery and death with a
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typical figure of 1% quoted. The main additional risk related specifically to ASA is the need for
permanent pacing due to damage to the conduction system, with rates up to 18% (178,179).
Commonly patients develop a right bundle branch block pattern on ECG following the procedure
(178,180).
With respect to exercise, a meta-analysis of 42 published series of ASA showed an improvement in
mean NYHA class from 2.9 at presentation to 1.2 at 1 year(P<0.001) (181). At 1-year follow-up, peak
VO2 increased from 17.8 to 23.6 mL/kg/min (P < 0.001) and mean exercise capacity on a treadmill
increased from 325.3 to 437.5 seconds (P <0.001).
2.9.4.4 Surgical myectomy
Surgical myectomy remains the gold standard treatment for drug-refractory LVOT obstruction.
Whilst overall operative success rates are very good, it is difficult pre-operatively to determine
factors pertaining to the actual surgery which may influence the post-operative symptoms. Surgical
technique has changed over the years, with many centres abandoning the classical Morrow
procedure in favour of an extended myectomy. The original Morrow operation involved access to
the heart via an oblique aortotomy, and a trench shaped resection was made into the LVOT basal
septum (figure 2.8). An extended myectomy results in a shallower trough, with the resection border
extending either laterally or posteriorly. The advantage of this approach is that the surgeon may deal
with more eccentric patterns of distribution of hypertrophy. Typically, patients have a left bundle
branch block pattern on ECG following myectomy.
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Figure 2.8. Surgical myectomy for hypertrophic cardiomyopathy with left ventricular outflow tract
obstruction (182).
Panel A: a standard rectangular Morrow myectomy trough. Panel B: an extended midventricular
resection due to extensive hypertrophy and anomalous papillary muscle insertion
Potential disadvantages include impaired left ventricular contractility of the resected muscle post-
operatively (possibly due to ischaemia or scar) and an increased likelihood of conduction problems.
In addition, it can be challenging for the surgeon to directly visualise the area to be resected,
particularly whilst on cardio-pulmonary bypass. Optimal pre and intra-operative imaging discussed
with the surgeon is therefore important for a successful outcome. At present, this usually includes
CMR, 2-D transthoracic and 3-D trans-oesophageal echocardiography.
In a recent report on surgical outcomes a mitral valve procedure was necessary in 13.5% (115/851),
including mitral valve replacement in 41.7% (48/115) (183). These data support the need for a
comprehensive patient specific assessment prior to surgery where the potential need for
contemporary mitral valve procedures (Alfieri, plication or papillary muscle re-orientation) can be
assessed.
No randomised controlled trials exist comparing myectomy and ASA. A recent meta-analysis of 5
studies including 183 patients undergoing ASA and 168 myectomy showed the ASA group tended to
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be older (mean age 54.4 +/- 6.3 vs. 45.0 +/- 4.4 years, P = 0.02), although similarly symptomatic and
with equivalent LVOT gradients (81.4 +/- 14.3 mmHg in ASA vs. 77.4 +/- 15.5 mmHg in myectomy, P
= 0.2) (179). Both treatments were effective at gradient reduction, although lower figures were
achieved in the surgical group (18.2 +/- 6.7 vs. 10.8 +/- 6.3 mmHg, P < 0.001). Reduction in NYHA
class was similar (1.5 +/- 0.3 in ASA vs. 1.3 +/- 0.2, P = 0.2). In hospital mortality was similar, although
more patients having ASA required a pacemaker (18.4 +/- 7.9 vs. 3.3 +/- 3.9%, P = 0.04).
A historical study in 1979 of 29 patients following myectomy showed an improvement in peak VO2
from 16 to 21 ml/min/kg (P<0.005) (184). Interestingly, surgery was associated with a significant
increase in cardiac index during maximal exercise (5.0 to 5.7 litres/min per m2, P<0.05). Another
from 1992 investigating exercise improvement following myectomy identified preoperative
impairment in peak VO2, and a post-operative reduction in LVOT gradient and LV filling pressures as
multivariable predictors of a positive change in peak VO2 at 6 months (185).
It is clear that randomised studies are required to fully investigate the differences between ASA and
myectomy. However, the heterogenous nature of HCM makes accurate randomisation difficult, and
the nature of the treatments means blinding is impossible. Furthermore, bias in individual centres is
evident from the literature, and appropriate trials with large numbers of patients seem unlikely.2.9.5 Unanswered questions
It is now widely accepted that LVOT pressure gradients can cause breathlessness, chest pain and
syncope and that their treatment with negative inotropic drugs or invasive reduction of septal
thickness results in clinical improvement (34). However, this does not explain the enormous
variability in symptoms associated with identical degrees of obstruction and the poor correlation
between LVOT gradients and objective measures of exercise capacity. Nor does it explain the
unfortunate clinical scenario of ongoing symptoms following ‘successful’ gradient reduction. There is
therefore the need for further understanding of the phenomenon, particularly its relation to
exercise.
It is increasingly recognised that assessment of cardiac parameters at rest in patients with any
cardiac disease is unrepresentative of the physiology behind symptoms, and efforts should be made
to perform investigations during exercise. With regard to HCM with LVOT obstruction, the gold
standard for diagnosing provocable obstruction is stress echocardiography during exercise in the
upright position. However, whilst this approach has proved useful for diagnosis of provocable
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obstruction, it provides little haemodynamic information on the functional consequences, which
may have implications for the correct treatment.
2.10 Aorto-septal angulation
In addition to abnormalities of the mitral valve discussed above, other geometric LVOT abnormalities
are frequently seen in HCM. One of these is aorto-septal angulation. The aorto-septal angle is the
angle formed between the aorta and the interventricular septum (figure 2.9).
Figure 2.9. Aortoseptal angulation
Transthoracic parasternal long axis echocardiogram demonstrating the plane of the inter-ventricular
septum (longer line), the aorta, and the aorto-septal angle between the two.
Whilst a standardised measurement technique using echocardiography has been described (186),
this has never been used in patients with HCM, in whom it might be expected to be difficult to apply
given the highly variable LVOT geometry. The most commonly adopted in the literature is the angle
formed by the long axis of the ascending aorta and the plane of the ventricular septum, initially
described by Fowles and colleagues (186-190). The normal range of aorto septal angle in patients
without structural heart disease in the Fowles’ study was 128o ± 1.9 (SEM), range 122-132. However,
patient numbers have been small (Barkhordarian, 21; Olafiranve 75; Sigfusson 45; Kleinert 58) and
in most studies no attempt was made to assess inter-observer variability. However, Sigfusson used 2
independent examiners and found an excellent inter-observer correlation (r=0.997, mean inter-
observer difference 4.8%).
Aorto-septal angulation is an anatomical feature commonly seen in advancing age, hypertension and
aortic stenosis (186,187,190-192). In addition, in children it has been associated with sub-aortic
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valve obstruction. In the case of aortic stenosis, increased aorto-septal angulation can be associated
with ASH (186). Abnormal flow in the LVOT made worse by acute angulation can increase left
ventricular intra-cavity pressure (193). In turn, re-modelling may be adversely affected.
Although not uncommonly seen in HCM, it has been little investigated. Recently however, aorto-
septal angulation has been shown to be predictive of LVOT obstruction in HCM using 3D imaging
techniques (191). Whether this is a pathological feature of HCM or a secondary result of the already
abnormal ventricular geometry is not known. Fluid modelling studies testing the effect of variable
flow angulation have demonstrated that the Shear stress on the basal septal surface increases with a
steeper aorto-septal angle (194), which in animal models is associated with vascular obstruction
(195). A steep angle is also associated with increased arterial pressure wave reflection and central
blood pressure, which is known to impact left ventricular hypertrophy (188).
In routine clinical practice, aorto-septal angulation in HCM is commonly described as being
suggestive of provocable LVOT obstruction, prompting further assessment often with stress
echocardiography. However the lack of a standardised method of measurement that can be used in
patients without recourse to complex 3-D imaging techniques limits the usefulness of this parameter
in day to day practice.
Diagnosis and treatment of provocable LVOT obstruction is recommended. However, access to stress
echocardiography is highly variable, dependent on equipment and expertise. A simple tool that
could help predict those patients who go on to develop significant gradients would be of benefit.
I therefore had two aims. Firstly I sought to determine whether aorto-septal angulation could be
reliably and accurately measured using a modification of the existing standard transthoracic
echocardiography technique, and validate this against CMR. Secondly I investigated whether this
was an anatomical predictor of provocable LVOT obstruction in a large cohort of patients with HCM
and no resting obstruction.2.10.1 LVOT orifice area
One would expect that the geometric changes in the LVOT during obstruction would result in a
reduced cross sectional area, and this has been demonstrated in several studies. An early 3D
echocardiographic study of 25 patients with HCM and SAM measured the minimal LVOT area in real
time and compared it to the maximal velocity of blood flow, and used a 2D measurement of SAM-
septal distance as ‘control’(196). The LVOT area ranged from 0.6 to 5.2 cm2 (mean: 2.2 +/- 1.4 cm2),
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and a highly significant inverse correlation was seen with blood velocity. A poorer although still
highly significant inverse correlation was seen between SAM – septal distance, prompting the
authors to conclude that 3D echocardiography is a useful tool for assessing patients with HCM. No
attempt was however made to evaluate the added benefit that this technique has on diagnosis or
treatment. However, the same group later performed real-time 3D echocardiography in 10 patients
undergoing myectomy. The exact location of SAM was shown with a predominant involvement of
the medial portion of the mitral valve in 4 patients and the middle portion in 6 patients. The smallest
area of the LVOT significantly increased after myectomy (1.4 +/- 0.7 vs 4.8 +/- 1.8 cm2, p <0.01).
Whether the addition of 3D contributed to additional operative benefit through improved intra-
operative anatomical visualisation was not directly assessed (197). Not surprisingly in Kim’s study
(140) the minimal LVOT area during systole, reflecting the combination of septal hypertrophy and
SAM, was smallest in patients with LVOT obstruction and smaller in patients without obstruction
than in controls (0.56±0.31 versus 2.75±0.66 versus 4.05±0.70 cm2; P<0.001). The LVOT area in
diastole also showed similar trends (3.33±1.01 versus 5.80±1.28 versus 7.92±1.44 cm2; P<0.001). The
minimal systolic LVOT area showed an excellent inverse correlation with peak LVOT pressure
gradient in patients with ASH (exponential curve fitting, R2=0.83, P<0.001).
2.11 Measurement of cardiac output
Physiological assessment of cardiac performance during exercise is an important part of clinical
assessment of the cardiovascular system. Peak VO2 in particular has been shown to be of prognostic
significance in heart failure and can be used to guide treatment (198-200). However, peak VO2 is
determined not only by cardiac output, but also by non-cardiac factors such as age, gender,
respiratory disease, haemoglobin concentration and level of training (201).
Most reference methods for the estimation of cardiac output are invasive, costly and often require
specialised catheter laboratory facilities and staff. A number of non-invasive alternatives, including
impedance cardiography (202), nuclear scintigraphy (202), Doppler echocardiography (203,204),
magnetic resonance imaging (205-207), and respiratory gas analysis (208) can be used to measure
resting cardiac output, but most of these methods are unsuited to routine clinical use during
exercise, particularly above the anaerobic threshold because they provide only periodic assessment
and are unable to capture rapid changes in physiologic variables. A summary of these technique is
shown in table 2.3. No single technique to date has been shown to be able to continuously measure
cardiac output accurately and non-invasively. Most methods suffer the drawback that determination
51
of cardiac output is made over several cardiac cycles. At rest this is usually not important, but
cardiac output can be highly variable on exercise leading to inaccuracies of measurement. Even
postural changes in cardiac output may not be accurately evaluated with these techniques. They do
not provide a continuous assessment, desirable for the monitoring of dynamic variables in which
changes could be missed by periodic assessment. There is, therefore, a need for a method that
accurately measures dynamic cardiac output during exercise.2.11.1 The Fick principle
First described in 1870 by Adolf Fick, this is the principal that VO2 is proportional to the rate of blood
flow, and the affinity of Haemoglobin for oxygen. By measuring the VO2 over time, and the oxygen
concentration of both arterial and venous blood it is possible to calculate cardiac output from the
equation:
Oxygen consumption (VO2) = (Q x Ca) – (Q x Cv)
Where
VO2 = oxygen consumption (L/min) measured using a respiratory flow meter
Ca = Oxygen concentration of arterial blood (usually taken from a peripheral artery)
Cv = Oxygen concentration of mixed venous blood (taken from the pulmonary artery)
Q = Cardiac output
When rearranged: Q = ୚୓ଶ
େୟି େ୴
× 100
Each gram of haemoglobin can carry 1.34 g of oxygen, therefore:
݋ݔ݃ݕ ݁݊ ܿ݋݊ ݁ݐ ݊ݐ݌݁ ݎ100݉ ݈ܾ ݋݈݋݀ ( ܽݎ݁ݐ ݅ݎ ݈ܽ ݋ݎ݁ݒ ݊݋ݑݏ)= ܪܾቀ݃
݀ܮ
ቁݔ1.34ݔܾ ݋݈݋݀ ݋ݔ݃ݕ ݁݊ ܽݏ ݐݑܽݎ ݅ݐ݋݊ (%)+ 0.0032ݔ݌ܽ ݎ݅ݐ݈ܽ ݌݁ݎ ݏݏݑ݁ݎ ݋݂ ݋ݔ݃ݕ ݁݊ (ݐ݋ܽܿܿ ݋ݑ݊ݐ݂݋ݎ݋ݔ݃ݕ ݁݊ ݀ ݅ݏݏ݋݈ ݁ݒ ݀݅݊ ܾ ݋݈݋݀ )
This technique is often considered the gold standard, but is invasive and performed in a cardiac
catheterisation laboratory. It is not therefore not well suited to (maximal) exercise. Another major
disadvantage of this technique is an inability to perform rapidly enough to capture the dynamic
nature of physiologic exercise variables. Its use tends to be restricted therefore to diagnostic
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procedures at rest, for example in the assessment of patients being considered for heart
transplantation.
Table 2.3 Comparison of cardiac output measurement techniques
Pros Cons
Direct Fick Gold standard accuracy (at rest) Invasive
Requires cardiac catheter
laboratory
Not well suited to maximal
exercise
Not continuous data
Pulmonary artery
thermodilution
Accurate (at rest) Invasive
Requires cardiac catheter
laboratory
Not well suited to maximal
exercise
Time consuming
Not continuous data
Doppler echocardiography Non-invasive
inexpensive
Dependent on operator
experience and good echo
window
Not well suited to exercise
Impedence cardiography Non-invasive Motion artefact on exercise
Limited at high workloads
2D echocardiography As for doppler echo As for doppler echo
CMR Highly accurate
Non-invasive
Additional data provided
Expensive
Difficulty resolving fast moving
structures during exercise limits
use
Inert gas techniques Non-invasive Only interval recordings
Complicated respiratory
manoeuvres required
Invasive pulse pressure analysis Continuous recording
Additional data provided
Invasive
Requires calibration
Expensive
Not well suited to exericse
Finger plethysmography Inexpensive
Non-invasive
Continuous recording
Suited to exercise – although
not validated
Affected by peripheral
vasoconstriction
Learning curve for use
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2.11.2 Pulmonary artery thermodilution
A pulmonary artery catheter is inserted with its tip at a terminal artery. A known quantity of cold
saline at a known temperature is injected into the right atrial port, and the temperature measured
distally, the cooled blood having traversed a thermistor in the catheter. Cardiac output can then be
estimated by measuring the area under the ‘thermodilution curve’. Often several recordings are
made and averaged. Differing cardiac outputs will deliver different curves. This method suffers the
same disadvantages of the Fick method, namely being invasive and time consuming. Accurate
delivery and recording of cold injectate, baseline temperature changes, hypovolaemia, and the need
for cardiac output to remain constant while a stroke volume assessment are made are all potential
limitations (209-211).
2.11.3 Doppler echocardiography
Cardiac output can be measured using Doppler using the following equations:
Cardiac output (Litres/minute) = (stroke volume (ml) x heart rate (bpm)) ÷ 1000
Stroke volume = Doppler velocity time integral x aortic valve cross sectional area (CSA) (cm2)
The valve CSA can be calculated from:
ܥ ܵܣ = ߨݎଶ
Where r = radius of the aortic valve orifice.
The Doppler signal can either be obtained from a supra-sternal notch or an apical window.
This method is non-invasive, inexpensive and provides continuous data but there are several
limitations. Estimating CSA depends on operator experience, a good echocardiographic window, and
being able to be aligned to the direction of flow. These latter two points are often difficult to achieve
on exercise, particularly in the upright position. Aortic CSA may also change with posture. Any
inaccuracies are compounded by using the square of the value used in the equation. Doppler derived
stroke volume has been shown to be comparable under resting conditions to modelflow, although
differences were noted during tilting (212). The trans-oesophageal route can be used by using the
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Doppler profile from the descending aorta. This method is still often used in the intensive care
setting to measure resting values but obviously not suited to exercise.
2.11.4 Invasive pulse pressure analysis
Pulse pressure methods use the waveform within an artery to derive information on cardiac output,
and can be performed non-invasively and invasively. Simple non-invasive methods (eg
sphygmomanometry and tonometry) tend to be inaccurate as both cardiac and peripheral changes
will affect the waveform. Invasive methods include LiDCO (LiDCO Ltd, London, England) and PiCCO
(PULSION Medical Systems AG, Munich, Germany). Both techniques involve inserting an arterial
catheter and measuring the waveform continuously from which cardiac output can be derived using
the method described by Wesseling (213). Both must also be calibrated. LiDCO uses lithium dilution
via a peripheral artery and vein. PiCCO used a trans-pulmonary thermodilution technique: similar to
trans pulmonary thermodilution, cold saline is injected into a central vein, and a thermodilution
curve derived from temperature data obtained at a peripheral artery (often radial or femoral). Once
calibrated this method will give continuous haemodynamic information. However, calibration itself
can be difficult to accurately reproduce, and should be repeated following any change in posture /
therapy or clinical status change. This later method also gives an estimation of cardiac filling
volumes, intrathoracic blood volume and extra-thoracic lung water. Both techniques are time
consuming, expensive, and poorly suited to assessment of cardiovascular physiology on exercise.
FloTrac (Edwards Lifesciences LLC, USA) is a self-calibrating pulse pressure device which derives
cardiac output through analysis of the pressure waveform from an arterial catheter (214). Pulse
contour analysis needs correction if it is to be accurate over changing haemodynamic conditions.
2.11.5 Impedance cardiography
Impedance cardiography measures the change in trans-thoracic impedance over the cardiac cycle: as
intra-thoracic blood flow and volume increase the impedance falls (215). This is a non-invasive
technique, providing continuous data, which has been used with some success particularly in the
heart failure population (216). Contemporary utility on exercise is however relatively limited, partly
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due to motion artefact. Moore et al demonstrated good agreement between cardiac output as
assessed by impedance cardiography and CO2 re-breathing in healthy young males at sub-maximal
exercise (217). There was also a similar correlation with VO2 in both groups. However, beyond a
workload of 120 W both methods were limited.
2.11.6 2D echocardiography
2D echocardiography has been used to assess cardiac output by tracing the endocardial border in
end systole and end diastole to generate the left ventricular area, from which a volume is derived.
Stroke volume is calculated by subtracting the left ventricular end systolic volume from the end
diastolic volume Multiplying by the heart rate and dividing by 1000 will give the cardiac output in
litres per minute. Inherent inaccuracies with this technique are well known, largely due to difficulties
in endocardial border definition, and are compounded when used during exercise. 3D
echocardiography may help to resolve these issues to some extent. However cardiac motion with
respiration significantly degrades the image quality, thus limiting its use during exercise.2.11.7 Magnetic resonance imaging
At rest, velocity encoded phase contrast MRI is highly accurate and reproducible when used to
measure flow in large vessels. An assessment of cardiac output is often made as part of a routine
CMR assessment. The utility of CMR on exercise is yet to be proven and is the subject of on-going
research. Certainly the ability of current technology to resolve fast-moving structures is limited,
which makes interpretation of exercise data difficult.
2.11.8 Inert gas re-breathing techniques
Inert gas re-breathing techniques have been extensively used for the calculation of cardiac output
(218-223). However, this method can only provide estimates of cardiac output at intervals during the
exercise test, and is technically challenging to perform, particularly in individuals with poor exercise
capacity. Patients must perform respiratory manoeuvres including breath holds at times indicated by
56
the person carrying out the test, making this technique unsuitable for routine clinical practice. On
exercise small A-V oxygen differences introduce error (217). In addition, in order to validate the
technique the assumption of steady state cardiac output is made, however performing the test will
introduce small changes in both circulation and ventilation (224).
2.11.9 Finger plethysmography
Finger plethysmography is a relatively inexpensive technique that provides a continuous beat to beat
assessment of cardiac output and additional parameters such as peripheral resistance. Early studies
on exercise appeared promising although accuracy was suboptimal without correction (225,226). My
hypothesis was that a contemporary, commercially available finger plethysmography device using
pulse waveform analysis with brachial cuff calibration would be comparable in the measurement of
cardiac output during submaximal exercise to a previously validated acetylene (C2H2) uptake
technique (227). Furthermore, if this was the case it could then be used to non-invasively assess
haemodynamic responses during routine clinical cardio-pulmonary exercise tests. The specific
technique is discussed in more detail in chapter 3.
2.12 Cardiac output response to exercise in normal individuals
In normal individuals stroke volume, heart rate (and hence cardiac output) all rise during exercise
and total peripheral resistance (TPR) falls (228-231). Historical studies have calculated normal ranges
for cardiac output and VO2. For adult males maximal VO2 is in the range 25 to 62 ml/kg per min and
cardiac output between 13 to 25 litres/min (232). These parameters have been shown to reduce
with age (233) although the relationship of cardiac output to VO2 between age groups or sexes at
submaximal exercise does not change (218).
Stroke volume normally increases up to exercise intensities of 40–60% of peak VO2 in sedentary
young subjects and then plateaus or falls slightly (234,235). Endurance training can affect this trend.
In trained individuals assessed using graded cycle ergometry, stroke volume increases from baseline
to 40% peak VO2 in men and women of all age groups (218). In this study between 40-70% peak VO2
the stroke volume continued to increase in men but not in women. At nearly maximal VO2, younger
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men continue to increase stroke volume slightly whilst older men maintained the same level.
Younger women maintained stroke volume at this intensity whilst older women did not. TPR
calculated by MAP divided by cardiac output was higher at rest in older versus younger patients,
although all groups demonstrated a similar reduction on exercise.
Although there are some contradictory data from previous studies looking at the relationship
between VO2 and cardiac output between men and women (220,236) (218), overall conclusions are
that there are no significant gender differences in cardiac output at a given VO2 in people of similar
ages, which has been replicated elsewhere 162]. In the case of HCM, no gender differences were
noted in the assessment of exercise capacity in HCM by Frenneaux et al (86).
2.12.1 Relationship between oxygen consumption and cardiac output
The relationship between VO2 and cardiac output is linear. Several historical studies have
investigated this using a variety of techniques to measure cardiac output, including both invasive
and non-invasive (237) (238-241). A much more recent study by Proctor et al noted the slopes of the
cardiac output :VO2 relationship across submaximal levels of cycling were similar among all four
groups tested (young / old men and young / old women) despite variations in resting and peak
values (218). They used the acetylene inhalation technique during submaximal cycle ergometry in a
chronically endurance trained population and found regression values between 5.4–5.9 l/l.
Relatively few data exist on the cardiac output : VO2 response to exercise in HCM. However, this has
been evaluated in heart failure. In patients awaiting transplantation for heart failure calculation of
the ratio of cardiac output : VO2 slope predicts survival (242). They characterised patients as either
normal or abnormal compared to a reference value of cardiac output = 5 VO2 + 3 (threshold
determined through an analysis of several studies (220,243-245)). They did not report the values for
gradients, but that 55% had an abnormal (flat) response. Patients with a normal cardiac output
response to exercise had a survival of 95% at 1 year, whereas survival in those with a reduced
cardiac output response was 72% (P <0.0001). No attempt was made to determine the physiological
cause for this flat response. The authors felt this method added additional information as a
prognostic tool and one that could be used to better predict those with a greater need for
transplantation.
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3 Methods - physiology
Much of the physiological methodology between the validation study and testing in patients is
common to both. I have therefore initially described general principles before detailing the
differences in appropriate sections. The study complied with the declaration of Helsinki and NHS
research governance arrangements. In chapter 4 I have presented the methods used to assess the
anatomical component, and how I investigated the role of aorto-septal angulation with respect to
LVOT obstruction in HCM.
3.1 Non-invasive measurement of cardiac output during exercise
using finger plethysmography
Measurement of the finger arterial waveform to non-invasively continuously assess blood pressure
has been practiced since the early 1980s. The accuracy of recording both at rest and on exertion
with Finapres (FINger Arterial PRESsure) / Portapres (Finometer medical systems, Amsterdam) is well
established (246). An image of a contemporary machine used in my work is shown in figure 3.1.
Figure 3.1. Image of the Finapres equipment
Finometer pro and brachial calibration cuff (Finapres Medical Systems, the Netherlands)
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3.1.1 Volume clamp technique
These devices measure blood pressure using the volume clamp method, developed by Czech
physiologist Penaz in the early 1970s. This is based on the dynamic pulsatile unloading of finger
arterial walls (246). An artery is kept at a constant diameter by pressure from a surrounding
inflatable cuff, despite changes in pressure with the cardiac cycle. Diameter changes are detected
with an infrared photo-plethysmograph built into a finger cuff housing an inflatable bladder (fig 3.2).
Figure 3.2. Finapres finger cuff (Finapres Medical Systems, the Netherlands)
This cuff contains an inflatable bladder and an infrared photo-plethysmograph to record
physiological data.
This in turn is attached to the main unit via an air hose and separate electric cable. During systole if
an increase in arterial diameter is detected the cuff rapidly inflates to keep the size constant. At zero
transmural pressure the artery is not collapsed (which would require cuff pressure > intra-arterial
pressure) but ‘unloaded’. This is the arteries unstressed diameter (246,247). Intra-cuff pressure
equals intra-arterial pressure at this point. The unloaded diameter is close to the average diameter
at a pressure where the amplitude of the pulsations in the plethysmogram is largest (246). Changes
in stress and tone of smooth muscle in the arterial wall and in haematocrit affect the unloaded
diameter, and therefore this diameter is subject to change and must be calibrated. The finometer
does this repeatedly, using a system designed to monitor the pressure waveform of the artery and
adjust cuff pressure accordingly to maintain diameter (247). It analyses the waveform at differing
pressure levels, and is not affected by changes in smooth muscle tone. In practice, the cuff inflates
to a constant pressure initially every 10 beats, becoming less frequent the longer the pressure
waveform remains unchanged. Monitoring is temporarily suspended during these inflations.
60
3.1.2 Waveform analysis
Finger pressure waveforms may differ substantially from the more proximal originating waveforms
(248-250). The systolic pressure waveform is augmented as it moves from brachial to finger level
(251,252). This is due to the pressure waveform being affected by changes in vessel compliance, and
reflection along the arterial tree. At any point in the course, the pressure waveform can be thought
of as a combination of the forward and reflected wave (253). In young healthy patients finger
systolic pressure may overestimate brachial systolic pressure due to this over-amplification
(248,249). As arterial diameter decreases towards the peripheries, a pressure gradient develops
which has the effect of underestimating the mean finger arterial pressure compared with brachial
(248). There is a reduction in pulse pressure amplification with increasing age (253) and vasoactive
agents (254) but an enhancement with heart rate (255). Assumption of the upright position from
supine will therefore alter the finger arterial pressure waveform by a combination of the effects of
reflex increase in heart rate and changes to vascular tone. The resultant effect would be a higher
systolic and lower diastolic and mean finger than brachial arterial pressure. An anti-resonance model
and a regression based level correction can be performed on the finger arterial pressure waveform
to allow for these effects (256,257). Following correction the reconstructed bias for systolic pressure
is 0mmHg and 1mmHg following 20 minute head-up tilt (258). Diastolic pressure is not affected by
reconstruction (256,257).
The finger waveform is further corrected by taking a return to flow measurement using a standard
brachial blood pressure cuff, corrected for the hydrostatic height of the finger with respect to the
heart level. The device has met clinical and research diagnostic criteria of the British Hypertension
Society and Association for the Advancement of Medical Instrumentation (AAMI) (reconstructed
finger pressure minus BAP: systolic, 3.7 mmHg; mean, 0.7 mmHg; diastolic, 1.0 mmHg)(256,259,260).
3.1.3 Modelflow method
Cardiac output is calculated by the finometer using the Modelflow method (213). The reaction of the
aorta to the arrival of blood ejected from the left ventricle is described by a model of aortic input
impedance (aortic characteristic impedance, arterial compliance, and TPR) (261-263). The finometer
simulates this model and applies it to the measured arterial pressure waveform in the finger, and
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the resulting waveform is integrated during systole to calculate stroke volume and from here cardiac
output by multiplying by the heart rate.
The aortic impedance during systole depends on the mechanical properties of the aorta, which are
influenced by the intra-arterial pressure (as blood remaining within the aorta from the previous
heart beat will offer resistance to further pulsatile flow towards it) and the external pressure exerted
on the walls (i.e. trans-mural pressure) (264). Two of the model parameters, aortic characteristic
impedance and arterial compliance (aortic elasticity), are derived from the age- and sex-dependent
aortic pressure–area relationship (265) and so patient’s age, sex, height and weight are manually
entered. This is because the reaction of the CSA of the aorta to pressure is non-linear, increasing
rapidly at lower pressures and more slowly at higher pressures, characteristics which vary between
individuals (266). An elastic aorta will expand with minimal rise in pressure, but it is well recognised
that aortic compliance decreases with ageing (267). The aortic impedance and arterial compliance
are the major determinants of systolic inflow, with peripheral resistance of less importance (213).
TPR is obtained by iteration and varied with each heartbeat. A reasonable initial value of TPR is
assumed at the start of the simulation. This value is entered into the model with aortic impedance to
derive cardiac output. The next beat ratio of arterial pressure to cardiac output defines a new value
for peripheral resistance, which is then used in the next model and so on. After a few heartbeats the
readings stabilise, but the model will continue to update on a beat by beat basis.
It has been suggested that in order to quantitatively assess an absolute value for cardiac output, the
finometer should be calibrated against a known method for example thermodilution at baseline,
because an individual’s aortic size (needed for the calculation) cannot be assumed (264,268-270).
However, the accuracy of measuring relative changes in cardiac output against baseline has been
demonstrated, as this is not influenced by changes in aortic size (213,226,271). It is well recognised
that conventional echocardiographic assessment of cardiac output in itself may differ to invasive
measurements, particularly in the upright position adopted during exercise. Doppler measurements
taken from a transducer positioned in the supra-sternal notch are technically more feasible than 2D
measurements, particularly on exercise (204). However in that study they only achieved diagnostic
quality 2D studies in 30% of subjects. Christie et al demonstrated an increase in aortic size of 2-3%
when assessed by echocardiography on assumption of an upright posture from supine, but no
further changes were observed during exercise up to 80% of maximum workload (204). A constant
aortic size on exercise would support the validity of using the finometer to assess cardiac output
62
during upright exercise. The prevalence of aortic dilatation in HCM has been reported as 4%, similar
to that for the general population, with similar mean aortic size (272,273).
There is no perfect gold standard for the accurate measurement of cardiac output on exercise. Early
studies comparing cardiac output derived by arterial pulse contour analysis of porta-pres derived
data showed a lower precision and accuracy compared to CO2 re-breathing, although this was prior
to implementation of contemporary algorithms, and lacked the brachial calibration of current
equipment (274). The validity of the technique outside of normal physiology has been questioned:
Modelflow has been shown to underestimate cardiac output via both brachial artery cannulation
and Finapres compared with thermodilution in normal individuals subjected to whole body heat
stress (275). However, Modelflow derived cardiac output has been shown to follow changes in inert-
gas rebreathing derived values during static exercise in the upright position (276). In addition, fast
changes in cardiac output are tracked by modelflow across various experimental protocols
(268,277,278), postural stress (212,264) static (276) and dynamic (225,226,279) exercise.
Although the accuracy of measurement of relative changes in cardiac output has already been
shown, in order to determine the accuracy of my absolute values for cardiac output using the
Finapres algorithms, it was first necessary to perform validation studies at rest and sub-maximal
exercise (see section 3.2.2) compared against a previously validated technique.
3.2 Cardiopulmonary exercise testing investigative protocol
Similarities exist between the protocols used for the validation study, and the subsequent clinical
cardiopulmonary exercise tests in patients with HCM. I have therefore outlined common points
before describing the specifics of each protocol.3.2.1 Common points
Peak VO2 is the product of cardiac output and the A-V oxygen difference, and therefore
abnormalities of oxygen utilisation will affect VO2 independent of cardiac output. It is therefore
important (although often overlooked) that respiratory function is determined and assessed in
conjunction with other haemodynamic data when interpreting the results of a cardio-pulmonary
exercise test. Formal arterial and venous blood sampling is impractical, but I sought to minimise
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potential error by measuring respiratory function. In my cohort of patients and controls all subjects
performed 3 flow volume loops prior to exercise testing , and FEV1, FVC and their ratio were
calculated. Anyone with a significant impairment was subsequently excluded. Time of day, caffeine
intake and smoking on the day of the exercise test were not routinely documented and
unstandardised.
Non-invasive beat-to-beat cardiac output assessment was made using a finometer and beatscope
software (Finapres Medical Systems, the Netherlands). A finger cuff was attached to the index finger
of the left hand. During preliminary data collection I found that the optimal signal was recorded with
the patient’s hand and forearm in a fairly neutral position. Excessive plantar or dorsiflexion on
occasion interrupted the finometer tracing, presumably by compressing the arterial wall against the
ergometer handlebars. I therefore had a bespoke moulded plastic splint made by the hand therapy
department at University College London Hospital in order to minimise this problem. Meticulous
attention to positioning of the finger cuff and avoidance of sudden movement has previously been
shown to be important for optimal data collection (212).
Patients were asked to grip the ergometer handlebars lightly and if possible to keep their hand in the
same position throughout the test duration. The automatic blood pressure cuff was attached to the
ispilateral upper arm and both were attached to the Finapres hardware. Arterial blood pressure
waveforms were measured continuously in the finger using the photoplethysmography method (200
Hz sampled analogue waveform). A height correction unit was used to compensate for hydrostatic
blood pressure changes in the finger waveforms.
Signals from a 12 lead ECG were displayed continuously for observation, and recorded at regular
intervals during the exercise and in the recovery phase. Citations were inserted into the software
during the test to form a permanent record of any relevant details, for example a non-invasive BP
recording, any symptoms reported, any reduction in quality of the tracing and a possible cause if
known.
All subjects were given the opportunity to become familiar with the cycle ergometer. The saddle
height and handlebars were individually adjusted. A previously calibrated and electronically braked
cycle ergometer (Ergoselect 200P, Ergoline, Germany) was used to exercise the subjects in an upright
position. This system provides an actual “zero” load with unloaded cycling—that is, a “motor assist”
overcomes the mechanical resistance normally present at zero load cycling (often 20 to 30 W or
more). Simultaneous 12 lead electrocardiography was performed throughout the test.
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The exercise tests were performed during working hours, in an air conditioned exercise laboratory
(average temperature of 21°C) with full resuscitation facilities and two investigators present at all
times. All subjects were told what was expected of them and were appraised of the signals to be
used to communicate with those in attendance during the test.
3.2.2 Validation study protocol: acetylene inhalation technique
Volunteers were familiarised with the technique of C2H2 inhalation prior to exercise (280). The
breathing circuit was flushed with test gas and the multi-gas sensor calibrated. Patients were
connected to the mouthpiece of a SensorMedics Encore Vmax 229 machine (Yorba Linda, California).
A nose clip was positioned. A certified gas mixture (CareFusion, Basingstoke) containing 0.3% carbon
monoxide, 0.3% methane, 0.3% acetylene, 21% oxygen and balance nitrogen was inhaled to vital
capacity and then exhaled at a slow, constant rate of 0.5L/second to residual volume. This flow rate
was achieved as follows: exhalation flow rate was displayed graphically on a computer screen,
overlayed on a fixed line representing 0.5L/second. The participant therefore exhaled at a rate
attempting to match the line. Measurement of inhaled and exhaled carbon monoxide
concentrations were used to calculate lung diffusion capacity. Measurement of inhaled and exhaled
unabsorbed / diluted methane were used to calculate alveolar volume. Normal values of these gases
exclude significant diffusion limitation across the pulmonary circulation, which may affect C2H2
absorption and hence calculation of cardiac output. Continuous assessment of the decreasing slope
of C2H2 concentration in expired gas reflects the uptake of C2H2 into the pulmonary circulation and is
used to calculate the right heart cardiac output (280,281). In the absence of intra-cardiac shunting
this equals left ventricular cardiac output. Mathematically, the relation between gas absorption and
pulmonary capillary blood flow is expressed as follows:
where F = fraction of gas; V = volume of gas; V
.
 = flow rate; α= bunsen coefficient for solubility of 
acetylene in tissue (t) or blood (b); A = alveolar; Ao = at full inspiration; IF = inspiratory flow; I =
inspiratory; E = expiratory and DS = dead space (227).
Three baseline recordings of cardiac output were obtained using the C2H2 technique with
simultaneous finger plethysmography recording. The exact time point of each C2H2 inhalation was
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marked on the finger plethysmography waveform for retrospective analysis. Volunteers were then
exercised on a bicycle ergometer (Ergoselect 200P, Ergoline, Germany) using a 10W ramp protocol to
a pre-determined workload chosen to reflect sub-maximal exercise, based on a subjective
assessment of their level of fitness, age and resting heart rate. The workload was then fixed and a
further three cardiac output measurements were made at steady state using the C2H2 technique with
simultaneous finger plethysmography recording. A single investigator performed respiratory gas
analysis and another independently assessed finger plethysmography data. The mean values for
cardiac output over 5 consecutive heart beats with a stable pulse pressure waveform collected
contemporaneously with C2H2 inhalation were used for comparison.
3.2.2.1 Statistics
Advice on statistical testing was obtained from Allan Hackshaw, Professor of epidemiology and
medical statistics, University College London. All continuous variables are presented as mean ±
standard deviation (SD). Analysis of all variables was carried out using SPSS statistical software
version 19 (SPSS for Windows, IBM, USA). The means of 3 resting and 3 exercise cardiac output
values from each method were assessed using two tailed independent t tests and Pearson’s
correlation coefficient. A Bland Altman plot of the differences between cardiac output values and
their mean was used to determine agreement between techniques. The fractional differences
between finger plethysmography derived cardiac output and the reference C2H2 method were
calculated to determine whether they fell within a 10% margin of accuracy.
3.2.3 Cardiopulmonary exercise test protocol
In patients with HCM, with the exception of amiodarone, cardioactive medications were withdrawn
for a minimum of 24 hours prior to the exercise test as is standard practice at the Heart Hospital.
One minute of baseline cardiorespiratory data was collected before the subjects began the
incremental ramp after one minute of unloaded pedalling. The work rate for the incremental
exercise ranged from 5 to 15 W/min and was based on patients’ account of daily physical activity,
age, sex, and medical history. The aim was to achieve an exercise time of 10 minutes by selecting the
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appropriate exercise ramp rate for each patient. Subjects rode to the limit of tolerance. A record was
made of the subject’s reason for termination of exercise, which fell into one of several categories:
general fatigue, tired legs, breathlessness, chest pain, dizziness. The reason for stopping is however
subjective, as sensations such as those above vary between individuals. Blood pressure was
determined by auscultation at three minute intervals during the test and recovery phase. A single
investigator (Dr Bryan Mist) performed respiratory gas analysis and another (Dr Chris Critoph)
independently assessed finometer data.
Cardiac power output, in watts, was calculated from the equation:
Cardiac power output = (CO x MAP) x K
where MAP is the mean arterial pressure in mmHg, CO is the cardiac output in L/min and K the
conversion factor 2·22 x 10-3 (282).
A-V oxygen difference at different workloads was derived from the Fick equation:
ܣ− ܸ݋ݔ݃ݕ ݁݊ ݀ ݂݅ ݂݁ ݁ݎ ݊ܿ݁ = ை௫௬௚௘௡஼௢௡௦௨௠ ௣௧௜௢௡(௏ைଶ)
஼௔௥ௗ௜௔௖ை௨௧௣௨௧
An picture of a participant during the exercise test is shown in figure 3.3
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Figure 3.3 Participant performing an exercise test
Mouthpiece, finometer, ECG electrodes and blood pressure cuff are attached and the individual is
performing incremental bicycle exercise (volunteer permission to reproduce image granted).
3.2.4 Oxygen uptake measurement
The formula of Wasserman et al was used to calculate the predicted peak VO2. Importantly, the
normal values for predicted VO2 were adjusted for an individual’s weight (283,284). This is because
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an overweight person would have a higher predicted VO2 than an age and sex matched individual
who was of ‘normal weight’, and thus would be less likely to achieve an ‘appropriate’ VO2.
Alternatively two individuals of the same age, height and weight should have different predicted VO2
if one person was overweight and the other lean. Patients breathed room air through a disposable,
low resistance (approximately 1.2 cm/l/min at 12 l/min), low dead space (39 ml) flow meter. The
flow meter was calibrated with a three litre syringe, using a range of flows. Respiratory gas was
sampled continuously from the mouthpiece and analysed using a zirconia cell for oxygen and an
infrared sensor for carbon dioxide (Sensormedics Vmax Encore 229, Viasys Healthcare, UK). These
signals underwent analogue to digital conversion for breath by breath calculation of VO2 and VCO2,
using algorithms based on the procedure of Beaver et al (285). The anaerobic threshold was
determined from the plot of VCO2 against VO2, as described by Beaver et al (285) and Sue et al(286),
where the slope of this linear relation increases owing to a rise in VCO2 (V slope) (fig 3.4). Further
confirmation of the anaerobic threshold was provided from VE/VCO2, VE/VO2, end tidal PCO2, and
end tidal PO2 relations, as described by Whipp et al (287), VE being ventilation (expired volume per
minute). The linear region of the plot of VO2 against work rate(fig 3.5) has been shown to be a major
determinant of the subject’s aerobic efficiency.
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Figure 3.4. Example of respiratory data collected during an exercise test and determination of
anaeorobic threshold (285,286).
AT – anaerobic threshold, BPM – beats per minute, HR – heart rate, PCO2 - partial pressure of
cardbon dioxide, PETCO2 – end tidal cardon dioxide tension, PETO2 - end tidal oxygen tension, PO2 -
partial pressure of oxygen, RQ – respiratory quotient, VCO2 - carbon dioxide production, VE –
ventilatory equivalent, VE/VCO2 - ventilatory equivalent for carbon dioxide, VE/VO2 - ventilatory
equivalent for oxygen, VO2- oxygen consumption.
Profile of response of VCO2 (uppermost panel), ventilatory equivalent for VO2 and VCO2 (lower
panels), and end tidal PO2 and end tidal PCO2 (lower panel) as a function of oxygen uptake during an
exercise test in a patient with hypertrophic cardiomyopathy.
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Figure 3.5. The profile of VO2response, as a function of work rate, in a cardiopulmonary exercise
test in a patient with hypertrophic cardiomyopathy
VO2 – oxygen consumption. Note the normal slope of the relationship between oxyen consumption
and work in this patient.
It should be noted that the peak VO2 mostly but not always corresponded to the last time point of
the exercise test. All were within 60 seconds of the test termination. The corresponding cardiac
output value was always taken, even if there was a slightly higher or lower value at the point of
exercise termination, to ensure reproducible methodology. This peak VO2 value was scrutinised on a
breath by breath basis to ensure that all values were reasonable. If, for example, a patient took a
very small breath amongst their normal tidal breaths, this would produce a very low VO2 value.
Conversely if a very large breath was taken the value would be very high. Outlying values such as
these are immediately obvious when reviewing the breath by breath VO2 data and are routinely
edited in clinical practice to ensure the final peak VO2 value is not falsely influenced. This explains
the sometimes apparent disparity between the peak VO2 value documented during the exercise test
and the 30 second averaged readings obtained throughout exercise.
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3.2.5 Data capture using finger plethysmography and Beatscope
Screen shot examples of data from Beatscope software are shown in figure 3.6. Time is on the x axis,
and on multiple y axes are plotted cardiac output, TPR, systolic, diastolic and mean arterial blood
pressure, and peripheral pulse waveform.
3.2.6 Analysis of an individual finger plethysmography dataset
The text file generated by Beatscope was imported into an Excel database, with fields for different
haemodynamic parameters separated into columns. The raw data was imported into one worksheet,
and the time of respiratory mouthpiece insertion, start of exercise, and end of exercise were noted.
Baseline data was defined as that in the immediate 30 second interval preceding exercise. The cell
corresponding to the start of baseline recording was entered into a formula that automatically
divided and averaged subsequent data into 30 second intervals. The exact times of any data not
meeting acceptable criteria for analysis were recorded, then any remaining acceptable data for a
given 30 second interval were averaged manually. An example of the resulting data table is shown in
table 3.1.
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Figure 3.6. Screen shots from Beatscope of (A) normal and (B) flat cardiac output response to
exercise. Panel (C) shows a close up to demonstrate the arterial waveform and measured
haemodynamic indices at the point of the vertical white line.
Time is on the x axis, and on multiple y axes are plotted cardiac output (pale blue), TPR (yellow),
systolic (red), diastolic (red) and mean (white) arterial blood pressure, heart rate (dark blue), and
peripheral pulse waveform (orange).
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Table 3.1. Example of individual patient’s exercise test. The total time is divided into 30 second
intervals, with corresponding mean cardiac output, stroke volume and heart rate.
Time (seconds) Cardiac output (L/min) Stroke volume (ml) Heart rate (bpm)
30 5.2 80 65
60 7 100 70
90 7.3 99 74
120 7.5 96 78
150 7.8 95 82
180 8.0 91 88
210 8.3 87 95
240 8.5 85 100
270 8.7 84 104
300 9.0 83 109
330 9.9 85 116
360 10.6 88 121
390 11.4 90 127
420 12 89 135
450 12.4 89 139
480 12.9 87 148
510 13.6 88 154
540 14.4 90 160
570 14.9 90 166
600 15.8 93 170
630 16.5 95 174
These data were then exported into another spread sheet, with additional columns for work (watts)
and VO2 (L/min). From this, a graph of cardiac output versus VO2 was drawn, and the slope and
intercept calculated. The cardiac output and VO2 at baseline, 25, 50, 75, 100, 150, 200 and 250 watts
(as applicable) was documented. Lastly a graph of VO2 : work ratio was drawn and the slope
calculated from the plots derived from breath by breath data recorded on the Sensormedics
workstation. Each individual patient’s demographic, echocardiographic, respiratory and
haemodynamic (both measured and derived) data was then tabulated in a master database as
described in section 3.3.5.
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The data displayed on screen (fig 3.6) are an average of 30 consecutive heart beats. Whilst not used
for offline calculation, they provide a good intra-test guide as to quality of signal, and are useful in
the assessment of outlying data points. Each heart beat contributes a line on a text file saved to the
computer’s hard disk. When an exercise test is complete therefore, there are the same numbers of
lines as there were heart beats during the test. Each line comprises a value for: systolic, diastolic,
mean arterial blood pressure, stroke volume, TPR, cardiac output, heart rate etc. Therefore over a 10
minute exercise test at a mean heart rate of 120bpm the file would be composed of 1200 lines of
data.
Each patient’s file was imported into a new Excel 2010 software database (Microsoft Office) for
initial analysis. The first step was to compare exercise duration from respiratory data to that
recorded using finometer to ensure they were identical and corresponded to the same time period.
Baseline, exercise, and where available recovery data were then averaged every 30 seconds and the
results displayed graphically. These data were then reviewed alongside the original beatscope graph
(fig 3.6). The individual pressure waveform for a patient’s exercise test was then scrutinised.
Examples of good, acceptable and poor waveforms are shown in figure 3.7.
Figure 3.7. Examples of (A) good, (B) acceptable and (C) unacceptable finger plethysmographic
pulse wave tracings. Note both (B) and (C) were recorded during maximal exercise.
If a waveform was deemed to be of insufficient quality to be reliable, the data from that time period
was excluded. In order to record a value for a 30 second period of exercise, a minimum of 5 seconds
of data with an accompanying acceptable pressure waveform had to be present. If an exercise test
terminated during a 30 second period, only the data up to the point of exercise termination was
included.
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During my initial analysis, the absolute and percentage change in cardiac output, heart rate and
stroke volume were measured from baseline to the 30 second interval prior to anaerobic threshold.
Absolute values and percentage change were then measured for the same parameters at the point
of highest VO2 for which corresponding haemodynamic data was available. A third global assessment
from baseline to peak VO2 was also calculated. However, in practice, I felt that any slight inaccuracy
in measuring anaerobic threshold would have a knock on effect on the time point at which cardiac
output was measured, and therefore affect both baseline to anaerobic threshold and anaerobic
threshold to peak results. To remedy this, I felt that rather than measuring the cardiac output at
different points in time, a more standardised method would be to use measure the cardiac output at
given workloads. This would also have the advantage of making comparison between individuals and
groups easier. I had both respiratory and haemodynamic data for every 30 second interval of the
exercise test, and therefore was able to determine values for cardiac output and VO2 at any given
workload. I chose workloads of 0, 25, 50, 75, 100, 150, 200 and 250 watts, and measured VO2, stroke
volume and heart rate (and derived cardiac output and A-V oxygen difference) at each, as I felt this
would be the best way of evaluating dynamic changes.
3.3 Study cohort
3.3.1 Inclusion criteria
Consecutive patients fulfilling conventional task force criteria for the diagnosis of HCM (34)
attending the cardiomyopathy clinic at The Heart Hospital between July 2011 to June 2012, who
were due to have cardiopulmonary exercise testing as part of their routine clinical care were
enrolled.
3.3.2 Exclusion criteria
 Patients under the age of 16
 Exercise limiting disease other than cardiac, eg severe peripheral vascular or joint
disease
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 Endurance athletic trained individuals (patient reported)
 Significant pulmonary disease (defined as FEV1 or FVC <80% predicted in accordance
with NICE guidelines for the diagnosis of chronic obstructive pulmonary disease (288))
 More than moderate valvular heart disease (European Association of Echocardiography
guidelines (289,290))
 Cardiac pacing
 Pulmonary hypertension (defined as mean pulmonary artery systolic pressure
≥25mmHg) 
 Left ventricular systolic dysfunction (defined as an ejection fraction measured by
echocardiography using Biplane Simpson’s method <55%)
 Permanent AF
 A pre-existing diagnosis of anaemia
3.3.3 Statistics
Continuous variables are presented as mean ± standard deviation (SD). Analysis was carried out
using SPSS statistical software version 19 (SPSS for Windows, IBM, USA). Differences between two
groups were assessed using independent 2 sample t test and within groups at different workloads
using paired t test. One way analysis of variance (ANOVA) with homogeneity of variance testing, and
post hoc Bonferonni or Games-Howell corrections were used as appropriate to assess differences
between multiple groups. Pearson’s coefficient was used to assess for correlation. Linear regression
analysis was used to assess the predictors of cardiac reserve in patients. A p value <0.05 was
considered significant.
3.3.4 Echocardiography
All patients underwent detailed transthoracic echocardiographic examination according to British
Society of Echocardiography protocol. The following parameters were entered into a microsoft excel
spread sheet:
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 Maximal left ventricular wall thickness (mm)
 Left ventricular diastolic cavity dimension (mm)
 Valvular lesions (none / mild / moderate / severe)
 Left ventricular systolic function (normal / mild / moderate / severe impairment)
 An ejection fraction was calculated by Simpson’s method. If images were of insufficient
quality, where possible another modality (eg MRI) was used (n=4), and in the absence of this
a visual assessment was made (n=19).
 Left ventricular diastolic function (Grade 1-4)
 Septal and lateral S wave, E wave and lateral E/E’ were documented. If a patient was in AF
the average of 5 consecutive beats was taken.
 Left Atrial size (mm, taken from parasternal long axis view)
 Resting LVOT gradient (mmHg)
o Care was taken to ensure the LVOT and not mitral regurgitation Doppler profile was
interrogated.
 Provocable LVOT gradient (following Valsalva manoeuvre - maximal attempted exhalation
against a closed airway for as long as is tolerated)
o Defined as a peak LVOT gradient ≥50mmHg during provocation. 
The gradient on Valsalva provocation was documented in every patient to give some measure of
propensity for provocable obstruction. It is however recognised that this will fail to identify a
proportion of patients with provocable LVOT obstruction (120). This is partly because it is often
performed in the lying position where preload is reduced and partly because the manoeuvre fails to
adequately increase afterload and contractility in the same manner as for example exercise. The
Heart Hospital protocol is for patients to perform the Valsalva manouvre in the upright position,
including after squatting if possible to maximise the sensitivity of the test. However the frequency
with which squatting was performed was not documented.
Following routine clinical assessment, patients suspected of having provocable obstruction during
exercise with no significant gradient at rest or during Valsalva manoeuvre were referred for and
underwent symptom limited bicycle ergometer or treadmill exercise echocardiography to determine
their maximum provocable LVOT gradient. This minimises the chance of grouping a patient
incorrectly, and is considered a gold standard in clinical practice for elucidating LVOT obstruction. In
practice, 11 patients had this investigation. A patient was classed as having non-obstructive
hypertrophic cardiomyopathy if the resting LVOT gradient was <30mmHg, obstructive HCM if
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≥30mmHg, and provocable HOCM if the gradient induced by provocation manoeuvre or exercise was 
≥50mmHg.  It is clear however that some patients who by this definition fall into the resting 
obstruction cohort also have an increase of this gradient on exercise and may therefore also be
considered provocable. I also therefore assessed LVOT gradient as a continuous variable. These
thresholds are determined by convention (291). A gradient of ≥50 mm Hg is usually considered to be 
the threshold at which LVOT obstruction becomes haemodynamically important. This concept comes
from studies that demonstrate progressive impedance to flow above this value (56).
3.3.5 Master database
All demographic, echocardiography, respiratory and haemodynamic data was recorded in a database
as follows:
 Demographic Data
o Unique patient identifier
o Date of birth
o Age
o Gender
o Ethnicity
o Weight (kg)
o Height (cm)
o Body surface area (calculated using the mosteller formula (292))
o Reason for stopping exercise
o Haemoglobin
o Diagnosis code
 Normal control
 HCM without LVOT obstruction
 HCM with LVOT obstruction
o Smoking history
o Level of exercise
 An assessment of patient’s training / physical status was made:
 0 = no regular physical activity
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 1 = some regular physical activity
 2 = regular aerobic physical activity (≤3 sessions per week)  
 3 = trained athlete
o NYHA functional class
o Medication (including time since last dose)
o History of previous intervention for LVOT obstruction
o Risk factors for sudden cardiac death
 History of ICD insertion
 Family history sudden cardiac death
 MWT ≥30mm 
 History of syncope
 ABPR to exercise
 History of non-sustained VT
 Heart Rate Data
o Resting heart rate
o Predicted peak heart rate (220 – age women, 210 – age men)
o Peak heart rate achieved
o Percent predicted heart rate achieved
o Heart rate at 25, 50, 75, 100, 150, 200, 250 Watts (where applicable)
o Heart rate deficit (predicted heart rate – achieved heart rate)
o Heart rate at 1 minute
o Percent fall in heart rate at 1 minute
o Heart rate at 3 minutes
o Percent fall in heart rate at 3 minutes
o Change in heart rate (peak heart rate – resting heart rate)
o Chronotropic incompetence (defined as a failure to reach 80% predicted heart rate)
 Respiratory data
o FEV1
o FVC
o FEV1 : FVC ratio
o Weight corrected predicted VO2
o Baseline VO2
o Peak VO2
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o Percent predicted VO2
o VO2 at 25, 50, 75, 100, 150, 200, 250 Watts (where applicable)
o Respiratory exchange ratio
o Anaerobic threshold
o Gradient of VO2 : work ratio
 Haemodynamic data
o Blood pressure
 Baseline systolic blood pressure (mmHg)
 Baseline diastolic blood pressure (mmHg)
 Baseline MAP (mmHg)
 Resting pulse pressure (mmHg)
 Peak exercise systolic blood pressure (mmHg)
 Peak exercise diastolic blood pressure (mmHg)
 Peak exercise MAP (mmHg)
 Blood pressure response (mmHg)
o Stroke volume
 Baseline stroke volume (ml)
 Stroke volume at 25, 50, 75, 100, 150, 200, 250 Watts (ml, where applicable)
o Cardiac output
 Cardiac output pre-mouthpiece (L/min)
 Baseline cardiac output (L/min) and index (L/min/m2)
 Peak cardiac output (L/min) and index (L/min/m2)
 Delta cardiac output (L/min)
 Percent change cardiac output
 Cardiac output at 25, 50, 75, 100, 150, 200, 250 Watts ((L/min), where
applicable)
 Cardiac output at peak VO2
o Peak cardiac power (watts)
 Cardiorespiratory data
o Peak workload (watts)
o Gradient of the slope of Cardiac output : VO2
o Intercept of the slope of Cardiac output : VO2
o Oxygen extraction (gradient of the slope of VO2: cardiac output (ml/100ml blood)
o A-V oxygen difference at rest (ml/100ml)
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o A-V oxygen difference at 25, 50, 75, 100, 150, 200, 250 Watts (where applicable)
o Delta A-V oxygen difference
 Echocardiographic data
o Maximal wall thickness (mm)
o Left atrial size (mm)
o Left atrial size index (mm/m2)
o Left ventricular end-diastolic diameter (mm)
o Left ventricular end-diastolic diameter (mm/m2)
o LVOT gradient at rest (mmHg)
o LVOT gradient on Valsalva provocation (mmHg)
o LVOT gradient during exercise (mmHg, where available)
o Left ventricular ejection fraction
o Tissue doppler velocities
 Septal Ea
 Septal S
 Lateral Ea
 Lateral S
 Lateral E:Ea ratio
o Valvular heart disease >moderate
o Presence of pulmonary hypertension
Patient data were grouped according to diagnosis for statistical analysis. Details of specific tests used
will be described in the relevant sections.
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4 Methods – anatomy
4.1 Assessment of the effect of aorto-septal angulation on
provocable left ventricular outflow tract obstruction in hypertrophic
cardiomyopathy
This was a retrospective cohort study. The study complied with the declaration of Helsinki and NHS
research governance arrangements. I reviewed the images and case-notes of 179 consecutive
patients fulfilling conventional diagnostic criteria for HCM (34) from our dedicated cardiomyopathy
clinic, in whom there was a clinical suspicion of provocable obstruction but no resting gradient,
referred for stress echocardiography between August 2004 and December 2008. None of the
patients had received interventional gradient reduction therapy (myectomy/ASA).
Contemporaneous peak oxygen consumption measured during symptom limited upright bicycle
ergometer exercise testing, functional class and medication data were recorded in all patients. The
control group consisted of 25 age and sex matched individuals referred for transthoracic
echocardiography to investigate symptoms of chest pain or breathlessness, who were subsequently
found to have normal studies, with no history of hypertension, myocardial or valvular heart disease.
Resting transthoracic echocardiography was performed using vivid i7 (GE Vingmed Ultrasound,
Horten, Norway) and Philips Sonos 7500 (Philips Medical Systems, Andover, MA, USA) platforms
using standard acquisition protocols (British Society of Echocardiography). Exercise
echocardiography was performed using the same equipment, simultaneously with symptom-limited
exercise on an upright bicycle ergometer using a ramp protocol. Echocardiographic parameters were
measured according to European Society of Echocardiography guidelines (289,290,293) using
EchoPAC (GE) software. Basal septal thickness was measured in the parasternal short axis view. SAM
was defined as incomplete if there was any movement of the mitral valve leaflets or chordae toward
the ventricular septal endocardium without septal contact; and as complete when there was contact
with the ventricular septum during systole. Mitral regurgitation was graded as none, mild, moderate
or severe at rest and during provocation (290). LVOT gradient was measured using continuous wave
Doppler in the apical 5 chamber view at rest, during exercise at 2 minute intervals, immediately on
cessation of exercise and 2 minutes into recovery. The maximal value was then reported. Care was
taken to interrogate the LVOT and not a mitral regurgitation or mid cavity obstruction Doppler
profile. Resting LVOT obstruction was defined as a peak LVOT gradient ≥30 mmHg, and provocable 
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LVOT obstruction was defined as a gradient ≥50mmHg during provocation. The smallest LVOT 
diameter below the aortic valve annulus during ventricular systole was measured in the parasternal
long axis view.
The mode of provocation is important. Valsalva is commonly performed to elicit a gradient during
echo, and has been used for decades (294,295). However, this has been shown to significantly
underestimate both the presence of provocable obstruction and the magnitude of the gradient
demonstrated during exercise. Exercise echocardiography, particularly in the upright position, is the
best method of diagnosing a latent gradient being more reproducible, and has the advantage of
being able to correlate imaging data with patient symptoms (119). Exercise triggers LVOT
obstruction because of increased contractility and an increase in heart rate which limit filling,
particularly if performed in the upright position when outflow tract gradients become higher still
(296,297). Rapid changes in preload during recovery represent the most likely explanation for the
post exercise development of outflow obstruction. Maron demonstrated that the Valsalva
manoeuvre had a sensitivity of only 40% for identifying the presence of an exercise-induced outflow
gradient (119). The specificity was 100% for assessing whether patients without obstruction at rest
would generate a gradient with exercise (positive predictive value, 100%; negative predictive value,
60%). In patients with both a Valsalva-induced and an exercise-induced gradient, the outflow
obstruction generated during the Valsalva manoeuver significantly underestimated the magnitude
generated during exercise. Exercise gradients exceeded Valsalva by 24±25 mm Hg (for the 30 to 49
mm Hg exercise-provocable group; P=0.04) and by 65±46 mm Hg (for the ≥50 mm Hg exercise-
provocable group; P<0.0001). Interestingly in this cohort 84% of those with an exercise induced
gradient of >50mmHg were in NYHA functional class II. What is not known is how many of these will
go on to develop symptoms or indeed a deteriorating physiological picture.
The LVOT gradient may reduce quickly on cessation of exercise in the supine position (296,297). A
similar study aimed to reproduce patient’s mode of exercise (i.e. patient do not often immediately
lie down following a period of exercise) and noted a continued increase in LVOT gradient on
cessation of exercise in the orthostatic position (298). This group contained patients with both
resting and latent obstruction, although a significant number were on cardiac medication which may
have reduced the gradient. Following immediate cessation of exercise, venous return is reduced as
peripheral muscles stop contracting leading to an increased intraventricular gradient. The
obstruction may then be ameliorated on assumption of a supine position after exercise. The authors
postulated this is the mechanism by which patients often experience symptoms of syncope / pre-
syncope following exercise.
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4.1.1 Measurement of aorto-septal angle
A parasternal long axis view taken at the R wave of the surface electrocardiogram was used for
analysis. The image was analysed using a DICOM image viewer (SOBOX version 2.3.0.1). The aorto-
septal angle was measured using a modification of the technique originally described by Fowles
(186), and defined as the angle between a line drawn along the border of the right and left inter-
ventricular septum (parallel to the proximal right ventricular endocardial border) and a line drawn
through the long axis of the aortic root (figure 4.1), where a value of 180 degrees would be a straight
line from septum to aorta and reducing values represent increasing angulation.
An additional cardiologist (Dr Joel Salazar) trained in echocardiography and cardiomyopathy
assessed all images, and measured the aorto-septal angle as above. In 29 patients,
contemporaneous CMR images were available, and 3-D datasets were loaded onto a standard offline
work station (Leonardo, Siemens Medical Solutions) for analysis of the LV-aortic root angle. This
angle was measured in a multi-planar reformatted LVOT view (intended to replicate the
echocardiographic images) using the same reference lines as for echocardiography.4.1.2 Statistics
Normally distributed variables are presented as mean ± standard deviation (SD), and non-normally
distributed data as median and interquartile range. Analysis was carried out using SPSS statistical
software version 19 (SPSS for Windows, IBM, USA). The mean value of the angle measured by two
observers was used as an independent variable, and assessed alongside the above additional
echocardiographic parameters using a linear regression model to determine the univariate
predictors of the peak provocable LVOT gradient. Significant factors were then entered into a
stepwise elimination model to determine multivariate predictors. A similar model was used to
determine the predictors of the aorto-septal angle. Binary logistic regression and receiver operator
characteristic (ROC) curve analysis was used to determine the sensitivity and specificity of the aorto-
septal angle alone or in combination with resting incomplete SAM to detect the presence of
provocable LVOTO. Differences between two groups were assessed using independent 2 sample t
test. One way ANOVA with homogeneity of variance testing, and post hoc Bonferonni or Games-
Howell corrections were used as appropriate to assess differences between multiple groups. Inter-
observer variability was assessed using a two-way mixed model intra-class correlation coefficient
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(absolute type) and Pearson’s correlation. Intra-observer variability was not assessed. Agreement
between echocardiography and CMR measured angles was assessed using Pearson’s correlation
coefficient and Bland-Altman analysis. For all tests a p value <0.05 was considered significant.
Figure 4.1. Transthoracic echocardiogram, parasternal long axis view: example of construction of
reference lines for aorto-septal angle calculation.
Panel A: The septal line was drawn along the junction of left and right inter-ventricular septum
(checked arrows), parallel to the proximal right endocardial border (white arrows). Panel B: The
aorto-septal angle was defined as the angle between the septal line, and a line drawn through the
long axis of the aortic root where a value of 180 degrees would be a straight line from septum to
aorta and reducing values represent increasing angulation.
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4.2 CT imaging of the left ventricular outflow tract in patients with
hypertrophic cardiomyopathy undergoing invasive septal reduction
therapy
Cardiac CT scanning can be performed in most patients, with rare contra-indications. Spatial
resolution is very good (0.4mm), and with contemporary scanners the ionising radiation dose is low.
Pre-and post-operative imaging is therefore feasible. Many patients with HCM have ICDs or
pacemakers precluding them from MRI scanning. Whilst leads and generators can degrade CT
images making resolution of small structures more difficult, adequate images in these cases are still
achievable. Additonally, imaging of the lung fields may yield further clinically useful information. This
technique was therefore chosen to assess cardiac structure before and after myectomy surgery.
Patients were recruited from specialist cardiomyopathy clinics at the Heart Hospital, who were being
assessed for LVOT gradient reduction therapy. Initially this included myectomy surgery only,
although was expanded to include ASA following continued suspension of the surgical program. The
study complied with the declaration of Helsinki and NHS research governance arrangements (REC
reference number 08/H0713/51).
Patients had their CT scan at Great Ormond Street Hospital, using a 64 slice Siemens Somatom
Definition scanner, supervised by Prof Andrew Taylor. Scans were retrospectively ECG-gated and
used 100mls Omnipaque 350 contrast. Auto bolus tracking was performed with a region of interest
drawn in the ascending aorta from a scout scan, and triggered at 100HU. Coverage began at the mid
aortic arch and included the whole heart.
CT image data were reconstructed by using Mimics software (Materialise, Ann Arbor, Mich). All
reconstructions were executed by one operator (Claudio Capelli) with 8 years of experience. Image
elaboration for each CT data-set took 4-5 hours. The Digital Imaging and Communications in
Medicine data were imported into the Mimics software for image processing. These data were
viewed in two dimensions (transverse, coronal, and sagittal sections) and in 3D after segmentation.
Segmentation masks were then used to detect the region of interest—in this case, the left ventricle.
Thresholding was the first action performed to create a segmentation mask. The region of interest
was selected by defining a range of gray values. The boundaries of this range were the lower and
upper threshold values. All pixels with a gray value in this range were highlighted in a mask. To
detect the inner arterial wall, two suitable threshold values were chosen.
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Next, a region-growing algorithm was used to eliminate noise and separate structures that were not
connected. Finally, manual editing functions were used to draw, erase, or restore parts of the image
by clicking on single pixels. When the region of interest was completely selected, the software
constructed a 3D model of the structure by means of pattern recognition and interpolation
algorithms. In this way, it was possible to generate the volume of the ventricle wall.
Once the first 3D model was generated 2 subsequent functions were performed. First, the dedicated
wrap was using to create a more uniform surface of the left ventricle. This tool was found useful in
consideration of the complex ventricle structure and to filter small inclusions or close small holes.
Following sensitivity analysis the following parameters were set up and kept consistent for each data
set: smallest detail = 0.5 mm and closing distance = 0.5 mm. Finally, a smoothing algorithm
(smoothing factor 1.0, iterations =3) was applied. These values were the results of a sensitivity
analysis performed on the entire cohort of reconstructions to identify the optimal setting to model
all the anatomies in this study without creating artefacts (i.e. increasing too much the smoothing
factor may lead to unrealistic anatomies). The values of such sensitivity analysis are reported to
guarantee repeatability of this study if the same commercially available software is used. The
obtained volume was eventually automatically calculated.
Volumes were calculated for the best systolic and diastolic frame pre and post-operatively. The
difference between the pre and post operative figures was intended therefore to represent the
volume of muscle resected plus any changes attributable to remodelling in the intervening period.4.2.1 Statistics
Normally distributed variables are presented as mean ± standard deviation (SD), and non-normally
distributed data as median and interquartile range. Analysis was carried out using SPSS statistical
software version 21 (SPSS for Windows, IBM, USA). Differences between groups were assessed using
independent 2 sample t tests. For all tests a p value <0.05 was considered significant.
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5 Results
5.1 Cardiac output measurement validation study
5.1.1 Cohort
The study cohort consisted of 24 healthy volunteers (12 male, ages 35 ± 8 years, height 174 ± 8cm,
weight 72 ± 13kg) with no history of cardiorespiratory disease. These volunteers were all National
Health Service employees at the time of testing.
Valid results at rest and on exercise were achieved in 20 of 24 participants. Two participants were
unable to successfully perform the respiratory manoeuvres required to measure cardiac output
using the C2H2 technique, and a further 2 participants had inconsistent finger pulse pressure
waveforms and were excluded. The overall correlation between all finger plethysmography and C2H2
data obtained during rest and exercise was r2 = 0.872, p <0.0001 (Figure 5.1).5.1.2 Rest
Resting heart rate was 77 ± 11 beats per minute. Mean finger plethysmography derived cardiac
output was 5.3 ± 1.1 L/min (5.7 ± 0.8 L/min in men and 4.9 ± 1.2 L/min in women). Corresponding
mean C2H2 uptake cardiac output was 5.2 ± 1.2 L/min (5.7 ± 0.8 L/min in men 4.6 ± 1.4 L/min in
women). There was no significant difference between the results obtained with each technique at
rest (p=0.712). The correlation coefficient was 0.902, p <0.0001. Mean difference (bias) between
techniques was -0.1 L/min with a standard deviation (precision) of 0.5 L/min. Bland Altman plots for
rest and exercise are shown in figure 5.2. The mean fractional deviation from C2H2 uptake derived
cardiac output at rest was -4 ± 15% (0 ± 9% in men and -8 ± 18% in women (figure 5.3)). At rest, 3 of
the 20 finger plethysmography values differed by >10% from the corresponding C2H2 values.
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Figure. 5.1. Graph showing correlation between acetylene and finger plethysmography derived
cardiac output
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Figure. 5.2 Bland-Altman plot showing difference between (a) resting and (b) sub-maximal
exercise cardiac output acetylene uptake and finger plethysmography values plotted against their
mean.
Solid lines represent mean differences, dotted lines represent mean differences ± 1.96 x SD.
A
B
91
Figure 5.3 Fractional difference between finger plethysmography derived cardiac output and the
acetylene uptake method.
Solid line represents mean difference, dotted lines represent ±10%. Top whisker - highest case
within 1.5 times inter-quartile range, top of box – third quartile, middle line – median, bottom of box
– first quartile, bottom whisker – lowest case within 1.5 times inter-quartile range5.1.3 Exercise
Mean exercise duration was 7 minutes 23 (± 68) seconds. Time taken to complete three steady state
C2H2 technique cardiac output measurements was 76 ± 12 seconds. Heart rate during sub-maximal
exercise was 120 ± 15 beats per minute at a workload of 77 ± 24 Watts. Mean finger
plethysmography derived cardiac output was 10.2 ± 2.3 L/min (11.1 ± 1.9 L/min in men and 9.2 ± 2.2
L/min in women). Corresponding mean C2H2 uptake cardiac output was 10.3 ± 2.1 L/min (11.6 ± 1.8
L/min in men and 8.9 ± 1.6 L/min in women). There was no significant difference between the
results obtained during exercise (p=0.898). The combined correlation coefficient was 0.767,
p<0.0001. Mean difference between techniques was 0.1 L/min (± 1.5 L/min). The mean fractional
deviation from C2H2 uptake derived cardiac output on exercise was 0 ± 15% (3 ± 15% in men and -2 ±
15% in women). On exercise 10 of the 20 finger plethysmography values differed by >10% from the
corresponding C2H2 uptake (figure 5.3).
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The mean absolute rise in cardiac output from rest to sub-maximal exercise was 5.1 ± 1.5 L/min
(C2H2) and 4.9 ± 1.5 L/min (finger plethysmography, p=0.64), figure 5.4. The mean percentage
increase in cardiac output from rest to sub-maximal exercise was 50 ± 9% (C2H2) and 47 ± 7% (finger
plethysmography, p=0.374).
Figure 5.4. Graph demonstrating the difference between techniques for the measurement of mean
increase in cardiac output from rest to sub-maximal exercise
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5.2 The effect of left ventricular outflow tract obstruction on cardiac
output response to exercise in hypertrophic cardiomyopathy
Eighty-eight consecutive patients with HCM undergoing cardiopulmonary exercise testing as part of
their routine clinical evaluation were assessed. A consort diagram showing patients included and
reasons for exclusion is shown in Figure 5.5.
Figure 5.5. Consort diagram demonstrating characteristics of HCM patients included and reasons
for exclusion
CPEX – cardiopulmonary exercise test, HCM – hypertrophic cardiomyopathy, LV – left ventricular,
LVOT – left ventricular outflow tract, MR – mitral regurgitation, PFT – pulmonary function test, PHT –
pulmonary hypertension,
The final cohort consisted of 70 consecutive adult patients (55 male, age 47 ± 13 years) with HCM
attending a dedicated cardiomyopathy clinic undergoing cardiopulmonary exercise testing as part of
their routine clinical evaluation and twenty eight normal healthy volunteers (14 male, age 41 ± 12
years). Fifteen on the normal volunteers had participated in the validation study. Patients with
anaemia, respiratory disease (defined as FEV1 or FVC <80% predicted), valvular heart disease, cardiac
pacing, pulmonary hypertension (defined as mean pulmonary artery systolic pressure ≥25mmHg), 
left ventricular systolic dysfunction (defined as an ejection fraction <55% measured by
88 consecutive HCM
patients undergoing
CPEX
40 with LVOT
obstruction
32 included
8 excluded:
1 anaemia
1 PHT
1 abnormal PFT
1 severe MR
2 atrial fibrillation
2 unacceptable finger trace
48 without LVOT
obstruction
38 included
10 excluded:
2 atrial fibrillation
2 PHT
3 severe LV systolic impairment
2 permanent pacing
1 unacceptable finger trace
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echocardiography using Biplane Simpson’s method) or permanent AF were excluded from the study.
Where possible medication was discontinued for 3 half-lives prior to exercise as per hospital
protocol. Patients were telephoned by nursing staff in advance of their appointment. If patients
required medication for symptomatic reasons and could not be withheld the time and date of
dosage was documented. The control group consisted of individuals who had no medical history of
cardiovascular or other systemic disorders. None was involved in heavy exercise or athletic training. I
attempted to age and sex match the control group to the patients, although the mean age of the
controls was slightly lower than the patients due to difficulties recruiting ‘older’ volunteers. It was
not possible to recruit the same number of individuals to the control group. They were employees of
the national health service at the time of testing. They should have undergone echocardiography to
confirm the absence of cardiac disease, although this was not performed. None reported any cardiac
symptoms.
5.2.1 Statistics
Professor Allan Hackshaw (Professor of medical statistics, University College London) reviewed my
data and advised on appropriate statistical testing. Continuous variables are presented as mean ±
standard deviation (SD). Analysis was carried out using SPSS statistical software version 19 (SPSS for
Windows, IBM, USA). Differences between two groups were assessed using independent 2 sample t
test and within groups at different workloads using paired t test. One way ANOVA with homogeneity
of variance testing, and post hoc Bonferonni or Games-Howell corrections were used as appropriate
to assess differences between multiple groups. Pearson’s coefficient was used to assess for
correlation. Linear regression analysis was used to assess the predictors of cardiac reserve in
patients. A p value <0.05 was considered significant.
5.2.2 Demographics
Descriptive clinical and echocardiographic statistics are shown in table 5.1. Thirty eight (54%)
patients had non obstructive HCM and 32 patients had LVOT obstruction (22 (31%) patients with
resting obstruction and 10 (14%) with provocable obstruction). Patients with obstruction had a
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worse functional class (p=0.004), larger maximal wall thickness (19 ± 5 vs 17 ± 4 mm, p=0.019) and
larger E:Ea ratio at the lateral mitral valve annulus, (p<0.0001) than those with non-obstructive
HCM. There was no difference in left atrial size or left ventricular end diastolic dimension between
patient groups.
5.2.3 Workload
Peak workload (Watts) achieved was higher in controls (199 ± 67 W, range 80-365) than non-
obstructive (148 ± 53 W, range 33-269, p=0.001) and obstructive groups (101 ± 47 W, range 26 –
194, p<0.0001). Patients without obstruction achieved a higher peak workload than obstructive
patients (p=0.002). Five non-obstructive patients and no patient with obstruction achieved a
workload >200W; 14 and 8 patients, respectively, achieved a workload between 150 and 200W
(Figure 5.6). No attempt was made to statistically compare patient groups at workloads above 150W
due to small numbers. I initially sought to evaluate haemodynamic responses before, at, and after
anaerobic threshold. However, I found the anaerobic threshold was not always determined with a
high enough degree of precision (ie to the exact percent), and I thought that by evaluating the
haemodynamic parameters at specific workloads this would allow better comparison between
groups. I acknowledge however that the haemodynamic responses will have differed before and
after anaerobic threshold, and therefore this would have been of interest and importance.
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Table 5.1. Descriptive clinical and echocardiographic statistics for cohort
Normal
controls
HCM without LVOT
obstruction
HCM with LVOT
obstruction
Number 28 38 32
Male 14 (50%) 32 (84%) 23 (72%)
Age (years) 41 ± 12 46 ± 13 48 ± 14
Height (cm) 172 ± 9 174 ± 7 172 ± 10
Weight (kg) 73 ± 15 90 ± 19* 86 ± 18†
Body surface area (Mosteller formula, m2) 1.87 ± 0.23 2.07 ± 0.25† 2.02 ± 0.25*
NYHA class I 28 (100%) 25 (66%)† 9 (28%)*, **
NYHA class II 0 12 (32%)† 18 (56%)*, **
NYHA class III 0 1 (3%)† 5 (16%)*, **
NYHA class IV 0 0 0
Left ventricular end diastolic diameter (mm) 48 ± 6 46 ± 5
Left ventricular maximal wall thickness (mm) 17 ± 4 19 ± 5**
Left atrial size (mm) 43 ± 6 43 ± 6
LVOT gradient rest (mmHg) 6 ± 4 55 ± 39**
LVOT gradient peak (mmHg) 11 ± 10 82 ± 31**
Ejection fraction (%) 66 ± 8 68 ± 4
Lateral mitral valve annulus E:Ea ratio 8.4 ± 3.6 13.6 ± 5.9**
Previous alcohol septal ablation 1 0
Previous myectomy surgery 4 1
Usual Medication (withheld >48 hours)
Beta blocker 15 21
Calcium channel blocker 4 6
ACE inhibitor 3 2
Amiodarone 1 0
ACE – angiotensin converting enzyme, HCM – hypertrophic cardiomyopathy, LVOT – left ventricular
outflow tract, NYHA – new york heart association
* HCM with LVOT obstruction vs controls p<0.05
Ώ, D ǁ ŝƚŚŽƵƚ>s KdŽďƐƚƌƵĐƟŽŶǀ ƐĐŽŶƚƌŽůƐƉфϬ.05
** HCM with LVOT obstruction vs HCM without LVOT obstruction p<0.05
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Figure 5.6. Haemodynamic and respiratory parameters during exercise in individuals with good
exercise tolerance.
HCM – hypertrophic cardiomyopathy, LVOT – left ventricular outflow tract
Stroke volume index (A), heart rate (B), cardiac index (C) and oxygen consumption (D) during bicycle
exercise in controls and patients with non-obstructive, and obstructive hypertrophic
cardiomyopathy who were able to exercise at workloads >150 Watts.
The number of individuals in each group at specific workloads was:
Workload 0 25 50 75 100 150 200 250
Normals
HCM with LVOT obstruction
28
32
28
32
28
28
28
23
28
16
28
8
13
2
5
0
HCM without LVOT obstruction 38 38 37 35 32 19 5 3
A
DC
B
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5.2.4 Oxygen consumption
Peak VO2 was higher in controls than patients (34.7 ± 7.7 vs 22.4 ± 6.1 ml/kg/min, p<0.0001). There
was no significant difference in peak VO2 between patients with and without LVOT obstruction (20.5
± 6 vs 24.1 ± 5.9 ml/kg/min, p=0.066). At low workloads (<50W) absolute and relative change in VO2
were comparable (table 5.2, Figure 5.7d) between controls and patients. Above 50W, VO2 was
higher in controls than patients. Patients with LVOT obstruction had a higher VO2 at baseline through
to 75W than patients without obstruction (table 5.3, Figure 5.7d). Above 75W, VO2 was similar
between patient groups.5.2.5 Stroke volume index
In the control group there was an increase in stroke volume index (SVI) from baseline to 50W
(p<0.0001) and 100W (p<0.0001), with a further rise from 100W to 150W (p=0.006), (table 5.2). In
the non-obstructive patients, there was an initial rise in SVI from baseline to 50W (p=0.014) and
100W (p=0.021) but no additional rise was seen between 100W and to 150W (p=0.655).
In patients with LVOT obstruction there was a failure to augment SVI at all workloads. In the small
number of patients able to achieve workloads ≥150W, SVI continued to fall in those with LVOT 
obstruction (fig 5.4). However, analysis of individual patient data demonstrated heterogeneous
responses, with some resembling that seen in the controls (Figure 5.8).
Resting SVI values were similar in patients and controls. The absolute and percentage rise in SVI was
greater at all workloads in controls when compared to patients (table 5.2, Figure 5.7a). Between
patient groups absolute SVI was comparable at rest and at all workloads. However, the percentage
rise from baseline was significantly higher in the non-obstructive group at workloads above 75W
(table 5.3, Figure 5.7a).
Baseline SVI correlated with peak workload achieved in the obstructive group (R = 0.417, p =0.018)
but not in those without obstruction (r= - 0.186, p=0.264) or controls (r= -0.088, p=0.658). However
although the correlation was statistically significant the attributable impact is likely to be very low,
and therefore not much variability in peak workload achieved is likely to be due to baseline SVI or
left ventricular end systolic volume.
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Figure 5.7. Haemodynamic and respiratory parameters during exercise
HCM – hypertrophic cardiomyopathy, LVOT – left ventricular outflow tract.
Stroke volume index (A), heart rate (B), cardiac index (C) and oxygen consumption (D) during bicycle
exercise from 0 – 150 Watts in controls and patients with non-obstructive, and obstructive
hypertrophic cardiomyopathy.
The number of individuals in each group at specific workloads was:
Workload 0 25 50 75 100 150
Normals
HCM with LVOT obstruction
28
32
28
32
28
28
28
23
28
16
28
8
HCM without LVOT obstruction 38 38 37 35 32 19
A
DC
B
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Table 5.2. Cardio-respiratory parameters in normal individuals and patients with hypertrophic
cardiomyopathy during bicycle exercise between 0-150 Watts
Workload (Watts)
0 25 50 75 100 150
Number
Normal
HCM
28
70
28
70
28
65
28
58
28
58
28
27
VO2 (ml/kg/min)
Normal
HCM
4.6 ± 1.6
4.5 ± 1.4
8.8 ± 1.5
8.9 ± 2
12.3 ± 2.9
12.3 ± 2.4
16.7 ± 4
15 ± 2.6
20.2 ± 4.5
17.9 ± 3.2
26.8 ± 5.9
23.2 ± 4.4
p 0.648 0.72 0.907 0.04 0.009 0.017
Heart rate (bpm)
Normal
HCM
81 ± 13
78 ± 14
99 ± 14
95 ± 15
106 ± 15
104 ± 17
118 ± 16
114 ± 17
132 ± 20
124 ± 18
146 ± 20
144 ± 18
p 0.311 0.196 0.523 0.292 0.093 0.813
SVI (ml/m2/beat)
Normal
HCM
42 ± 11
39 ± 11
47 ± 13
41 ± 10
50 ± 14
42 ± 10
50 ± 13
42 ± 10
50 ± 13
42 ± 10
53 ± 13
42 ± 12
p 0.346 0.014 0.001 0.001 0.001 0.002
Cardiac Index (L/min/m2)
Normal
HCM
3.3 ± 0.8
3 ± 0.8
4.6 ± 1.1
3.8 ± 0.9
5.2 ± 1.3
4.3 ± 1
5.8 ± 1.3
4.7 ± 1.2
6.5 ± 1.6
5.3 ± 1.4
7.7 ± 1.8
6 ± 2.1
p 0.037 0.002 <0.0001 <0.0001 0.002 0.003
TPR (dyn.sec/cm5)
Normal
HCM
1360 ± 375
1427 ± 386
1088 ± 420
1264 ± 426
997 ± 346
1181 ± 380
915 ± 276
1042 ± 300
876 ± 303
999 ± 313
739 ± 196
952 ± 326
p 0.433 0.071 0.031 0.063 0.106 0.009
HCM – hypertrophic cardiomyopathy, SVI – stroke volume index, TPR – total peripheral resistance,
VO2 – oxygen consumption
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Table 5.3. Cardio-respiratory parameters in patients with hypertrophic cardiomyopathy with and
without left ventricular outflow tract obstruction during bicycle exercise between 0-150 Watts
Workload (Watts)
0 25 50 75 100 150
Number
HCM with LVOTO 32 32 28 23 16 8
HCM without LVOTO 38 38 37 35 32 19
VO2 (ml/kg/min)
HCM with LVOTO
HCM without LVOTO
4.9 ± 1.4
4.1 ± 1.4
9.7 ± 1.8
8.2 ± 1.8
13.2 ± 2.3
11.6 ± 2.3
16 ± 2.6
14.3 ± 2.4
18.9 ± 3.5
17.3 ± 3
24.1 ± 5.5
22.8 ± 4
p 0.003 <0.0001 0.006 0.014 0.105 0.521
Heart rate (bpm)
HCM with LVOTO
HCM without LVOTO
79 ± 14
77 ± 14
97 ± 16
94 ± 14
107 ± 18
102 ± 16
116 ± 18
112 ± 17
127 ±14
122 ±19
157 ± 16
140 ± 17
p 0.518 0.423 0.309 0.421 0.38 0.026
SVI (ml/m2/beat)
HCM with LVOTO
HCM without LVOTO
41 ± 14
38 ± 9
41 ± 10
41 ± 9
41 ± 10
42 ± 9
41 ± 11
42 ± 10
43 ± 11
43 ± 10
40 ± 9
42 ± 13
p 0.441 0.997 0.648 0.614 0.871 0.626
Cardiac Index (L/min/m2)
HCM with LVOTO
HCM without LVOTO
3.1 ± 0.9
2.8 ± 0.7
3.8 ± 0.9
3.8 ± 1
4.3 ± 1.1
4.3 ± 1
4.7 ± 1.2
4.8 ± 1.3
5.5 ± 1.5
5.2 ± 1.5
6.2 ± 1.9
5.9 ± 2.2
p 0.209 0.87 0.9 0.828 0.582 0.744
TPR (dyn.sec/cm5)
HCM with LVOTO
HCM without LVOTO
1389 ± 404
1459 ± 372
1285 ± 420
1246 ± 436
1187 ± 389
1176 ± 378
1011 ± 315
1063 ± 293
908 ± 233
1044 ± 341
969 ± 324
946 ± 336
p 0.453 0.709 0.917 0.519 0.17 0.879
HCM – hypertrophic cardiomyopathy, LVOTO – left ventricular outflow tract obstruction, SVI – stroke
volume index, TPR – total peripheral resistance, VO2 – oxygen consumption
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Figure 5.8. Differing haemodynamic responses during exercise in two individual patients with
hypertrophic cardiomyopathy and resting left ventricular outflow tract obstruction
Examples shown are of stroke volume index (A), heart rate (B) and cardiac index (C) response during
incremental exercise. The patient with an appropriate stroke volume response was a 37 year old
man, New York Heart Association (NYHA) class I, maximal wall thickness 17mm, left atrial size 44mm,
left ventricular end diastolic dimension 48mm, ejection fraction 65%, resting left ventricular outflow
tract (LVOT) gradient 46 mmHg (increasing to 87mmHg with Valsalva provocation). The patient with
a blunted stroke volume response was a 40 year old man, NYHA class II, maximal wall thickness
16mm, left atrial size 38mm, left ventricular end diastolic dimension 46mm, ejection fraction 73%,
resting LVOT gradient 31 mmHg (increasing to 106mmHg with Valsalva provocation).
A B
C
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5.2.6 Heart rate
Between workloads of 0-150 W, there was no difference in absolute or change in heart rate between
patients and controls (table 5.2, figures 5.5b). At peak exercise, heart rate (146 ± 27 vs 173 ± 17
bpm, p<0.0001) and heart rate reserve (62 ± 26 vs 88 ± 15 bpm, p<0.0001) were lower in patients.
Heart rate at peak exercise was lower in obstructive compared to non-obstructive patients (138 ± 29
vs 152 ± 24 bpm, p=0.035). At individual workloads heart rate was similar in obstructive and non-
obstructive HCM (table 5.3, Figure 5.7c) until 150 W when heart rate was greater in patients with
obstruction (N = 8 obstructive, 19 non-obstructive , 157 ± 16 vs 140 ± 17 bpm, p=0.026). Above
150W, patients with LVOT obstruction had the highest heart rates of any group (Figure 5.6),
although the patient numbers were small.
In the group with LVOT obstruction, 9 patients (28%) were in functional class I, and of these only 1
had chronotropic incompetence (defined as a failure to reach 80% predicted peak HR) which itself
was marginal (76%). 3 of 16 patients achieving >100W and 0 of 8 patients achieving >150W had
chronotropic incompetence.
5.2.7 Cardiac index
Cardiac index was higher at rest in patients than controls (3.3 ± 0.8 vs 3 ± 0.8 L/min/m2, p=0.037),
although during exercise at all workloads both absolute values and magnitude of increase were
lower (table 5.2, Figure 5.7c). Peak cardiac index was higher in controls than patients (9.4 ± 2.9 vs 5.5
± 1.9 L/min/m2, p<0.0001) as was cardiac output reserve (11.6 ± 6 vs 5.3 ± 3.4 L/min, p<0.0001).
Resting (3.1 ± 0.9 vs 2.8 ± 0.7 L/min/m2, p=0.209) and peak (5.3 ± 1.8 vs 5.8 ± 2 L/min/m2, p=0.302)
cardiac index were similar in obstructive and non-obstructive HCM although cardiac reserve was
lower (4.4 ± 2.7 vs 6.3 ± 3.6 L/min, p=0.025) in the obstructive group. The increase in cardiac index in
those with obstruction was significantly lower than that observed in the non-obstructive group at
75W only. There was a trend towards a difference at 50W and 100W (table 5.3).
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5.2.8 Relationship of cardiac index to oxygen consumption
The mean slope of the relationship between cardiac output and VO2 was higher in normal controls
than patients with HCM (5 ± 1.8 vs 3.4 ± 2.1, p=0.001). The slopes were similar in patients with and
without LVOT obstruction (3.3 ± 2.4 vs 3.5 ± 1.8, p=0.661). The linear region of the plot of VO2
against work rate was similar in controls and HCM (10.5 ± 1.1 vs 10.5 ± 1.1, p=0.992), although 4
patients had an abnormal slope (<9). One might expect that the slope would be more shallow in
patients with HCM, and this finding may therefore be indicative that the sample size is too small to
show a statistically significant difference.
5.2.9 Arterio-venous oxygen difference
Analysis of the A-V oxygen difference at different workloads is shown in table 5.4. There were no
differences in A-V oxygen difference at rest between controls and patients. The difference was
significantly wider at all levels of exercise in patients. A-V difference was greater in patients with
LVOT obstruction during submaximal exercise, although this did not reach statistical significance.
In the subgroup of patients able to achieve workloads of ≥150W, patients with LVOTO had the same 
resting A-V oxygen difference as HCM (6.9 ± 2.6 vs 6.1 ± 2.5 ml/100ml, p=0.281), but this became
significantly higher during sub-maximal (50W, 12.2 ± 3.5 vs 9.7 ± 3.1 ml/100ml, p=0.011) and
maximal (19.3 ± 4.8 vs 15.5 ± 4 ml/100ml, p=0.007) exercise.
The maximum oxygen pulse (A-V oxygen difference x stroke volume) was reduced in patients
compared to controls (18 ± 4 ml / beat vs 21 ± 4, p=0.001), although there was no difference in
patients with and without LVOT obstruction 18 ± 5 ml / beat vs 17 ± 3, p=0.415).
5.2.10 Predictors of cardiac reserve
Univariable analysis of the predictors of cardiac reserve in patients is shown in table 5.5. Resting
ejection fraction, left ventricular end diastolic dimension and left atrial size did not correlate with
the increase in cardiac output on exercise. Age, gender, peak LVOT gradient and E:Ea ratio at the
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lateral mitral valve annulus were all significantly associated with cardiac output reserve and were
entered into a stepwise multivariable analysis model. The final significant multivariable factors were
age (β -0.11, CI -0.162 - -0.057, p<0.0001), peak LVOT gradient (β -0.018, CI -0.034 - -0.002, p=0.031) 
and gender (β-2.286, CI -0.162 - -0.577, p=0.01).
Table 5.4. Arterio-venous oxygen difference during exercise in patients with hypertrophic
cardiomyopathy vs controls
Normal
Controls
HCM without LVOT
obstruction
HCM with LVOT
obstruction
A-V O2 at rest
(ml/100ml)
5.8 ± 2.5 6.5 ± 2.6 7.1 ± 2.6
A-V O2 at 25W 7.9 ± 2.8* 9.9 ± 3.7 11.3 ± 3.6
A-V O2 at 50W 9.6 ± 3.2*,† 12.5 ± 3.9 13.7 ± 4
A-V O2 at 100 W 12.7 ± 3.9 15.5 ± 5.1 15.6 ± 4.1
A-V O2 at 150 W 14.4 ± 4.7† 18.8 ± 5.4 17.9 ± 6.8
A-V O2 at peak exercise 14.8 ± 4† 18.4 ± 6 17 ± 4.5
Δ A-V O2 8.9 ± 3† 11.6 ± 4.9 9.9 ± 3.7
A-V O2 – arterio-venous oxygen difference, LVOT – left ventricular outflow tract.
* HCM with LVOT obstruction vs controls p<0.05
†HCM without LVOT obstruction vs controls p<0.05
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Table 5.5. Univariate predictors of cardiac reserve during exercise in hypertrophic cardiomyopathy
Correlation coefficient (r) P value β Lower CI Upper CI
Age -0.511 <0.0001 -0.128 -0.183 -0.073
Female Gender -0.376 0.002 -3.093 -5.043 -1.144
Maximal wall thickness 0.22 0.083 0.163 -0.022 0.347
Left atrial size -0.037 0.773 -0.021 -0.164 0.123
Left ventricular end
diastolic diameter
0.04 0.757 0.024 -0.129 0.176
Peak left ventricular
outflow tract gradient
-0.273 0.03 -0.022 -0.041 0.002
Ejection Fraction 0.145 0.258 0.07 -0.052 0.192
Lateral mitral valve
annulus E:Ea ratio
-0.286 0.027 -0.178 -0.334 -0.021
5.2.11 Predictors of stroke volume augmentation
Univariate analysis of the predictors of increase in stroke volume from baseline to 75 W in patients
with hypertrophic cardiomyopathy is shown in table 5.6. Variables with a p-value <0.2 were entered
into a stepwise multivariate analysis model. The final predictors were peak LVOT gradient (p=0.047)
and the change in heart rate to 75 W (p<0.0001), overall r=0.56, p<0.0001.
Univariate analysis of the predictors of increase in stroke volume from baseline to peak exercise in
patients with hypertrophic cardiomyopathy is shown in table 5.7. Variables with a p-value <0.2 were
entered into a stepwise multivariate analysis model. The final predictors were peak LVOT gradient
(p=0.002), MWT (p=0.001) and heart rate reserve (p=0.006), overall r=0.511, p<0.001.
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Table 5.6. Predictors of percentage stroke volume augmentation (%) from baseline to moderate
exercise (75W)
Correlation coefficient (r) P value β Lower
CI
Upper
CI
Age 0.014 0.92 0.023 -0.439 0.485
Female Gender -0.146 0.277 -11.316 -31.979 9.348
Maximal wall thickness 0.144 0.285 0.706 -0.605 2.017
Left atrial size 0.284 0.032 0.953 0.084 1.822
Left ventricular end diastolic
diameter
0.008 0.955 0.029 -1.004 1.063
Peak left ventricular outflow
tract gradient
-0.263 0.048 -0.141 -0.281 -0.001
Ejection Fraction -0.002 0.989 -0.006 -0.829 0.818
E/Ea lateral -0.123 0.374 -0.562 -1.819 0.695
change in heart rate to 75W
(bpm)
-0.51 <0.0001 -0.742 -1.079 -0.404
5.2.12 Blood pressure
MAP at rest (90 ± 12 vs 90 ± 8 mmHg, p=0.791) and peak exercise (108 ± 16 vs 114 ± 13 mmHg,
p=0.117) was similar in patients and controls. Resting systolic (118 ± 18 vs 124 ± 17 mmHg, p=0.154)
and mean arterial (88 ± 11 vs 92 ± 12 mmHg, p=0.099) blood pressure was similar in patients with
and without obstruction; patients with obstruction had a lower peak systolic (152 ± 28 vs 168 ± 29
mmHg, p=0.018) and mean arterial (104 ± 16 vs 112 ± 16 mmHg, p=0.033) blood pressure than non-
obstructive patients. Magnitude of blood pressure response in patients with obstruction was 34 ±
21 vs 44 ± 21 mmHg (p=0.106). An ABPR (failure to increase systolic blood pressure >20mmHg)
during exercise was seen 13 (19%) patients (8 (25%) with vs 5 (13%) without LVOT obstruction,
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p=0.2). There were no differences in resting pulse pressure, heart rate, heart rate reserve, VO2, peak
cardiac output, cardiac reserve and peak and delta SVI between patients with and without an ABPR
to exercise.
Table 5.7. Predictors of stroke volume augmentation (%) from baseline to peak exercise
Correlation coefficient (r) P
value
Β Lower
CI
Upper
CI
Age -0.161 0.207 -0.374 -0.962 0.213
Female Gender -0.057 0.659 -4.309 -23.766 15.149
Maximal wall thickness 0.272 0.031 1.861 0.174 3.547
Left atrial size 0.117 0.361 0.609 -0.713 1.931
Left ventricular end diastolic
dimension
-0.082 0.525 -0.449 -1.855 0.957
Peak left ventricular outflow
tract gradient
-0.193 0.129 -0.141 -0.325 0.042
Ejection Fraction 0.099 0.442 0.44 -0.698 1.578
E/Ea lateral -0.089 0.499 -0.505 -1.99 0.98
Heart rate reserve -0.198 0.12 -0.237 -0.537 0.063
5.2.13 Total peripheral vascular resistance
There was no difference in TPR at rest between patients and the control group (1360 ± 375
dyn.sec/cm5 vs 1427 ± 386, p=0.433). During exercise, TPR was higher in patients than controls (table
5.8, Figure 5.9a). There was no significant difference in TPR at rest or during exercise in patients with
and without LVOT obstruction (table 5.3). There was no difference in TPR at rest between patients
with and without an ABPR to exercise (1333 ± 316 dyn.sec/cm5 vs 1449 ± 399, p=0.334). During
exercise, TPR was lower in patients with an ABPR, with values similar to normal individuals (table
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5.8, Figure 5.9b). Although lower at all workloads, this was statistically significant at 25 and 100
watts only. This may be a reflection of statistical power, as the numbers of patients with an ABPR to
exercise was small. Ninteen percent of patients were found to have an ABPR to exericse, which is
slightly lower than one third of cases reported in previous (larger) series (85,86).5.2.14 Cardiac power
There was a trend towards lower peak cardiac power in patients with LVOT obstruction (2.51 ± 1.14
vs 3.04 ± 1.28 W, p=0.086). There was no relationship between peak cardiac power output and the
number of conventional risk factors for SCD, p=0.534. Three (9%) patients with HCM and 12 (40%)
with HOCM had peak cardiac power values <1.96W (p=0.04).
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Table 5.8. Total Peripheral Resistance in patients with hypertrophic cardiomyopathy with and
without an abnormal blood pressure to exercise during bicycle testing between 0-150 Watts
Workload
(Watts)
Parameter Patients without ABPR Patients with ABPR P Value
0 Number 57 13
TPR (dyn.sec/cm5) 1449 ± 399 1333 ± 316 0.334
25 Number 57 13
TPR (dyn.sec/cm5) 1312 ± 447 1052 ± 231 0.005
Percent change in TPR from
baseline
-7 ± 30 -19 ± 16 0.184
50 Number 52 11
TPR (dyn.sec/cm5) 1212 ± 377 1037 ± 377 0.168
Percent change in TPR from
baseline
-13 ± 23 -18 ± 23 0.508
75 Number 47 10
TPR (dyn.sec/cm5) 1068 ± 306 921 ± 249 0.16
Percent change in TPR from
baseline
-21 ± 21 -29 ± 8 0.057
100 Number 38 7
TPR (dyn.sec/cm5) 1036 ± 325 800 ± 114 0.002
Percent change in TPR from
baseline
-25 ± 19 -34 ± 15 0.245
150 Number 22 3
TPR (dyn.sec/cm5) 985 ± 325 716 ± 275 0.187
Percent change in TPR from
baseline
-28 ± 24 -34 ± 11 0.679
ABPR – abnormal blood pressure response, TPR – total peripheral resistance
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Figure 5.9. Total peripheral resistance (dyn.sec/cm5) during increasing bicycle workload between
(A) controls and patients with HCM (B) patients with and without LVOT obstruction (C) patients
with and without an abnormal blood pressure response to exercise (D) controls and patients with
and without an abnormal blood pressure response to exercise
ABPR – abnormal blood pressure response, CI – confidence intervals, HCM – hypertrophic
cardiomyopathy, LVOT – left ventricular outflow tract, TPR – total peripheral resistance
A B
DC
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5.3 The influence of aorto-septal angulation on provocable left
ventricular outflow tract obstruction in hypertrophic cardiomyopathy
On the day of exercise 19 patients were found to have a LVOT gradient at rest ≥30mmHg at rest and 
were excluded from analysis. The final study cohort therefore consisted of 160 patients (105 males,
age 48 ± 14 years). Descriptive demographic and echocardiographic statistics are shown in table 5.9.
12 (8%) patients were unable to perform exercise and underwent measurement of the LVOT
gradient following the administration of sublingual glyceryl tri-nitrate in combination with Valsalva
manoeuvre. 59 (37%) patients were taking either a beta blocker or calcium channel blocker and
were unable to discontinue before the test for symptomatic reasons; a further 40 (25%) patients
withheld these drugs for a minimum of 48 hours prior to study. No patient was taking any other
medication likely to have impacted upon pre- or afterload. Provocable LVOTO was present in 60
(38%) patients. There was no difference in absolute (22.0 ± 8.1 vs 20.3 ± 7 ml/kg/min, p=0.199) or
percent predicted (71 ± 20 vs 68 ± 19 %, p=0.415) peak oxygen consumption between patients with
or without provocable LVOTO. 12 (20%) patients with and 10 (10%) without provocable LVOTO were
in NYHA class III (p=0.097).
5.3.1 Aorto-septal angle
Patients with HCM had a smaller aorto-septal angle than controls (1130 ± 12 vs 1260 ± 6, p<0.0001).
There was no difference in aorto-septal angle between men and women (1120 ± 13 vs 1140 ± 11,
p=0.297). There was a weak negative correlation between aorto-septal angle and both age (r= -
0.242, p=0.002) and height (r= -0.181, p=0.036). With increasing age, there was a trend towards a
steeper aorto-septal angle, p=0.083, Figure 5.10. There was no relationship between aorto-septal
angle and body weight. There was no correlation between aorto-septal angle and basal septal
thickness or LVOT systolic diameter.
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Table 5.9. Patient demographics, clinical and echocardiographic characteristics
Patients with HCM Controls
Demographics & baseline data
Age (years)
Male gender
Height (cm)
Weight (kg)
Peak oxygen consumption (ml/kg/min)
Percent predicted peak oxygen consumption
50 (19), range 16-82
105 (66%)
173 (14)
82 ± 16
19.0 (11.4)
67 (32)
47 (11)
16 (64%)
171 (18)
79 ± 14
n/a
n/a
Medication
Calcium antagonist or beta-blocker on day of test
Calcium antagonist or beta-blocker withheld >48 hours pre-test
59 (37%)
40 (25%)
New York Heart Association functional class
2
3
138 (86%)
22 (14%)
Echocardiographic parameters
Basal septal thickness (mm)
Left ventricular outflow tract systolic diameter (mm)
Aorto-septal angle (degrees)
16 ± 4
19 ± 3
113 ± 12 (range 79-140)
9 ± 1
27 ± 3
126 ± 6
Left ventricular outflow tract gradient (mmHg),
Whole cohort
<30
30-49
50-69
≥70 
Systolic anterior motion of the mitral valve
None
Incomplete
Complete
Mitral regurgitation
None
Mild
Moderate
Severe
Rest
7 (6)
160 (100%)
-
-
-
82 (51%)
78 (49%)
0
19 (12%)
139 (87%)
2 (1%)
0
Provocation
28 (69)
81 (51%)
19 (12%)
12 (8%)
48 (29%)
62 (39%)
39 (24%)
59 (37%)
17 (11%)
120 (75%)
20 (13%)
3 (2%)
3 ± 1
25 (100%)
16 (64%)
9 (36%)
Normally distributed data mean ± standard deviation, non-parametric data median (inter-quartile
range). Note no change in parameters with provocation in normal controls.
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Figure 5.10. Box plot showing aorto-septal angle by age group
Top whisker - highest case within 1.5 times inter-quartile range, top of box – third quartile, middle
line – median, bottom of box – first quartile, bottom whisker – lowest case within 1.5 times inter-
quartile range.
5.3.2 Relationship between echocardiographic variables and provocableLVOT obstruction
Univariate analysis of echocardiographic variables and their relationship to peak provocable LVOT
gradient is shown in table 5.10. Aorto-septal angle (β: -1.18; CI -1.68, -0.68; p<0.0001), incomplete 
SAM at rest (β: 30.59; CI 18.15, 43.04; p<0.0001) and degree of resting mitral regurgitation (β: 20.61; 
CI 2.64, 38.59; p=0.025), overall r=0.508, p<0.0001, were independently associated with peak
provocable LVOT gradient.
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Table 5.10. Univariate predictors of peak provocable left ventricular outflow tract gradient
Factor r β CI P
Lower Upper
Aorto-septal angle 0.319 -1.165 -1.708 -0.622 <0.0001
Basal septal thickness 0.048 -0.613 -2.618 1.392 0.547
Incomplete systolic anterior motion of the mitral valve
(rest)
0.366 33.06 19.861 46.259 <0.0001
Mitral regurgitation grade (rest) 0.197 25.604 5.535 45.677 0.013
Left ventricular outflow tract systolic diameter 0.014 -0.24 -2.949 2.469 0.861
The aorto-septal angle was smaller in patients with provocable LVOTO (1080 ± 12 vs 1160 ± 12,
p<0.0001), Figure 5.11. When grouped by LVOT gradient, a smaller aorto-septal angle was found in
patients with increasingly severe LVOTO, p=0.004, Figure 5.12.
Figure 5.11. Histogram showing variation in aorto-septal angle between patients with
hypertrophic cardiomyopathy with and without provocable left ventricular outflow tract
obstruction (LVOTO).
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Figure 5.12. Box plot showing decreasing aorto-septal angle with increasing severity of provocable
left ventricular outflow tract gradient.
LVOT - left ventricular outflow tract. Top whisker - highest case within 1.5 times inter-quartile range,
top of box – third quartile, middle line – median, bottom of box – first quartile, bottom whisker –
lowest case within 1.5 times inter-quartile range.
Area under receiver operator curves for aorto-septal angle, incomplete rest SAM, and the two
parameters combined for the prediction of provocable LVOTO were 0.68 (95% CI 0.59 – 0.76,
p<0.0001), 0.67 (95% CI 0.58 – 0.76, p<0.0001 and 0.76 (95% CI 0.68 – 0.83, p<0.0001), respectively
(Figure 5.13). Sensitivity, specificity and positive predictive value for SAM and aorto-septal
angulation are shown in table 5.11.
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Figure 5.13. Receiver operator characteristic curves showing the probability that aorto-septal
angle, presence of systolic anterior motion of the mitral valve and both combined predict patients
who develop provocable left ventricular outflow tract obstruction during exercise.
ROC – receiver operating characteristic, SAM - systolic anterior motion of the mitral valve
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Table 5.11. Sensitivity, specificity and positive predictive value to predict provocable left
ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy using resting
echocardiographic parameters.
Sensitivity (%) Specificity (%) Positive predictive value (%)
Incomplete SAM rest 70 64 54
Aorto-septal angle ≤ 100o
N=25 (16%)
27 91 59
Aorto-septal angle ≤ 100o
and incomplete SAM rest
N=8 (5%)
12 99 88
Aorto-septal angle ≤ 110o
N=37 (23%)
62 71 56
Aorto-septal angle ≤ 110o
and incomplete SAM rest
N=19 (12%)
23 95 74
SAM – systolic anterior motion of the mitral valve5.3.3 Reproducibility
All images were deemed usable for the purpose of angle measurement by both observers. The intra-
class correlation coefficient of the aorto-septal angles measured by the two observers was 0.90 (95%
CI 0.87-0.93, p<0.0001), with Pearson’s coefficient r=0.82, p<0.0001). Correlation between the
aorto-septal angle measured using echocardiography and CMR was r=0.50, p=0.006. The mean
difference between the echocardiography angle – CMR angle was -6o (SD 11). A Bland-Altman plot of
the differences in angle measured using the two modalities plotted against their mean is shown in
Figure 5.14.
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Figure 5.14. Bland-Altman plot of the differences between aorto-septal angulation measured using
transthoracic echocardiography and cardiac magnetic resonance (CMR) imaging. Solid line
represents mean, dashed line represents mean ± 2 standard deviations
CMR - cardiac magnetic resonance
120
5.4 CT imaging before and after left ventricular outflow tract
gradient reduction therapy
In total, 21 patients had a CT scan prior to planned LVOT reduction therapy (16 myectomy, 5 ASA).
As previously discussed, this project was hampered by by temporary halting of the myectomy
surgical program. As such, the final study cohort consisted of 10 patients, who had pre and post-
operative CT scans between May 2010 and August 2012. Tabulated data and illustrative figures
follow. Two patients were operated on at the Heart Hospital, and 7 at St Georges Hospital, London.
One patient had ASA at the Heart Hospital. In those operated on at the Heart Hospital, the
myectomy sample was weighed. Of the 10 patients, reconstructions were not possible in 2 patients
due to inadequate scan resolution. In the remaining 8 patients’ pre-operative CT scans, all diastolic
images were adequate, and 5 systolic images were adequate. In the post-operative scans, 7 diastolic
and 6 systolic images were adequate.
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Table 5.12. Surgical and functional data for study cohort
ID age procedure
tissue
removed
(grams)
complications
NYHA
pre
NYHA
post
time pre-
op CT to
surgery
(days)
Time to
post-op
CT
(days)
1 44
extended
septal
myectomy,
PFO closure,
AV repair,
LAA excision
10.7
required aortic valve
repair
3 1 27 219
2 56
septal
myectomy,
LAA excision
4 none 2 2 15 184
3 46 myectomy
Atrial fibrillation
requiring hospitalisation
3 2 381 363
5 51 myectomy
stroke, pericarditis,
wound infection
requiring VAC dressing
and re-operation
3 2 283 356
6 36 myectomy coronary artery fistula 3 2 164 207
7 67 myectomy none 3 2 24 188
11 59
myectomy,
maze, LAA
excision
amiodarone
thyrotoxicosis
3 2 353 209
13 45
myectomy
CABG and
PFO closure
bleeding requiring
return to theatre
3 2 322 193
20 45 myectomy
pericardial effusion,
became infected with
pseudomonas, sternal
destruction and pain.
Small VSD 40mmHg
3 2 134 235
16 42
Alcohol
septal
ablation
none 3 2 113 286
CABG- Coronary artery bypass grafting, CT- computed tomography, LAA- Left atrial appendage,
NYHA- New York Heart Association, PFO- Patent foramen ovale, VAC- vacuum assited closure, VSD-
Ventricular septal defect
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Table 5.13. Pre and post operative cardiopulmonary exercise testing
ID
VO2 (ml/kg/min-1)
pre
% predicted
VO2 pre
VO2 (ml/kg/min-1)
post
% predicted
VO2 post
change in
VO2 (%)
1 11.6 55 9.8 47 -16
2 13.5 45 n/a n/a n/a
3 na Na n/a n/a n/a
5 23.3 72 24.2 n/a 4
6 24 60 23.4 63 -3
7 13.3 49 16.3 64 23
11 17.4 58 13.5 48 -22
13 16.1 50 13.7 44 -15
20 16.2 47 n/a n/a n/a
16 24 68 n/a n/a n/a
VO2 – oxygen consumption
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Table 5.14. Echocardiographic parameters for the study group
ID
LA
(mm)
LVEDD
(mm)
BST
pre
(mm)
BST
post
(mm)
Change in
BST (%)
MWT
(mm)
EF pre
(%)
EF post
(%)
E/E’
pre
E/E’
post
1 39 47 16 11 -31 16 65 60 10 n/a
2 45 44 16 9 -44 16 65 56 12 12
3 40 49 19 12 -37 19 60 50 9 af
5 42 40 18 9 -50 18 72 50 n/a 9
6 36 35 33 9 -73 33 68 60 n/a 7
7 41 42 18 13 -28 18 75 65 n/a 10
11 51 48 18 13 -28 19 66 60 n/a n/a
13 56 63 18 10 -44 18 65 65 13 10
20 45 43 15 13 -13 15 60 60 9 n/a
16 45 51 14 14 0 16 60 60 5 10
BST- basal septal thickness, EF- ejection fraction, LA- left atrial dimension, LVEDD- left ventricular
end diastolic diameter, MWT- maximal wall thickness, SAM- systolic anterior motion of the mitral
valve
ID SAM LVOT gradient (mmHg) Mitral regurgitation
pre post
Pre-
op
rest
pre-op
Valsalva
pre-op
stress
Post-op
rest
Post op
Valsalva
post op
stress
Pre-op
rest
pre-
op
stress
Post
-op
1 2 0 100 123 n/a 13 13 n/a mild n/a mild
2 1 1 42 62 65 8 8 50 mild Mild mild
3 2 0 116 n/a n/a 11 11 n/a mild n/a mild
5 1 0 48 55 104 5 5 n/a mild mod mild
6 1 0 7 22 90 8 8 16 trace Mild mild
7 1 1 80 105 n/a 40 52 75 mild n/a mild
11 1 0 15 45 105 4 4 n/a mild n/a mild
13 2 1 107 n/a n/a 11 11 n/a mild n/a mild
20 2 0 63 63 n/a 3 3 n/a mild n/a mild
16 1 0 6 11 64 4 4 11 trace n/a trace
LVOT – left ventricular outflow tract, SAM – systolic anterior motion of the mitral valve
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Figure 5.15. Assessment of myocardial volume change pre- and post- operatively
The yellow image is pre-operative, and the purple image post-operative. By subtracting the volume
of one from the other it is possible to assess change in myocardial volume.
Figure 5.16. Assessment of change in intra-cardiac blood volume
By tracing the endocardial border before and after surgery, it is possible to determine the change in
blood volume of the left ventricular cavity
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Figure 5.17. Example of how imaging issues can affect accurate data collection.
Panel A: best systolic frame. Panel B: best diastolic frame. Note significant degradation of images as
the heart moves during systole (patient weight 124 kg)
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Figure 5.18 Changes in diastolic ventricular volume following left ventricular outflow tract gradient
reduction therapy
Figure 5.19 Changes in systolic ventricular volume following left ventricular outflow tract gradient
reduction therapy
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Table 5.15. Measured post-operative changes in cardiac ventricular volume
Patient
difference in volume
(diastole, cm3)
difference in volume
(systole, cm3)
Mass of tissue removed at
operation (g)
1 -16 -26 10.7
2 -89 -101 4
3 -199
5 -47
6 -14 1
7 -78
11 53 -12
16 35 N/A – Alcohol septal ablation
5.4.1 Statistical analysis
Median time from pre-operative CT to myectomy was 149 (304) days, and from surgery to post-
operative CT was 214 (112) days.
Mean pre-operative VO2 was 17.7 ± 4.9 ml/kg/min-1 (56 ± 9% predicted). Post-operative VO2 was
16.8 ± 5.8 ml/kg/min-1 (53 ± 10% predicted), p=0.752. Mean change in VO2 post-operatively was -5 ±
17%.
Mean pre-operative LA size was 44 ± 6mm, LVEDd 46 ± 8 mm, BST 19 ± 5mm, EF 66 ±5%. Post
operative mean BST was 11 ± 2 mm (a reduction of 35 ± 20%, p=0.001), EF 59 ± 5% (p=0.012).
Mean pre-operative LVOT gradients (mmHg) were 58 ± 42 (rest), 61 ± 38 (Valsalva), 86 ± 20
(exercise). Mean post-operative LVOT gradients (mmHg) were 13 ± 12 (rest, p=0.008) and 14 ± 16
(Valsalva, p=0.006).
Mean change in diastolic volume was a reduction of 22 ± 54 cm3, and in systolic volume was a
reduction of 67 ± 84 cm3.
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6 Discussion
6.1 Assessment of finger plethysmography as a tool for the
measurement of cardiac output on exercise
Finger plethysmography with brachial calibration appears to be a useful tool for the non-invasive
assessment of haemodynamics on exercise and provides additional information to that of routine
respiratory gas analysis.
In this study I examined the values for cardiac output at rest and sub-maximal exercise in a cohort of
normal individuals derived from finger plethysmography and the single breath C2H2 uptake
technique. At rest there was good agreement between the techniques. There was a good correlation
between techniques at both rest and exercise, although correlation does not necessarily denote
accuracy. At rest the C2H2 technique values were very slightly lower than finger plethysmography, a
trend which was reversed on exercise. Given the difficulties of assessment of cardiac output on
exercise, the spread of results in this study suggest that the precision of values is within acceptable
limits, and could identify a deficit in cardiac reserve likely to be of significance in clinical practice. The
magnitude of rise in cardiac output from rest to exercise was consistent with the workload achieved
using both techniques.
Inert gas rebreathing techniques have been extensively used for the calculation of cardiac output
(208,218). They are non-invasive, relatively inexpensive and can be performed in conjunction with
routine cardio-pulmonary exercise tests. In our institution non-invasive cardiac output measurement
is routinely performed using a single breath C2H2 technique, the accuracy of which is comparable to
re-breathing techniques (299). However, the respiratory manoeuvres are technically challenging to
perform, particularly at high workloads and in individuals with cardiorespiratory disease. Inert gas
techniques have been validated against invasive techniques at rest (227,300-302) and during
exercise (203,303-307) in both health and disease states and thus provide a valid measure against
which other non-invasive techniques can be measured.
Cardiac output is calculated by the finometer using the Modelflow method (213). The dynamic
changes in aortic dimensions during the cardiac cycle are described by a model of aortic input
impedance (aortic characteristic impedance, arterial compliance and TPR) (261-263). The finometer
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simulates this model and applies it to the measured arterial pressure waveform in the finger. The
resulting waveform is integrated during systole to calculate stroke volume and hence cardiac output
by multiplying by the heart rate.
The aortic impedance during systole depends on the mechanical properties of the aorta, which are
influenced by the intra-arterial pressure (as blood remaining within the aorta from the previous
heart beat will offer resistance to further pulsatile flow towards it) and the external pressure exerted
on the walls (i.e. trans-mural pressure) (264). Two of the model parameters, aortic characteristic
impedance and arterial compliance (aortic elasticity), are derived from the age- and sex-dependent
aortic pressure–area relationship (265) and so age, sex, height and weight are manually entered.
This is because the relationship between the cross-sectional area of the aorta and pressure is non-
linear, increasing rapidly at lower pressures and more slowly at higher pressures, characteristics
which vary between individuals (266). An elastic aorta will expand with minimal rise in pressure, but
it is well recognised that aortic compliance decreases with ageing (267). The aortic impedance and
arterial compliance are the major determinants of systolic inflow, with peripheral resistance of less
importance (213).
Early studies comparing cardiac output derived by arterial pulse wave analysis of Portapres (Finapres
Medical Systems, the Netherlands) derived data showed a lower precision and accuracy compared
to CO2 re-breathing, although this was prior to implementation of contemporary algorithms (274).
Modelflow derived cardiac output has been shown to correlate with inert-gas rebreathing derived
cardiac output during static exercise in the upright position (276). Changes in cardiac output are
tracked by Modelflow across various experimental protocols (268,277,278) and postural stress
(212,264). Two studies have examined finger plethysmography during dynamic exercise (225,226).
Sugawara et al used exercise in the semi-supine position on a bicycle ergometer and compared
finger plethysmography derived cardiac output with that calculated using the Doppler velocity
profile of flow in the ascending aorta taken from a non-imaging transducer in the supra-sternal
notch whereas Tam et al used an open-circuit C2H2 technique. Importantly both methods used the
Portapres device, which lacks the brachial calibration cuff of the Finapres, which improves the
accuracy of the pressure measurement being entered into the Modelflow equation (256,308). In
comparison to this previous work assessing finger plethysmography on exercise, the additional use
of brachial calibration appears to improve accuracy compared with Doppler and C2H2 techniques
respectively. In addition, I felt the use of a splint to maintain the hand in a neutral position may have
helped improve the peripheral pulse wave signal which could be compromised by forceful gripping
of handlebars during exercise. The index (rather than middle) finger was splinted for participant
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comfort whilst wearing the splint. Bland Altman analysis of uncorrected data in the former study
showed a mean difference of 1.8 L/min (SD 1.9 L/min). In the latter study the mean difference was
1.83 L/min (SD 4.11 L/min) improving to 0.24 L/min (SD 3.48 L/min) following correction by an
independent method. Recently Bartels et al published a study comparing the Nexfin monitoring
system (BMEYE B.V.,Amsterdam, The Netherlands) with an inert gas rebreathing technique (309).
This also uses pulse contour analysis and was found to reliably measure cardiac output on exercise in
normal individuals, and my data supports the use of finger plethysmography for the measurement of
cardiac output on exercise despite the differences in equipment and methodology.
Routine cardio-pulmonary exercise testing does not incorporate an assessment of the cardiac output
response to exercise which alongside respiratory data may be fundamental to both diagnosis and an
understanding of symptoms in patients with cardiac disease. Whilst the limitations of non-invasive
techniques of assessing haemodynamic variables on exercise are acknowledged, finger
plethysmography with brachial calibration may provide useful adjunctive information during cardio-
pulmonary exercise testing.
6.1.1 Limitations - general
Time of day, caffeine intake and smoking on the day of the exercise test were not routinely
documented and unstandardised, and might have been of influence. Two volunteers were excluded
because a reliable finger plethysmography trace could not be achieved. The ability of a participant to
exhale at a constant flow rate of 0.5L / second during exercise was variable due to breathlessness,
although was achieved in the majority of cases.Two people were excluded due to a failure to
successfully perform the respiratory manoeuvres, a common barrier to effective employment of the
C2H2 technique in clinical practice. In some cases the forced expiration and maximal inhalation
manoeuvres required for the C2H2 uptake technique altered the finger plethysmography waveform
amplitude. In these cases values with a stable waveform immediately preceding the respiratory
manoeuvres were used. In no case did the time of acquisition of corresponding values differ by more
than seven seconds.
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6.1.2 Limitations - HCM
The acetylene inhalation technique to calculate cardiac output has not been validated in patients
with HCM. One might imagine this to be problematic to perform, as patients may have abnormalities
of anatomical and physiological deadspace and VQ mismatching, given the alterations in VE/VCO2
slopes. This may affect tissue and plasma solubility of the gases used in the calculation of cardiac
output. In turn, this may affect the reliability of the method as a tool for validation of finger
plethysmography in this population. I did not have the resources to validate finger plethysmography
against an invasive technique, particularly during exercise.
The Finapres technique makes several assumptions of normality when calculating cardiac output, for
example aortic size and pressure waveform reflection along the arterial tree, each of which may be
affected by abnormalities of arterial compliance and peripheral resistance. LVOT obstruction itself
may alter the measured arterial waveform as blood flow is abnormal during cardiac ejection. Aortic
elastic properties (strain, distensibility and stiffness) assessed using echocardiography (310) and
CMR (97),and arteriograph-derived pulse wave velocity and augmentation index (310) have been
shown to be abnormal in HCM. The lack of validation during exercise of the method against a
technique known to be accurate in HCM is therefore a significant limitation.
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6.2 Functional consequences and associations of left ventricular
outflow tract obstruction in hypertrophic cardiomyopathy
Several assumptions have been made in the interpreting of these finger plethysmography data,
including the central and peripheral arterial waveform, and the compliance, size and elasticity of the
aorta in patients with HCM which pose significant limitations. Notwithstanding those assumptions,
these data indicate that cardiac index during exercise in HCM is limited by a failure to augment SVI
and to a lesser extent heart rate at peak exercise. Patients with resting LVOT obstruction have a
greater reduction in cardiac reserve than non-obstructive patients at all stages of exercise and a fall
in SVI at higher workloads accompanied by a compensatory increase in heart rate. Within the cohort
with LVOT obstruction, different patterns of stroke volume responses were observed in patients that
otherwise appeared similar using standard clinical and echocardiographic criteria.
Patients with LVOT obstruction who were able to achieve higher workloads had a larger resting
stroke volume than those who were more limited. Furthermore, within the cohort of patients with
LVOT obstruction, different patterns of stroke volume responses could be elicited in patients who
otherwise appeared similar using standard clinical and echocardiographic criteria. These findings
suggest that non-invasive cardiac output measurement might be of value in selecting those patients
who would most benefit from invasive treatments to reduce LVOT gradients. Lastly, for the first
time, I demonstrated that during early exercise, VO2 is higher in patients with LVOT obstruction, but
fails to increase during exercise. The mechanism appears to be an abnormal increase in A-V oxygen
difference during exercise compared to normal individuals.
6.2.1 Mechanisms of impaired cardiac output response
There are many potential mechanisms for an impaired cardiac output response to exercise in
patients with HCM, including LVOT obstruction, systolic and diastolic dysfunction, mitral
regurgitation, chronotropic incompetence and myocardial ischemia. The incidence and prevalence of
severe systolic impairment in HCM is relatively low (35,43) although contractile impairment is often
overlooked as clinically significant reductions in systolic performance may occur while the measured
ejection fraction remains within the normal range. Relatively little is known about cardiac output
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and stroke volume response during exercise, due to the difficulties in accurate measurement of
dynamic physiological variables.
A few studies using continuous nuclear ventriculography have shown that patients with non-
obstructive HCM have a reduction in systolic performance on exercise unrelated to the degree of
septal hypertrophy (83,92,93). My findings show that the cardiac response to exercise is severely
constrained by an inability to increase stroke volume and, to a lesser extent, heart rate. At the
extremes of work in the LVOTO group, high compensatory heart rate responses that coincided with a
fall in stroke volume were evident in some patients.
Although VO2 may be influenced by several factors, a linear relationship exists between VO2 and
cardiac output in normal individuals during exercise (235). Previous invasive work in HCM showed a
significant association between the rise (but not resting or peak) in cardiac index on exercise and
peak VO2 (81). I used the cardiac reserve, measured non -invasively from baseline as a dependant
variable to assess exercise limitation in HCM and investigate the association with several
haemodynamic parameters. Stroke volume may fall at peak exercise in normal individuals, and so
the measurement at peak VO2 may be difficult to interpret. I therefore also assessed the percentage
change in stroke volume at both peak and sub-maximal workloads as a dependent variable to
remove some of the influence of resting left ventricular cavity size, and gain more information on
dynamic change. The haemodynamic measurements made non-invasively in this study are
comparable with previous radionuclide (89,311) studies. Peak exercise cardiac output values were
slightly lower than in invasive studies by Frenneaux (81,107), although my cohort were older with
lower peak VO2 which may explain this. The resting values for cardiac output may seem slightly
higher than one would expect which in part is explained by an anticipation reaction to the imminent
exercise test.
6.2.2 Left ventricular outflow tract obstruction and stroke volume
In normal individuals at low levels of exercise, cardiac output increases linearly as result of an
increase in both stroke volume and heart rate (243). Stroke volume increases as a result of an
increase in left ventricular filling pressure (increased inotropy) and end diastolic volume and to a
smaller extent by a fall in end systolic volume (increased preload) through the Starling mechanism
(230,243).
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Whether LVOT obstruction represents a true physical barrier to the ejection of blood during left
ventricular systole, and therefore what role it plays in stroke volume and exercise limitation in HCM
has not been proven and remains a source of controversy. Discrepancies are often seen between
exercise limitation and the magnitude of left ventricular outflow tract gradient (81,110) implying
additional factors are important. Despite this, successful treatment of LVOT obstruction is often
reported to be accompanied by an improvement in functional class, maximal VO2 and blood pressure
response (101,184,312). However, reduction of LVOT gradient is not always associated with an
improved exercise capacity (176), the mechanism by which this occurs is incompletely understood. It
may be that patient selection can be refined to target those patients with LVOT obstruction who
neither augment stroke volume on exercise nor mount a compensatory tachycardic response and
therefore may benefit more.
I hypothesised that LVOT obstruction results in reduced anterograde aortic flow, which could be
measured during exercise using finger plethysmography. My results suggest that patients with HCM
are unable to augment their stroke volume during exercise compared to normal individuals, but
importantly that the presence of LVOT obstruction further limits the cardiac output response.
A few studies using continuous nuclear ventriculography have shown that patients with non-
obstructive HCM have evidence of a reduction in systolic performance on exercise that is unrelated
to the degree of septal hypertrophy (83,92,93).
Stroke volume was an important determinant of exercise capacity in 23 patients with HCM studied
invasively, although only 4 of these had LVOT obstruction (107). Another early invasive study did not
demonstrate any significant relationship between the incidence and magnitude of resting LVOT
gradient and peak VO2 (108). However, in the presence of obstruction, radionuclide and
echocardiographic indices of impaired left ventricular systolic performance and atrial systolic failure
were related to percent predicted VO2. In the non-obstructive group, diastolic function was of more
importance in identifying those with a reduction in percent predicted VO2 <70%.
Jones et al investigated the relationship of gas exchange indices during incremental exercise in
patients with HCM compared to a control group (79). They found a low maximum value of oxygen
pulse in patients (numerically equivalent to the product of stroke volume x A-V oxygen difference).
Although not measured directly, they felt this was consistent with the failure to continue to increase
stroke volume during exercise although a widening of the A-V oxygen difference could not be
excluded (79). Only 12 patients with LVOT obstruction were included in the cohort, but no additional
differences in submaximal or maximal exercise response were seen compared to patients without
135
obstruction. The same investigators later showed in a larger study the magnitude of LVOT gradient
to be inversely proportional to peak VO2, anaerobic threshold and oxygen pulse (75). My results
expand on these findings, demonstrating not only a failure of stroke volume augmentation, but also,
for the first time, a widening of the A-V oxygen difference, and heterogenous haemodynamic
responses between otherwise clinically similar patients.
In comparison, an early study in 1984 using radionuclide angiography in 57 patients (26 with
obstruction at rest) investigated the proportion of blood ejected from the left ventricle during
systole, and concluded there was no difference between those patients with and without
obstruction, although ejection was earlier in both groups compared to normal individuals (313).
My results showed that MWT was higher in patients with obstruction, and a univariate predictor of
stroke volume augmentation from base to peak exercise with a weak positive correlation. However,
the β value of 1.861 is very small when considering the units of wall thickness measurement are 
millimetres, therefore so is the magnitude of its influence, and was not significant in multivariate
analysis. Potentially this could reflect some patients with longstanding ‘burnt out’ disease with
thinner myocardium, who despite ‘normal’ ejection fraction by Simpsons method do have left
ventricular contractile impairment and as such are likely to have depressed cardiac output response
to exercise.
LVOT obstruction was the only consistently significant multivariate predictor of cardiac reserve,
stroke volume augmentation at both moderate and intense physical activity. As expected, age was
negatively correlated with cardiac reserve, as was female gender on account of size. Heart rate
reserve was weakly negatively correlated with stroke volume augmentation from base to peak
exercise; similarly the delta heart rate at 75W was weakly negatively correlated with stroke volume
augmentation at this workload. Viewed inversely, this suggests that patients with an impairment of
stroke volume augmentation maintain their cardiac output through tachycardia, which is consistent
with the other heart rate data collected.
6.2.3 Diastolic function
I used resting E/Ea ratio as a marker of diastolic function, and found it to be significantly higher in
patients with LVOT obstruction than non-obstructive disease, and a significant univariate predictor
of cardiac reserve.
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The ability to increase diastolic dimensions on exercise plays an important role in increasing stroke
volume. During exercise at higher heart rates, filling time is shorter therefore magnifying the
importance of volume. During pharmacological provocation of LVOT obstruction in HCM, the
development of LVOT obstruction causes prolongation of systole at the expense of diastolic time
(314). In addition, patients with obstruction have been shown to have abnormally short resting
diastolic times compared to controls. This is aggravated during exercise, where significant reductions
in filling time are seen compared with both controls and non-obstructive HCM (311). In this study by
Plehn loss of diastolic filling time was associated with lower stroke volume at both rest and exercise,
and at peak exercise was a significant multivariate predictor of the rise in cardiac output. There was
a positive correlation between baseline outflow gradient and the corresponding loss of diastolic time
in patients with obstruction, although the effect on cardiac reserve was not directly assessed. In my
cohort peak heart rate and heart rate reserve was significantly lower in patients with LVOT
obstruction which coupled with a reduction in stroke volume augmentation further reduces cardiac
output response.
6.2.4 Relation between cardiac output and oxygen consumption
The relationship between cardiac output and VO2 is assumed to be linear (237,238) and the slope
similar across different age groups (218). In this study the mean slope of the relationship between
cardiac output and VO2 was higher in normal controls than patients with HCM, consistent with the
observation that cardiac output response to exercise is limited and therefore A-V oxygen difference
must be widened to perform work.
At maximal exercise, oxygen extraction reaches values of 14-18 ml / 100 ml blood (234,235,243). In
my study the A-V oxygen difference was similar between patients and controls at rest, but became
wider in patients from early to peak exercise, possibly to help compensate for an inability to
appropriately increase cardiac output. This implies that the impairment of stroke volume
augmentation in HCM, and the additional barrier to flow posed by mechanical LVOT obstruction is
associated with a chronic increase in oxygen extraction, akin to the effects of athletic training. Whilst
at first glance the ability for patients with HCM to appear trained in this way seems counter-
intuitive, it does make sense in going part way to explain the large number of patients (and
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undiagnosed individuals) who have relatively few symptoms despite anatomically significant heart
muscle disease.
However, a wide A-V oxygen difference is not necessarily the result of supra-normal oxygen kinetics
because fractional oxygen extraction is related to the ratio of the diffusive oxygen capacity to the
perfusive oxygen delivery (ie blood flow to the exercising muscle) (315). When blood flow to
exercising muscle is reduced (for example in HCM) the ratio of diffusion to perfusion becomes
relatively exaggerated, and oxygen extraction is increased. The relationship between factors
affecting oxygen diffusion and perfusion therefore determines overall A-V oxygen extraction,
although both are affected in cardiovascular disease. Chronic heart failure (CHF), for example, causes
a multitude of deleterious effects in peripheral muscle, including increased vasoconstriction and
metaboreflex (316), and decreased endothelial function (317), capillarity (318) and functional
capillarity haematocrit (315). However, a wider A-V oxygen difference in CHF does not necessarily
lead to improved exercise performance because the capacity of skeletal muscle to use oxygen is
impaired with reductions in mitochondrial oxidative enzyme activity and volume density as well as
mitochondrial dysfunction (319,320). Similarly, patients with HCM and β myosin heavy chain (321) 
and to a lesser extent troponin T (322) mutations have been shown to have peripheral abnormalities
of oxygen metabolism and in these patients with both muscle diffusion and perfusion abnormalities,
it may be that a relatively higher degree of dysfunction in the former causes a reduced capacity for
overall A-V oxygen transport and consequently more severe impairment of exercise performance.
Abnormal endothelial function may also contribute to exercise intolerance in HCM. Although the
underlying mechanism is uncertain, endothelial dysfunction has been demonstrated in several ways
in patients with HCM. Stressor tests to measure endothelium-dependent vasomotor function in the
coronary arteries are abnormal (323,324). Microvascular dysfunction is common in HCM, in part
related to myocardial hypertrophy, causing impairment of myocardial perfusion (325). Other
biochemical markers of endothelial dysfunction have been shown to be elevated in HCM compared
to healthy individuals (326-328) with higher values in patients with LVOT obstruction.
Although to my knowledge A-V oxygen difference has not been investigated in HCM, data exists in
CHF literature suggesting that patients with systolic impairment (left venricular ejection fraction
≤40%) have a higher resting A-V oxygen difference than those with normal ejection fraction, which 
becomes wider still on exercise (329). Another study directly measuring A-V oxygen difference in
CHF patients showed higher values at rest, anaerobic threshold and peak exercise in patients with
lower compared to higher peak VO2 (330). During exercise, patients with severe heart failure have a
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greater capability to divert blood from tissue not actively involved in exercise to exercising muscle
(331) possibly as a result of neuro-humoral activation. In this context a wide A-V difference must
occur with a significant local oxygen transport abnormality.
Exercise training in CHF has been shown to improve peripheral structural and functional oxygen
transport (including both widening of the A-V oxygen difference and uptake at a local level) without
increasing central cardiac output (332-334). The underlying mechanism is unclear, although does
not appear to be associated with a reduction in circulating catecholamine levels, a marker of chronic
over-activation of the sympathetic nervous system, common in CHF. Similarly, drugs that affect
oxidative function and muscle oxygen diffusing capacity may have a positive effect on exercise
tolerance in heart failure (335,336) (337,338).
In my study patients with LVOT obstruction had slightly higher values for A-V oxygen difference. If
we assume that oxygen kinetics and diffusion are similar between patients this implies that reduced
muscle perfusion as a consequence of obstruction determines the observed increased A-V oxygen
difference in that sub-group. The ability to actually utilise extracted oxygen effectively has not been
assessed here, and a large A-V oxygen difference may not necessarily correlate with functional
status because of impaired cellular metabolism in the exercising muscle. This may be due to chronic
degenerative changes in the skeletal muscle such as those seen in heart failure with poor nutritional
flow. Alternatively, primary abnormalities of muscle oxygen utilisation such as is recognised in
mitochondrial disease may be the cause (339), and the potential for overlap syndromes with HCM
has previously been discussed.
The relationship between cardiac output and VO2 is assumed to be linear (237,238) and the slope
similar across different age groups (218). The slope in my control group is in good agreement with
previous physiological studies (234,238,340). In my study the mean slope of the relationship
between cardiac output and VO2 was higher in normal controls than patients with HCM, and the
flatter slope seen in patients suggests a larger increase in VO2 is required for a given rise in cardiac
output, consistent with the observation that the cardiac output response to exercise is limited and
therefore A-V oxygen difference must be widened to perform work. Although the slopes were
similar, VO2 was significantly higher in patients with obstruction at rest and during early exercise
despite no significant difference in cardiac or stroke volume index at low workloads, in keeping with
a wider A-V oxygen difference. This may provide part of the explanation for the relative lack of
symptoms in some patients with obstruction.
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6.2.5 Heart rate
Eight patients with obstruction achieved a workload of ≥150W. In these individuals the enhanced 
exercise capacity was driven by a disproportionate tachycardia at higher workloads. Chronotropic
incompetence (defined as a failure to achieve a maximal predicted heart rate >80% predicted) is
relatively common in HCM and associated with a reduction in VO2 (75). These results suggest
patients with a ‘normal’ chronotropic response have the advantage of being able to increase cardiac
output through a disproportionate rise in heart rate even during a continued fall in stroke volume,
which may be an additional explanation for the apparently good functional status of some patients
with LVOT obstruction.
6.2.6 Cardiac power
Cardiac power is thought to be a more direct measurement of cardiac work (242,341), and either as
a continuous variable or dichotomized at a level of 1·96W, is the best predictor of outcome in
patients with congestive heart failure (282). I found there was a trend towards a lower peak cardiac
power in patients with LVOT obstruction, and a significantly higher proportion of patients in this
group fell below the 1.96W threshold. Although overall peak cardiac power did not correlate with
the number of risk factors for SCD, 2 patients with 3 risk factors had very low values (1.5 ± 0.1W).
Prospective data is needed to identify if cardiac work predicts mortality in HCM.
6.2.7 Blood pressure response and peripheral resistance
In spite of a poor cardiac output response, most patients with HCM had mean arterial pressures
during exercise similar to control values due to a compensatory increase in TPR. However, within the
patient cohort a subgroup had an ABPR and yet inappropriately ‘normal’ TPR values. This
observation is consistent with prior data showing that approximately one third of patients with HCM
fail to augment systolic pressure due to excessive vasodilatation (85,86). The mechanism remains
unproven but in part is probably explained by excessive LV mechanoreceptor stimulation. As a
similar ABPR has been reported in aortic stenosis, it might be expected that increased left ventricular
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afterload associated with LVOT obstruction is the trigger for mechanoreceptor activity, but there
was no correlation between the magnitude of blood pressure response and peak resting LVOT
gradient. This suggests that other factors such as heterogeneous stress-strain relations within the
myocardium caused by patchy myocyte disarray and fibrosis are responsible.
Counihan et al showed no association between peripheral haemodynamic indices and LVOT
gradient, although those with abnormal responses had smaller left atrial and left ventricular end
diastolic size (85). There was also a significant association with a family history of SCD, prompting the
authors to conclude that abnormal peripheral responses could be a marker of haemodynamic
instability causing this increased risk. In a subset of HCM patients studied invasively, there was no
significant difference in peak cardiac index between those with and without ABPR to exercise
although this was marginally higher in the former group (86). Cardiac index increased fivefold in both
groups though magnitude of increase was greater in hypotensive patients, implying change in blood
pressure during exercise was not related to cardiac output. There was no difference in LVOT
obstruction between groups suggesting that this was not a factor in exercise hypotension. My results
concur, as I found no difference in the incidence of ABPR to exercise in patients with and without
LVOT obstruction. Nor were there differences in heart rate, heart rate reserve, VO2, peak cardiac
output, cardiac reserve or peak stroke volume between patients with and without an ABPR to
exercise.
In contrast, cardiac output response during exercise was assessed using ambulatory radionuclide
monitoring in 43 patients with HCM by Ciampi (89) who demonstrated that in patients with an ABPR,
ejection fraction and stroke volume fell more (p = 0.032 and p = 0.009, respectively) and cardiac
output increased less (p = 0.001) than they did in patients with HCM with a normal blood pressure
response. The incidence of significant LVOT obstruction in their cohort was the same in both normal
and ABPR groups. Impaired cardiac output response was related to an increase in left ventricular end
diastolic and systolic volumes, potentially secondary to myocardial ischaemia which could be related
to increased oxygen demand seen with higher heart rates during exercise (342).
Resting pulse pressure was shown in a study of 70 patients with HCM to be a predictor of ABPR,
although MAP did not differ significantly between groups (94). The ABPR group also had a higher
resting pulse pressure. My results contradict this, as pulse pressure was nearly identical in patients
with normal and abnormal responses (47 ± 13 vs 47 ± 12 mmHg, p=0.975). Peak and increase in
systolic blood pressure was lower in patients with LVOT obstruction, although I found a similar
proportion of patients with ABPR in each group.
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The relationship between peripheral resistance, mean arterial and venous pressure and cardiac
output is expressed as follows:
ܶ݋ܽݐ ݈ܲ ݁݅ݎ݌ℎ ݁ܽݎ ݈ܴ ݁݅ݏݏܽݐ ݊ܿ݁ = ܯ ݁ܽ ݊ܣݎ݁ݐ ݅ݎ ݈ܽ ܲ ݁ݎ ݏݏݑ݁ݎ − ܯ ݁ܽ ݊ܸ ݁݊ ݋ݑݏܲ ݁ݎ ݏݏݑ݁ݎ
ܥ ܽ݀ݎ ݅ܽ ܱܿ ݑ݌ݑݐ
It was not possible to measure mean central venous pressure, which was assumed to be relatively
constant between groups for the purpose of calculating TPR. Patients with LVOT obstruction had a
lower peak MAP and cardiac output than those without. One may therefore expect TPR to be similar
between the groups, which I demonstrated. By comparison, patients overall had a similar MAP, and
a lower cardiac output at peak exercise to controls; I found the TPR to be correspondingly higher in
patients. It is interesting to note that patients with an ABPR during exercise have very similar TPR
absolute values to normal individuals. MAP and TPR during exercise were lower in patients with an
ABPR, with an appropriately similar rise in cardiac output. My non-invasive data is in close
agreement with the results demonstrated in previous invasive studies (86), although in my study TPR
in the ABPR group fell earlier in the course of exercise. These results show that in the majority of
patients with HCM, the primary cardiovascular abnormality during exercise is an inability to augment
cardiac output, but that a proportion of patients have an independent abnormality of peripheral
vascular response which is associated with exercise hypotension.
6.2.8 Clinical implications
This study shows that patients with HCM have a complex response to physical exercise that is
dominated by a limited cardiac output reserve. LVOT obstruction imposes an additional burden by
further compromising SV during exercise. In addition, I demonstrated heterogeneous
haemodynamic responses between patients with similar clinical characteristics. This implies that in
individual patients, the predominant mechanism of exercise limitation is likely to vary, with central
and peripheral mechanisms playing a greater or lesser role. Recent supporting evidence for this
comes from a study reporting paradoxical falls in LVOT obstruction during exercise in some patients
(343). The corollary is that the response to therapy will also vary. For example, blunting of the
relative tachycardia towards peak exercise with ß-blockade might adversely affect cardiac output
reserve and increase symptoms. Similarly patients with similar degrees of LVOT obstruction may
have a variable response to invasive gradient reduction strategies depending on the degree to which
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LVOT obstruction contributes to exercise intolerance. I hypothesise that non-invasive
haemodynamic assessment of individual patient exercise responses may improve the targeting of
pharmacological and invasive therapies.
Debate exists as to the effect on VO2 of therapies designed to reduce LVOT gradients. The reduction
of LVOT obstruction by ASA (101,312) or myectomy (184) is associated with an improvement in VO2.
Although both procedures effectively treat LVOT obstruction, myectomy has been shown to be
superior to ASA in terms of objective improvement in exercise parameters (344). This improvement
was shown in a recent large surgical series to extend to patients with provocable obstruction but no
significant resting gradient (156). In 249 patients symptoms and functional class were similar to
patients with high resting gradients, and surgical success rates were comparable. In comparison,
Nishimura demonstrated no significant change in VO2 despite a reduction in LVOT obstruction with
DDD pacing (176).
No study has prospectively evaluated the effect of LVOT obstruction reduction therapy on cardiac
output response to exercise. It would seem plausible that either ASA or myectomy should increase
the capacity for stroke volume augmentation on exercise and thus improve the response. Difficulties
to overcome however include the use of negatively inotropic agents commonly prescribed to
patients with symptomatic HCM, and their effect on cardiac output which would be difficult to
correct for. Indeed, it is interesting to note that in patients in whom stroke volume limitation is
deemed contributory to symptoms, that negatively inotropic agents exert a beneficial effect. In
addition, negative chronotropy should in theory improve filling on one hand, but if stroke volume is
limited on exercise, the ability to increase heart rate should be important to increase cardiac output
and thus perform work. The original studies investigating the effect of beta blockers (345-347) and
calcium channel antagonists (162-166) were in small numbers of patients with largely surrogate
echocardiographic or cardiac catheter based endpoints.
6.2.9 Limitations
Time of day, caffeine intake and smoking on the day of the exercise test were not routinely
documented and unstandardised and may have been of influence. The study of cardiovascular
parameters during high intensity exercise is technically challenging, particularly using invasive
methods. Finger plethysmography has been validated at sub-maximal exercise only, and not in
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patients with HCM. However, the workloads achieved and values measured in this cohort during
maximal exercise are comparable to those in normal individuals during my validation study (348) and
in HCM using invasive techniques by others (86). At high workloads the number of patients in the
obstruction group was small making it difficult to show statistical differences between groups.
There were more males in the controls, although there was no gender difference between patient
groups and heterogeneity of haemodynamic response was seen in both sexes. Because of the
relatively small sample size, I could not stratify haemodynamic responses based on gender without
the requirement for many more comparison groups which in itself may introduce error. Based on
their NYHA functional class, I feel this cohort is representative of the wider HCM population,
however I acknowledge there may be an element of referral bias towards more symptomatic
patients given this hospital’s tertiary referral status.
I cannot exclude the possibility that patients deemed to be non-obstructive at rest did not develop
LVOT obstruction on exercise. However, any patient with symptoms suggestive of provocable
obstruction on clinical review had an upright symptom limited stress echocardiogram to document
an exercise induced gradient. In addition if this were the case, it would likely strengthen my results.
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6.3 Structural determinants of left ventricular outflow tract
obstruction in hypertrophic cardiomyopathy
6.3.1 Aorto-septal angulation
The main findings of this study are that patients with HCM have a smaller aorto-septal angle than
controls, and individuals who develop provocable LVOT obstruction during exercise have a smaller
angle than those without obstruction. The angle can be easily and reliably measured using standard
2-D transthoracic echocardiography in patients with HCM, and is more specific than the presence of
SAM for the identification of provocable LVOT obstruction.
6.3.2 Determinants of provocable LVOT obstruction and aorto-septalangulation
A variety of structural features are associated with LVOT obstruction including anterior displacement
of papillary muscles (140), reduced LVOT area (196) and primary mitral valve abnormalities
(127,143,144), but the essential component in the majority of patients is contact between the mitral
valve and the inter-ventricular septum caused by SAM of the anterior and less commonly the
posterior leaflets. Incomplete SAM at rest has long been recognised as a clue to the presence of
provocable LVOT obstruction but this study demonstrates for the first time that reduced aorto-
septal angle has a higher specificity when used as a single measure. The relatively low sensitivity of
both parameters is expected given the high prevalence and complexity of LVOT obstruction, which is
related to many additional factors.
Variation in LVOT geometry is characteristic not only of HCM, but also of aortic valve disease and
hypertension in which a ‘sigmoid’ configuration is common, particularly with advancing age and
reduction in left ventricular cavity size (349-353). In adults, a smaller aorto-septal angle is associated
with increased aortic pressure wave reflection and higher central blood pressure (300) although no
causal relationship has been demonstrated to date and in children a smaller aorto-septal angle is a
highly sensitive, specific and positive predictive marker for the development of sub-aortic stenosis
(354) and can be used as an echocardiographic feature to identify individuals at risk (190).
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Previous studies have recognised the importance of LVOT geometry in provocable obstruction.
Minimal systolic mitral-septal distance (measured using M-Mode in parasternal long axis view) has
been shown to be a predictor of patients with provocable LVOT obstruction (297). In contrast in the
study by Shah there was no correlation between the change in LVOT gradient on exercise and LVOT
diameter measured at the onset of systole using the initial echo of the anterior mitral leaflet in the
parasternal long axis view (120). Indeed the only independent predictors were a history of
presyncope/syncope, incomplete/complete SAM at rest and Wigle score. The difference in
methodology explains the discrepancy in results. I feel that retrospective measurement of mitral-
septal distance using M-mode would be difficult to accurately achieve, and so measured the LVOT
diameter in the parasternal long axis view using standard criteria. I found that the systolic LVOT
diameter did not influence the presence or magnitude of LVOT gradient. This measurement is
however distal to the point of SAM-septal contact and relatively fixed, and therefore the lack of
variation is not surprising given the dynamic nature of provocable LVOT obstruction.
Data on the importance of LVOT diameter in predicting patients with provocable obstruction are
conflicting possibly due to differences in methodology (120,297,355). Due to the dynamic nature of
provocable LVOT obstruction, measurement of this parameter may often be distal to the point of
SAM-septal contact and relatively fixed, therefore may not accurately reflect 3-D LVOT area. The lack
of an unequivocal association is not therefore surprising. I measured the LVOT diameter using 2-D
images in the parasternal long axis view and found no influence on the presence or magnitude of
LVOT gradient.
6.3.3 Technique of aorto-septal angulation measurement
CMR or computed tomography imaging provide a 3-D measurement of aorto-septal angulation,
which has been shown to predict LVOT obstruction provoked using Valsalva or amyl nitrite
independent of basal septal thickness (191). Real-time 3D echocardiography has been shown to be
superior to 2D in the measurement of myocardial hypertrophy, left ventricular volume, ejection
fraction and mass (356), and can accurately identify resting and provocable LVOT obstruction in
patients with HCM (357). Although widespread availability and expertise is currently lacking, this
may be a useful future tool for the assessment of aorto-septal angulation. In current clinical practice
however routine scanning of all patients with HCM using these modalities is often not possible, and
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for the specific purpose of measuring the aorto-septal angle I feel my methodology using standard
transthoracic echocardiography is accurate and robust.
A variety of methods have been used for measurement of the aorto-septal angle using 2-D trans-
thoracic echocardiography. The most commonly adopted is the angle formed by the long axis of the
ascending aorta and the plane of the ventricular septum, which has excellent inter-observer
correlation (186,187,189,190). Whilst 2-D echocardiography has been used multiple times to
measure aorto-septal angulation, it has not been evaluated in HCM. The left ventricular endocardial
border in HCM rarely forms a straight line, particularly in patients with a basal septal bulge. I
recognised the difficulties of finding consistent echocardiographic landmarks from which to
accurately quantify the aorto-septal angle from standard 2-D images in HCM, and so attempted to
determine reference lines which would be most consistently applicable across echocardiographic
studies and between observers. I therefore modified the method originally described by Fowles
(186). Instead of using a line bisecting the septum at the level of the mitral valve leaflets and 2cm
apically, I constructed one at the junction of the left and right inter-ventricular septum, parallel to
the proximal right endocardial border. I hypothesised that this technique would be a more accurate
representation of the true septal orientation in HCM and more likely to fit a straight line. The quality
of echocardiographic images varies between individuals, and in a minority of patients fit to a straight
line can be challenging. However, the results of my inter-observer analysis support the reliability of
my method across a large number of studies, and comparison with CMR data shows acceptable
agreement. 3-D imaging techniques including CMR and computed tomography are the gold standard
for measuring aorto-septal angulation. In my retrospective cohort data a minority of patients had
CMR images available. Although it may have been statistically underpowered, the gold standard
technique should have been assessed first for the prediction of provocable LVOT obstuction. I could
have then compared how 2-D echocardiography compared against this. Compared to the 2004-2008
when these data were collected, the majority of patients attending the HCM clinic at the Heart
Hospital now undergo CMR. It would therefore be of interest to repeat this work prospectively.6.3.4 Clinical relevance and applicability
Patients with refractory symptoms and resting LVOT obstruction should be considered for myectomy
(198,358) or ASA (179,181,359). Provocable LVOT obstruction is associated with functional
impairment and heart failure symptoms (154,155,159) and there is good evidence that invasive
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treatments should be offered to these patients (156,157). Therefore a simple clinical tool which
helps identify patients at risk of developing provocable LVOT obstruction would be of benefit.
I propose that reduced aorto-septal angle serve as a ‘red flag’ for the presence of provocable LVOT
obstruction, even in the absence of resting SAM on 2-D echocardiography, and prompt further
evaluation with stress echocardiography. Availability of expertise for stress echocardiography in
patients with HCM is variable, although it can be performed safely (360), and as such the relatively
low sensitivity of aorto-septal angle measurement demonstrated here is of less importance.
However the high specificity is likely to identify patients who may then benefit from treatment. As
used here, current guidelines to diagnose provocable LVOT obstruction recommend use of either a
treadmill or bicycle in combination with Doppler echocardiography during and / or immediately
following exercise (198).
I have demonstrated my methodology for aorto-septal angle quantification using standard 2-D
transthoracic echocardiography provides a simple, relatively inexpensive, robust method, which is
comparable to magnetic resonance and provides additional information which may be of clinical
benefit to patients with HCM. Furthermore, the results may be equally relevant in other patients
with reduced aorto-septal angle, for example those with hypertension and the elderly. Further study
in these groups is warranted.
6.3.5 Limitations
This is a retrospective observational study on a consecutive cohort of patients selected for stress
echocardiography from a specialist cardiomyopathy clinic. I did not assess specific abnormalities of
the mitral valve and supporting structures. Only symptomatic patients were referred for stress
echocardiography, and so the relevance of aorto-septal angulation in asymptomatic patients is
unknown. One third of patients were unable to discontinue medication for symptomatic reasons;
this reflects real-world practice, but may have underestimated prevalence and magnitude of LVOT
obstruction. The fact that some patients continued on these medications for symptomatic reasons
may have introduced a confounding factor, as it is uncertain if there are specific characteristics in
this population, for example a propensity to aorto-septal angulation.
Basal septal thickness was relatively modest in my cohort. However, increase in this measurement is
associated with a reduction in aorto-septal angle (191). Inclusion of patients with more prominent
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basal septal hypertrophy may therefore be expected to increase sensitivity and specificity of aorto-
septal angulation for the diagnosis of provocable LVOT obstruction. I did not assess for intra-
observer variability with repeated measures, which in retrospect would have been a useful way of
strengthening recommendation for the technique.
6.4 CT assessment of cardiac morphology before and after
myectomy surgery
6.4.1 Changes in left ventricular volume
The major finding in this cohort is that in 6 of 8 of cases there was a reduction in cardiac volume
following relief of LVOT obstruction. In the two patients whose volumes increased, one had
myectomy sugery and one ASA. Both had a reduction in NYHA class from three to two, although the
surgical patient had a reduction in VO2 from 17.4 ml/kg/min-1 (58% predicted) to 13.5 ml/kg/min-1
(48% predicted).
While one might expect that ventricular volumes would be increased rather decreased by a
reduction in left ventricular septal thickness, the net effect is likely to be extremely small. For
example, in one case, only just over 4g of tissue was removed but, the difference in diastolic volume
post-operatively was 89 cm3. If we assume a cardiac mass density of 1.05 g/cm-3(361), this would
equate to a tissue mass of 93g. It is much more likely that the reduction in left ventricular volumes
represents reverse remodelling following the relief of LVOT obstruction. This phenomenon is poorly
studied in HCM but is well recognisd in aortic stenosis. Regression in left ventricular hypertrophy
following surgical aortic valve replacement has been demonstrated, particularly in the first six
months (362,363). In another study of 24 patients using CMR, left ventricular diastolic volume index,
having been high pre-operatively, decreased rapidly in the first six months, with further reduction at
one year (364). However, left ventricular mass/volume, a 3D measure of ventricular geometry,
remained unchanged over 4 years. In patients undergoing trans-catheter aortic valve implantation
for aortic stenosis, reverse remodelling has been demonstrated using CMR six months following the
procedure, identified by a reduction in LV mass index (365). However, left ventricular diastolic
volume index, ejection fraction and stroke volume did not change.
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Circumferential strain and rotation have been shown to decrease in patients following myectomy
surgery (366). Data from patients with operated aortic stenosis suggests that unloading a chronically
pressure overloaded ventricle normalises low preoperative longitudinal and abnormally high
circumferential strain (367). Given the haemodynamic similarities between the conditions, one
would expect a similar result following myectomy in HCM. The mechanical outcome shown in the
two studies above was similar, although pre-operative longitudinal strain was not as low in HCM,
and did not normalise post-operatively. One may speculate what effect these mechanical forces
have on ventricular reverse remodelling in HCM, and it does not seem unreasonable that a reduction
in afterload and ‘net strain’ could have the effect of reducing ventricular volume over time.
With regard to functional parameters, there was a small but statistically significant reduction in
ejection fraction post-operatively. This may be partly as a result of a reduction in afterload, but may
also reflect a change in septal activation which is extremely common following surgery. Diastolic
parameters assessed using echocardiography remained unchanged.6.4.2 Relationship to symptoms
It is widely accepted that invasive treatment of LVOT obstruction increases exercise capacity, and it
has been reported that VO2 also increases. A meta-analysis of 42 published series of ASA showed an
improvement in mean NYHA class from 2.9 at presentation to 1.2 at 1 year(P<0.001) (181). At 1-year
follow-up, peak VO2 increased from 17.8 to 23.6 mL/kg/min (P < 0.001) and mean exercise capacity
on a treadmill increased from 325.3 to 437.5 seconds (P <0.001). A historical study in the 1970s of
29 patients following myectomy showed an improvement in peak VO2 from 16 to 21 ml/min/kg
(P<0.005) (184). Interestingly, surgery was associated with a significant increase in cardiac index
during maximal exercise (5.0 to 5.7 litres/min per m2, P<0.05). Another from 1992 investigating
exercise improvement following myectomy identified preoperative impairment in peak VO2, and a
post-operative reduction in LVOT gradient and left ventricular filling pressures as multivariable
predictors of a positive change in peak VO2 at 6 months (185).
In my cohort 6 patients had pre and post operative exercise tests: in 3 the peak VO2 fell, in 1 it
increased and in 2 it remained the same. Despite this, all of these patients reported an improvement
in functional class. In 8 patients, a reduction in 1 NYHA class from 3 to 2 was seen; 1 patient moved
from class 3 to 1, and 1 remained in class 2. Interestingly, the only patient whose VO2 increased was
the same individual who still had a significant LVOT gradient at follow up (40mmHg at rest). Whilst a
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reduction in VO2 yet an improvement in symptoms following surgery seems counter-intuitive, this is
exactly what my experience of seeing these patients in the clinical scenario has been over the last
few years. However, the absolute change in VO2 seen in this cohort and my clinical experince is
relatively small. The timing of a cardio-pulmonary exercise test is likely to be of importance, as
performed too early may be confounded by post-operative recovery time and de-training. In
addition, there are several alternative explanations for an improvement in symptoms unrelated to
oxygen consumption, including a reduction in mitral regurgitation and ischaemia and increase in
skeletal and respiratory muscle perfusion.
I demonstrated that AV oxygen extraction in HCM is increased. The reason for this is uncertain, but I
believe it to be a compensatory mechanism to allow a patient with a severe reduction in exercise
cardiac output to be able to perform work. If one considers the Fick equation, by improving cardiac
output through myectomy surgery, this obviates the need for an increased AV oxygen difference and
perhaps the observed increase in VO2 in the literature is a reflection of this. I do acknowledge
however that this may be an over-simplification of what may be a complex physiological adaptation
with considerable difficult in determining which is the chicken and which the egg. It would therefore
be of great interest to perform non-invasive haemodynamic assessment on patients before and at
least two post myectomy timepoints.
6.4.3 Limitations
Whilst the number of patients with complete datasets before and after myectomy surgery is small, I
believe that it has still been possible to explore the concept of reverse remodelling in patients
undergoing invasive LVOT reduction therapy. This project has shown some promising pilot data, but
also highlighted several difficulties. From a logistic viewpoint, there was a significant delay in time in
many cases (in 4 around 1 year) from pre-operative imaging to surgery. The effect this may have had
on remodelling is unknown.
The original intent was to use multi-modality imaging to optimise morphological information that
can be displayed to a surgeon before myectomy. Unfortunately a significant number of patients with
HCM undergoing LVOT reduction therapy will have an ICD, precluding the use of MRI. In this cohort
50% of the patients had an ICD. Leads and generators can also degrade CT images making resolution
of small structures more difficult.The original plan had been to utilise 3-D echocardiography.
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Although 2 of the patients were operated on here and had this investigation intra-operatively, it was
not possible to access the raw data due to technical restrictions by the hardware manufacturers. The
remaining patients did not undergo 3-D echocardiography at the surgical centre.
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7 Conclusions
7.1 Use of finger plethysmography for the measurement of cardiac
output on exercise
Finger plethysmography with brachial calibration determined cardiac output values at rest are not
significantly different to those obtained using the single breath C2H2 uptake technique in normal
individuals. During sub-maximal exercise the agreement was less precise, although the measured
relative rise in cardiac output from rest to sub-maximal exercise was similar between techniques.
Finger plethysmography was easier to perform during exercise than the single breath C2H2 uptake
technique. Overall these results support the use of finger plethysmography to measure cardiac
output at sub-maximal intensity, although caution and clinical acumen should be exercised when
using the results to make clinical decisions.
7.2 Functional consequences of left ventricular outflow tract
obstruction in hypertrophic cardiomyopathy
Cardiac output response to exercise is impaired in HCM, caused largely by a failure to appropriately
augment stroke volume. LVOT obstruction is associated with a greater impairment of stroke volume
at peak exercise and is an independent and modifiable predictor of cardiac output reserve. During
exercise patients with HCM widen their A-V oxygen difference further than normal individuals. The
non-invasive measurement of haemodynamic indices during exercise is practical, aids understanding
of the complex physiological basis behind symptoms and may help to tailor therapy for HCM, and in
particular LVOT obstruction.
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7.3 Structural determinants of left ventricular outflow tract
obstruction in hypertrophic cardiomyopathy7.3.1 Aortoseptal angulation
Measurement of aorto-septal angulation using transthoracic echocardiography in patients with HCM
is easy, reproducible, comparable to magnetic resonance imaging, and can be calculated using
standard echocardiographic software. Patients with HCM have a smaller aorto-septal angle than
controls, where it is associated with higher peak LVOT gradient. A reduced aorto-septal angle is
highly specific for provocable LVOT obstruction and should prompt further evaluation in
symptomatic patients without resting obstruction.
7.3.2 Multi-modality imaging to optimise myectomy surgery in HCM
CT scanning of patients with HCM undergoing myectomy or ASA is feasible, and potentially could
help with pre-operative surgical planning. Combination with other modalities including CMR and 3-D
echocardiography should be explored in suitable patients. Reverse remodelling was demonstrated
post-operatively in the majority of patients by a reduction in left ventricular volume.
7.4 Implications of this thesis for future work
A number of questions have occurred to me during the collection and analysis of these data. The
most striking question, is if patients with HCM and LVOT obstruction have an impaired cardiac
output response to exercise, predominantly driven by a blunted stroke volume, then what is the
impact of successful gradient reduction therapy on that response? If it is normalised, is this
associated with functional improvement? At first glance this should be straightforward to
investigate: we routinely perform cardio-pulmonary exercise testing before and after myectomy
surgery for example, so simply measure haemodynamic parameters using finger plethysmography at
the same time. Firstly however, there is the need for robust validation of finger plethysmography
during exercise in patients with HCM. Unfortunately even with this validation, a number of
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methodological concerns may muddy the water: most patients being assessed for interventional
procedures are dependent on negatively inotropic drugs pre-operatively, and in the majority of
cases when sufficient time has elapsed post-operatively for a patient to be able to perform an
exercise test, medication has often changed. It would be very difficult to accurately account for the
effect of medication on haemodynamic parameters during exercise. Despite this however, it does
seem intuitive to collect these data for analysis. Lastly, this work has raised interesting questions
regarding the mechanism behind the observed increased A-V oxygen difference in HCM during
exercise, which has no good explanation in the literature.
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9 Appendix
9.1 Abbreviations
ABPR - abnormal blood pressure response
AF - atrial fibrillation
ANOVA - analysis of variance
ASA – alcohol septal ablation
ASH - Asymmetric septal hypertrophy
A-V – Arterio-venous
CHF – Chronic heart failure
CI – Cardiac Index
CMR - Cardiac Magnetic Resonance
CSA - Cross sectional area
ECG – Electrocardiogram
FEV1 – Forced expiratory volume in 1 second
FVC – Forced vital capacity
HCM – Hypertrophic cardiomyopathy
ICD – Implantable cardioverter defibrillator
LVOT - Left ventricular outflow tract
MAP - Mean arterial pressure
MET - metabolic equivalents
MWT - maximal wall thickness
177
NICE – National institute for health and care excellence
NYHA - New York Heart Association
PCWP - pulmonary capillary wedge pressure
PPM – permanent pacemaker
SAM – systolic anterior motion
SCD - sudden cardiac death
SVI – stroke volume index
SVR - systemic vascular resistance
TPR – Total peripheral resistance
VO2 - oxygen consumption
VT – ventricular tachycardia
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